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The aims of this thesis are firstly, to establish reference ranges of serum thyroid 
stimulating hormone (TSH), free triiodothyronine (FT3) and free thryroxin (FT4) at 
11-13 weeks’ gestation in singleton and twin pregnancies and to examine the 
effect of maternal characteristics and serum antithyroid antibodies and free ß-hCG 
on the levels of TSH, FT3 and FT4, and secondly to investigate the possible 
association between maternal thyroid dysfunction in pregnancies complicated by 
fetal death, preeclampsia (PE), delivery of small for gestational age (SGA) 
neonates, preterm delivery and fetal aneuploidies. 
 
The study population was derived from a prospective screening study for adverse 





 weeks’ gestation. In some of the pregnancy complication 
groups, we identified additional cases that were examined after screening period. 
Serum concentrations of FT3, FT4, TSH, anti-TPO and anti-Tg were measured by 
immunoassay using direct, chemiluminometric technology. 
 
In normal pregnancy (n=4318), TSH increased whereas FT3 and FT4 decreased 
with gestation and all three were lower in Afro-Caribbean than in Caucasian women. 
Serum FT3 and FT4 decreased, but TSH did not change significantly with maternal 
age, TSH and FT3 increased whereas FT4 decreased with body mass index, TSH 
decreased whereas FT3 and FT4 increased with serum free ß-hCG. In the antibody 
positive group, compared to the negative group, median TSH was higher and 
median FT3 and FT4 were lower. 
 
In 45% of women with known hypothyroidism (n=164) diagnosed before 
pregnancy and receiving levothyroxine at least one of the three biochemical tests 
was suggestive of persistent hypothyroidism. In pregnancies resulting in 
miscarriage or fetal death (n=202), the median serum TSH was increased and FT4 
was decreased. In pregnancies that developed PE (n=102), there was evidence of 
hypothyroidism and increased serum TSH was observed in 5 times as many cases 
with PE compared with those who did not develop PE. In pregnancies delivering 
SGA neonates (n=212) and in those ending in spontaneous early preterm delivery 
(n=102) maternal thyroid function was not significantly different from pregnancies 
with normal outcome. In pregnancies with fetal trisomy 21 (n=30) free ß-hCG was 
increased and TSH was decreased and in cases with trisomy 18 (n=25) free ß-
hCG was decreased and TSH was increased. In normal twin pregnancies (n=235), 
compared to singletons, serum FT4 was not significantly different but TSH was 
about 40% lower. The levels of serum TSH and FT4 were similar in dichorionic 
and monochorionic twins, with or without twin-to-twin transfusion syndrome (n=19) 
and there were no significant differences between the three groups in serum free 
ß-hCG.  
 
The thesis established reference ranges of maternal thyroid function in early 
pregnancy and demonstrated altered function in association with certain 
pregnancy complications. 
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Figure 1.1 Gross anatomy of the thyroid gland, anterior view.  
 
Figure 1.2 The iodide cycle. Ingested iodide is trapped in the thyroid, oxidized, 
and bound to tyrosine to form iodotyrosines in thyroglobulin (TG); 
coupling of iodotyrosyl residues forms T4 and T3. Hormone 
secreted by the gland is transported in serum. Some T4 is 
deiodinated to T3. The hormone exerts its metabolic effect on the 
cell and is ultimately deiodinated; the iodide is reused or excreted in 
the kidney. A second cycle goes on inside the thyroid gland, with 
deiodination of iodotyrosines generating iodide, some of which is 
reused without leaving the thyroid. Taken from 
www.thyroidmanager.org 
 
Figure 1.3 Thyroid physiological changes that occur during pregnancy. TRH, 
thyrotropin-releasing hormone; T4, thyroxine; TBG, thyroxine-binding 
globulin; hCG, human chorionic gonadotropin; PRL, prolactin). 
http://www.eje-online.org/content/162/3/453/F4.expansion.html 
 
Figure 1.4 Forest plot showing the association between thyroid antibodies and 
risk of preterm delivery (He et al., 2012). 
 
Figure 1.5 Forest plot of Odds Ratios and 95% Confidence Interval of pooled 
studies comparing euthyroid thyroid antibody positive patients with 
euthyroid antibody negative controls according to the risk of 
unexplained subfertility (van den Boogaard et al., 2011). 
 
Figure 1.6 Forest plot of Odds Ratio’s and 95% Confidence Interval of pooled 
studies comparing euthyroid thyroid antibody positive patients with 
euthyroid antibody negative controls according to the risk of 
miscarriage (van den Boogaard et al., 2011). 
 
Figure 1.7 Forest plot of Odds Ratio’s and 95% Confidence Interval of pooled 
studies comparing euthyroid thyroid antibody positive patients with 
euthyroid antibody negative controls according to the risk of 
recurrent miscarriage (van den Boogaard et al., 2011). 
 
Figure 1.8 Forest plot of Odds Ratio’s and 95% Confidence Interval of pooled 
studies comparing (a) patients with subclinical hypothyroidism with 
eythyroid controls and (b) euthyroid thyroid antibody positive 
patients with euthyroid antibody negative controls according to the 







Figure 2.1 Constituents of the TSH Adiva Centaur assay.  
 
Figure 2.2 Graph showing chemiluminescence signal on y-axis and TSH 
concentration in mIU/L on x-axis. 
 
Figure 2.3 Constituents of the FT4 Adiva Centaur assay.  
 
Figure 2.4 This figure demonstrates the competition for binding between the 
AE-labelled T4 analogue and the free serum T4. 
 
Figure 2.5 Graph showing chemiluminescence signal on y-axis and FT4 
concentration in pmol/L on x-axis. 
 
Figure 2.6 Constituents of the FT3 Adiva Centaur assay.  
 
Figure 2.7 Graph showing chemiluminescence signal on y-axis and FT3 
concentration in pmol/L on x-axis. 
 
Figure 2.8 Competitive immunoassay for anti-TPO assay. 
 
Figure 2.9 Competitive immunoassay for anti-Tg assay. 
 
Figure 2.10 Graphs showing the inverse relationship between the signal in 
relative light units (y-axis) and level of anti-TPO antibody (left) and 
anti-TG antibody (right) on the x-axis in U/ml. In our study 60 U/ml 
was the cutoff for positivity in both antibodies.  
 
Figure 3.1 Frequency distribution of  TSH, log10 FT3 and log10 FT4. 
 
Figure 3.2 Reference range of maternal serum TSH with gestational age in 
Caucasian (black lines) and Afro-Caribbean (red lines) women. 
 
Figure 4.1 Relationship between maternal serum thyroid stimulating hormone 
(TSH) free tri-idothyronine (FT3) and free thyroxine (FT4) and in 
multiples of the expected normal median (MoM) at 11-13 weeks of 
gestation in pregnancies with pre-existing hypothyroidism treated 





percentiles of the normal ranges for FT3 and FT4 and the 
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Figure 4.2 Relationship between maternal serum free tri-idothyronine (FT3) 
and free thyroxine (FT4) and in multiples of the expected normal 
median (MoM) at 11-13 weeks of gestation in pregnancies with pre-
existing hypothyroidism treated with levothyroxine. The interrupted 
lines represent the 2.5
th
 centiles of the normal ranges for FT3 and 
FT4. 







Figure 5.1 Gestational age distribution of miscarriage or fetal death. 
 
Figure 6.1 Relationship between maternal serum thyroid stimulating hormone 
(TSH) and free thyroxine (FT4) and free triidothyronine (FT3) in 
multiples of the expected normal median (MoM) at 11-13 weeks of 
gestation in pregnancies that subsequently developed 





centiles of the normal ranges for FT4 and FT3 and the interrupted 
horizontal lines the 97.5
th
 centile for TSH. 
 
Figure 7.1 Distribution of birth weight of the small for gestational age fetuses 
(black dots) plotted on the reference range of birth weight for 




 percentiles (red lines). 
 
Figure 8.1 Relationship between maternal serum thyroid stimulating hormone 
(TSH) and free thyroxine (FT4) in multiples of the expected normal 
median (MoM) at 11-13 weeks of gestation in pregnancies that 
subsequently resulted in spontaneous delivery before 34 weeks. 
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Figure 10.1 Maternal serum thyroid stimulating hormone concentration of twin 
pregnancies in Caucasian (left) and African (right) women plotted 
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Figure 10.2 Box-whisker plots of the multiples of median (MoM) thyroid 
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This chapter is divided into 6 sections. The first section presents an overview of the 
anatomy, embryology, and physiology of the thyroid gland and the role of thyroid 
hormones.  
 
The second section describes thyroid function in pregnancy, including physiological 
changes in the mother, thyroid function in the fetus and transfer of maternal thyroid 
hormones to the fetus. 
 
The third and fourth sections describe thyroid dysfunction, including clinical 
hypothyroidism, clinical hyperthyroidism and euthyroid autoimmune thyroiditis, and 
subclinical hypothyroidism, their associated obstetric complications and the effect of 
treatment of thyroid dysfunction.  
 
The fifth section describes what is known on maternal thyroid function in normal 
pregnancies and in those complicated by miscarriage and stillbirth, fetal aneuploidies, 
preeclampsia, preterm delivery and delivery of small for gestational age neonates  
 
The sixth section summarises the objectives of the studies in this thesis. 





1.1 THYROID PHYSIOLOGY AND THE THYROID GLAND 
 
1.1.1. Anatomy of the thyroid gland 
 
The thyroid gland is the shape of a butterfly composed of two cone-like lobes joined by 
the isthmus. It lies just below the cricoid cartilage and wraps itself around the anterior 
and lateral aspects of the larynx and trachea (Figure 1.1). The lateral lobes extend 






Figure 1.1. Gross anatomy of the thyroid gland, anterior view  
 
The thyroid gland weighs 6-20g depending on body weight, age, iodine and pregnancy 
status (Sari et al., 2003; Hegedus et al., 1983; Berghout et al., 1987; Smyth et al., 





The parathyroid glands are positioned on the posterior surface of the lateral lobes. 
 
The blood supply of the thyroid gland is provided by the superior thyroid artery (branch 
of external carotid) and inferior thyroid artery (branch of thyrocervical trunk of the 
subclavian artery) bilaterally and usually a fifth artery the thyreoidea ima from the arch 
of the aorta enters in the midline. The blood supply to the thyroid gland accounts for 
2% of the cardiac output although it only accounts for 0.4% of the body weight. The 
blood drains inferiorly into the internal jugular and the brachiocephalic vein. 
 
 
1.1.2. Embryology of the thyroid gland 
 
The thyroid gland is composed of follicular and parafollicular cells which are also called 
C-cells. The follicular cells form follicules of varying sizes, they secrete the thyroid 
hormones which are then stored in the lumen. The lumen contains homogeneous 
colloid, thyroglobulin (TG) and other proteins such as albumin. In between the follicles 
are the C-cells that secrete calcitonin in response to an increase in serum calcium 
levels. Calcitonin acts mainly be inhibiting bone resorption and therefore lowering 
serum calcium levels. 
 
The thyroid gland is the first endocrine gland to develop on the 24
th
 day of gestation 
(Trueba et al., 2005). It originates from the endodermal epithelial cells on the median 
surface of the developing pharyngeal floor arising from the first pharyngeal arch. The 
C-cells arise from neural crest cells that migrated to the ultimobranchial body which 
then fuses with the thyroid gland. The timing of events is outlined below (Table 1.1). 
 
If the above process fails and the thyroid gland does not form, congenital 
hypothyroidism occurs. Congenital hypothyroidism affects 1 in 4000 newborns, it is 
usually caused by thyroid dysgenesis (85%) and the other 15% is due to disorders of 
hormone synthesis (Trueba et al., 2005). Thyroid dysgenesis is usually sporadic with 
only 2% having a positive family history (Castanet et al., 2001). The main genes 
involved in dysgenesis are PAX8, TITF1 and FOXE1. 
 











Anatomical or morphological events in thyroid development 
22 days Thickening of the floor of the primitive pharynx between the diverging aorta 
26 days Outgrowth and budding of the median thyroid primordium from the floor of the 
primitive pharynx. The inferior part of the fourth pharyngeal pouch forms the 
ultimobranchial body. 
28 days The median primordium grows caudally and appears bilobed. It is connected to 
the primitive pharynx by the thyroglossal duct. 
32 days Migration of the median primordium, still connected to the epithelium of the 
primitive pharynx 
33 days The thyroglossal duct starts to break down. 
37 days The median primordium consists of two lobes, an isthmus and a pedicle 
remnant. The continuity with the primitive pharynx is lost. 
44 days Median primordium fuses with the lateral components derived from the 
ultimobranchial bodies. 
48 days The thyroid reaches its final position in front of the trachea just inferior to the 
cricoid cartilage. It begins to form follicles. 
10–12 wk Follicles containing colloid become visible. The thyroid is able to incorporate 
iodine into thyroid hormones. 
 
 
1.1.3. Thyroid physiology 
 
The thyroid gland produces two principal hormones, thyroxine (T4) and triiodothyronine 
(T3) both dipeptides containing 4 and 3 iodine molecules respectively. Iodine supply is 
essential for the production of both hormones and they are the only iodine-containing 
compounds with established physiological significance. In the fetal life, this supply is 
received transplacentally and in the adult through absorption of Iodine from the 
intestine. Excess iodine can also cause hyperthyroidism and if occurs acutely then 
possibly hypothyroidism through the Wolf-Chaikoff effect by inhibiting hydrogen 
peroxide generation and therefore blocking TG iodination (Wolff and Chaikoff 1948). 
Therefore, there needs to be continuous monitoring to assess trends in iodine intake.  
 
Iodine is converted to iodide before absorption in the small intestine and transported in 
the plasma to the thyroid gland. There it is actively transported by the sodium/iodine 





follicular cell where its concentration is 20 to 50 times that of the serum (Figure 1.2; 
Berson and Yalow 1955) depending on thyroid stimulating hormone (TSH) stimulation 




Figure 1.2. The iodide cycle. Ingested iodide is trapped in the thyroid, oxidized, and bound to 
tyrosine to form iodotyrosines in thyroglobulin (TG); coupling of iodotyrosyl residues forms T4 
and T3. Hormone secreted by the gland is transported in serum. Some T4 is deiodinated to T3. 
The hormone exerts its metabolic effect on the cell and is ultimately deiodinated; the iodide is 
reused or excreted in the kidney. A second cycle goes on inside the thyroid gland, with 
deiodination of iodotyrosines generating iodide, some of which is reused without leaving the 
thyroid. Taken from www.thyroidmanager.org 
 
 
TG is a glycoprotein secreted into the follicular lumen whose tyrosyls act as substrate 
for iodination and hormone formation. The iodide taken up by the cell is oxidized by 
thyroperoxidase (TPO) and then incorporated into TG to form monoiodotyrosine (MIT) 
and diiodotyrosine (DIT) which later form T3(MIT+DIT) and T4(DIT+DIT) (Virion et al., 
1981). This occurs at the apical plasma membrane-lumen boundary. When thyroid 
hormone is needed, TG is internalised at the apical membrane, transported in 
endosomes and lysosomes and broken down by protease to release T4 and T3. 





Thyroid releasing hormone (TRH) is released from the paraventricular nucleus of the 
hypothalamus and it stimulates the release of TSH from the anterior pituitary gland. In 
hypothyroid patients, there is an increase in secretion and decrease in clearance of 
TSH (Ridgeway et al., 1974). TSH is important in stimulating every step of thyroid 
hormone synthesis and secretion through the Gq/phospholipase C and cAMP cascade 
respectively (Song et al., 2010). TSH binds to cell surface receptors to increase cAMP 
this stimulates the expression of iodine uptake transporters, TPO, TG and generation 
of hydrogen peroxide (H2O2) and increases the formation of T3 relative to T4, and 
internalisation of TG by thyrocytes through transcription factors such as TTF-1, TTF-2 
and Pax-8. 
 
Thyroid hormones in the blood stream are mostly bound to proteins with varying 
affinity. The 3 most common ones are, thyroxine-binding globulin (TBG), thyroid 
binding prealbumin (TBPA) and albumin. Approximately 99.98% of T4 is bound to 3 
serum proteins:  Thyroid binding globulin (TBG) ~75%; Thyroid binding prealbumin 
(TBPA or transthyretin) 15-20% and albumin ~5-10%. Only ~0.02% of the total T4 in 
blood is unbound or free (FT4) (Woeber and Ingbar 1968; Robbins 1992) and only 
~0.4% of total T3 is free (FT3) (75% bound to TBG, ~5% to TBPA and 20% to 
albumin) in blood is free. The activity of thyroid hormones is determined by the 
unbound free fraction since only the unbound form enters the cell. The interaction of 
T4 and T3 with these proteins follows a reversible binding equilibrium. Thus, an 
increase TBG concentration will cause a shift of hormone from free to bound state and 
so the concentration of hormone will increase to restore the equilibrium and keep the 
free hormone levels the same in order not to alter the metabolic rate. If, however, there 
is a change in the total concentration of the hormone this will cause a change in the 
concentration of free hormone and so will affect the metabolic state of the patient. 
Serum T3 and T4 inhibit the release of TRH and TSH in a negative feedback cycle. 
 
Three deiodinases (D1, D2 & D3) catalyze the generation and/disposal of bioactive 
thyroid hormone. They activate thyroid hormone by removing a single outer-ring iodine 
atom from T4 to form T3, an activating pathwaty (ORD) or inactivate thyroid hormone 






pathway (IRD) (Bianco and Kim 2006; Bianco et al., 2002). Normally one-third of T4 is 
converted to T3 and one-third is converted to rT3 and the remainder is metabolised by 
glucuronidation and sulfation. All family members of the deiodinases contain the novel 
amino acid selenocysteine (SeC) in their catalytic center. D1 is expressed mainly in the 
liver, kidneys and thyroid, it has ORD activity to produce peripheral T3 and clear rT3 
but also has IRD activity to clear T4. D2 is mainly localised to the central nervous 
system and only has ORD activity, its role is to maintain tissue T3 levels with varying 
plasma T4 and T3. The role of D3 is to degrade thyroid hormone as it only has IRD 
activity and it is mainly expressed in the brain. However, it has been shown to be 
expressed in the placenta, uterus and fetal tissue possibly preventing excess levels of 
T3 in the fetus. However, it has been shown in mice animal models that these 
enzymes not only control the levels of thyroid hormones but also control their 
bioactivity (Ng et al., 2004). 
 
Most of the thyroid hormone actions are initiated by the binding of T3 to the nuclear 
receptors. There are 2 sources of intracellular T3, from plasma T3 or T3 locally 
produced from T4. In the liver and kidney for example, most the T3 is directly from 
plasma T3 however in the central nervous system a larger proportion of tissue T3 is 
locally produced from T4 (Marsili et al., 2011).  
 
The levels of T4 and T3 in the brain are very well regulated by thyroid hormone serum 
levels, transport into cells and deiodinase expression. A study conducted on 
thyroidectomised rats and given a constant infusion of T4 to determine what doses are 
needed to normalise tissue T3 (Escobar-Morreale et al., 1995). It showed that 
supraphysiological levels of serum T4 are needed to normalise tissue T3 in most 
organs except cerebral cortex and cerebellum where levels were normal over a wide 
range of T4 doses and independent of tissue T4. The maintenance of tissue T3 
homeostasis over a wide range of T4 levels in the brain is partly explained by the down 
regulation of cerebral cortex 5’D-II with higher doses of infused T4 avoiding T3 excess 
(Escobar-Morreale et al., 1995). The same group showed that when thyroidectomised 
rats are given an infusion of T3, the level of tissue T3 in the cerebral cortex and 





cerebellum are much lower at similar plasma concentrations of T3 (Escobar-Morreale 




Characteristically pregnancy is a physiological state of lowered immune 
responsiveness, resulting in an improvement of most autoimmune conditions such as 





 T-cells (Treg) which peaks in the second trimester mainly in the decidual 
tissue and peripheral blood, this is possibly due to fetal antigen presentation and 
oestrogen-induced expression of chemokines. These regulatory cells inhibit both Th1 
(T helper cell-1 responsible for cellular immunity) and Th2 (T helper cell-2 responsible 
for humoral immunity) cells however there is a shift towards Th2 due to a lower 
sensitivity to Treg cells therefore avoiding the detrimental effects of Th1 which can 
cause fetal loss. During the couple of weeks before delivery the levels of Treg decline 
which results in a shift back to Th1 cells after delivery increasing the risk of 
autoimmune exacerbation 4-8 month after delivery such as postpartum thyroiditis 
(Saito et al., 2010; Guerin et al., 2009; Mjosberg et al., 2007; Adams Waldorf and 
Nelson 2008; Weetman 2010; Galofre and Davies 2009).  
 
Autoimmune thyroid disease is a spectrum of diseases that include Graves’ disease, 
Hashimoto’s thyroiditis and postpartum thyroiditis. The pathogenesis of autoimmune 
thyroiditis involves activation of the T-cell lymphocytes which in turn activate the B-cells 
to produce antibodies. These antibodies can either stimulate the TSH receptor such as 
anti-TSH receptor or block the production of thyroid antibodies such as anti-TPO 
antibodies and cause hyper- and hypothyroidism. They are also used to predict 
progression from subclinical to overt disease. The most prevalent antibodies in 
hypothyroid patients are anti-TPO and anti-TG antibodies and should be tested to 
identify autoimmune cause of hypothyroidism (American Thyroid Association 1995). 
Anti-TPO is more sensitive and specific (McLachlan and Rapoport 2004), however the 
prevalence of both these antibodies varies dramatically depending on the cut-off used 






of patients with Hashimoto’s thyroiditis however on treatment levels can decrease by 
up 50% (Engler et al., 1994). Anti-TG antibodies is prevalent in 50% of Graves’ 
disease and 80-90% of patients with Hashimoto’s thyroiditis (HT) (McLachlan and 
Rapoport 2004). Therefore, both these antibodies are generally used to screen for 
thyroid autoimmune disease and if positive further testing performed. During the 
course of pregnancy, levels of autoimmune thyroid antibodies decrease by an average 
of 60%, however even in the euthyroid women serum TSH levels are still relatively 
higher than controls throughout gestation (Glinoer et al., 1994).  It is important to note 
that autoimmune thyroid disease in pregnancy increases the risk of progression of 
thyroid disease 20 years later (Mannisto et al., 2010). 
 
 
1.1.4. Role of thyroid hormones 
 
Thyroid hormones are important for development, growth and metabolism 
(Oppenheimer et al., 1987; Yen 2001) of all tissues. They regulate basal metabolic 
rate, increasing oxygen consumption in most target tissues, increase sensitivity of 
target tissues to catecholamines, thereby elevating lipolysis, glycogenolysis, and 
gluconeogenesis. The diverse features of hypo- and hyperthyroidism emphasize the 
different pathways and target organs these hormones act on. The major effects of 
thyroid hormone occur through nuclear receptors that mediate gene expression, 
however nongenomic actions also occur at the plasma membrane or cytoplasm 
(Cheng et al., 2010) such as uncoupling oxidative phosphorylation, stimulation of 
energy expenditure by the activation of Na+-K+ ATPase activity, direct modulation of 
TH transporters and enzymes in the plasma membrane and mitochondria. 
 
Biologically, some of the functions of TH include normal development of the skeletal 
system and musculature as well as being essential for normal brain development and 
regulates synaptogenesis, neuronal integration, myelination and cell migration. Based 
on studies on rats, the action of thyroid hormones on the brain involves 
oligodendrocyte differentiation, glial maturation in the cerebral cortex, cerebellum and 
hippocampus (Billon et al., 2002; Martinez-Galan et al., 1997). 






The awareness of thyroid disease in the general population is rising as it is emerging 
as a potential contributor to morbidity from osteoporosis, hyperlipidaemia, 
hypercholesterolemia, hyperhomocysteinemia and cardiovascular and neuropsychiatric 
disease (Surks and Ocampo 1996; Helfand and Redfern 1998; Cooper 1998; Hak et 
al., 2000; Morris et al., 2001).  
 
 
1.2 THYROID FUNCTION IN PREGNANCY  
 
1.2.1 Changes during pregnancy 
  
During pregnancy numerous physiological changes occur to provide the fetus with 
sufficient thyroid hormones, and these result in profound and complex effects on 
thyroid function (Figure 1.3). Firstly, the thyrotropic action of human chorionic 
gonadotrophin (hCG) results in low levels of TSH in the first trimester with a clear 
mirror image between the two. hCG is a glycoprotein hormone which consists of a 92 
amino acid α-subunit and a 145 amino acid β-subunit coded by different chromosomes 
and are bound non-covalently before entering the circulation (Visconti and Zite 2012). 
The α-subunit is structurally homologous to that of TSH and their receptors are also 
analogous. The comparison was initially made when patients with trophoblastic 
tumours or hyperemesis gravidarum were reported to be hyperthyroid. hCG is 
produced by the gestational cytotrophoblasts which differentiate into extravillous 
cytotrophoblast and syncytiotrophoblast.  
 
During implantation (first two weeks) the extravillious cytotrophoblast produces 
hyperglycosylated hCG which promotes invasion of the uterine wall, forming anchoring 
villi and increasing the circulation in the spiral arteries (Cole 2010, Sasaki et al., 2008). 
The syncytiotrophoblasts form the epithelium lining the villous tree and produces 
regular hCG which maintains production of progesterone from corpus luteum until 






The level of hCG peaks at 10 weeks when TSH reaches a nadir, the thyrotrophic 
impact seems to be the strongest at that gestation (Haddow et al., 2008). The levels of 
hCG then decrease up to 20 weeks’ gestation then reaches a plateau (Kennedy et al., 
2010). In twin pregnancies these levels are nearly double and the peak period lasts for 





Figure 1.3. Thyroid physiological changes that occur during pregnancy. TRH, thyrotropin-
releasing hormone; T4, thyroxine; TBG, thyroxine-binding globulin; hCG, human chorionic 




The relationship between hCG and TSH is stronger at the lower TSH centiles possibly 
due to an adaptive mechanism where patients with higher TSH values need the thyroid 
gland to be stimulated by both TSH and hCG to produce adequate levels of thyroid 
hormones for the mother and fetus (Haddow et al., 2008). The metabolism of hCG 
affects its thyrotropic activity where truncated β-hCG has higher thyrotropic potency 
than intact hCG (Yoshimura and Hershman 1995). However the stimulatory action of 





hCG is relatively weak, a 10,000IU/L increment results in a mean FT4 increase of 0.6 
pmol/L and lowering TSH by 0.1 mU/L (Glinoer et al., 1990) therefore thyrotoxic levels 
are rare and probably restricted to the first trimester of pregnancy. After the hCG peak 
in the first trimester, TSH levels gradually increase and are highest in the 3
rd
 trimester 
due to about a 30% reduction in free T4 and T3 in late pregnancy compared to values 
in earlier pregnancy (Glinoer et al., 1990; Whitworth et al., 1982). These changes in 
thyroid hormone levels in the 3
rd
 trimester occur even in an iodine sufficient 
environment (Fister et al., 2011). It is important therefore to use gestation specific 
reference ranges of thyroid hormones (Stricker et al., 2007). Studies have shown that 
FT3 and FT4 levels start to increase 3-4 days postpartum (Kurioka et al., 2005) 
however TSH levels start to decrease between 4 months to 1 year postpartum (Fister 
et al., 2011; Soldin et al., 2004). 
 
During pregnancy there is a high level of oestrogen production reaching 60 mg/day 
during the last trimester (Katz and Kappas 1967). Estradiol more specifically has been 
shown to increase synthesis of TBG by the hepatocytes (Katz and Kappas 1967; 
Glinoer et al., 1977) and it also increases sialylation of TBG (oligosaccharide 
modification) decreasing clearance (Bartalena 1990; Ain et al., 1987). The increase in 
thyroid binding globulin (TBG) occurs throughout the first half of pregnancy, it plateaus 
at 24 weeks and stays unchanged until term (Skjoldebrand et al., 1982; Glinoer et al., 
1990) however there is also an alteration in affinity for T4 due to a reversible change in 
structure that modulates thyroid hormone delivery to tissues (Zhou et al 2006). The 
high levels of TBG stimulate the production of thyroid hormones with an increase in 
total T4 and T3 however maintaining a normal active FT4 and FT3 levels in the first 
half of pregnancy (Glinoer et al., 1990, Figure 1.3).  
 
There is an increase in the level of TG during pregnancy with 2 out of 3 women having 
a significant increase from initial evaluation until delivery  (p<0.001).  Studies have not 
shown any correlation between TG and thyroid hormones, hCG or urinary iodine 
(Glinoer et al., 1990) however there is a positive correlation with thyroid gland volume 







As discussed above iodine is essential for the production of thyroid hormones. During 
pregnancy iodine requirements increase due to increased synthesis of thyroid 
hormones, an increase in iodide excretion due to increased renal blood flow and 
glomerular filtration rate and placental transfer and metabolism. The prevalence of 
Iodine deficiency in the population varies depending on location, a recent review of 
iodine status claims that approximately 70% of households worldwide have access to 
iodized salt (Zimmermann and Andersson 2012). Regions with greatest access are 
Western Pacific and Americas and those with least access are residing in the Eastern 
Mediterranean. The method that is mostly commonly used by the WHO to assess 
iodine status of a population is median urinary iodine concentration (UIC) since it 
reflects current iodine status and identifies acute changes in iodine intake (normal 
range for children and non-pregnant women 100-299 µg/l, and for pregnant women 
150-249 µg/L). Surveys on UIC are available for 117 countries and show that 28.9% of 
the general population have low median UIC. However these surveys are done on 
children and non-pregnant women and do not truly reflect the iodine status of pregnant 
women or women of reproductive age (Zimmermann and Anderson 2012). Due to the 
physiological changes during pregnancy UIC is not a good indicator of iodine status 
especially in the first trimester of pregnancy when there is an increase in glomerular 
filtration rate and therefore increased excretion of iodine even when iodine deficient. 
During the later stages in pregnancy, placental and fetal demand of iodine also 
increase.  
 
A recent study was conducted to assess whether median UIC in school children and 
non-pregnant women can be used to predict iodine status of pregnant women (Wong 
et al., 2011). This study showed that when median UIC was adequate or above 
requirements in school aged children or non-pregnant women, approximately 50% of 
the time pregnant women were iodine deficient. Body reserves are reduced by 40% 
during pregnancy and therefore women during this period are more susceptible to 
iodine deficiency even in iodine replete areas. Marchioni et al., measured mean UIC in 
51 pregnant women and 100 matched controls and showed that despite adequate 
supplementation 92% of pregnant women were iodine deficient compared to 4% in the 
control group (Marchioni et al., 2008). Another group in France reported that the 





prevalence of maternal iodine deficiency defined as UIC < 150 is 66.3% in the first 
trimester and 85.8% in the 3
rd
 trimester (Brucker-Davis et al., 2012; Hiéronimus et al., 
2009), the reduced rate in the first trimester is likely due to the increased excretion rate 
of iodine early in pregnancy. Other studies however suggested that the increase in 
excretion rate of iodine is stable through all 3 trimesters (Beckers 1991; Smyth et al., 
1997). The world health organisation (WHO) currently recommends iodine 
supplementation in countries with iodine deficiency for women of child-bearing age 
(150 µg/day or annual dose of 400 mg) and pregnant and lactating women (250 µg/day 
or annual dose of 400 mg).  
 
Thyroid gland volume has been used to reflect long-term iodine status in a population; 
it is thought to develop due to the increased TSH stimulation of the gland in response 
to reduced thyroid hormone production. Until recently volume has been measured 
visually or by palpation. The WHO described ‘goitre’ as a thyroid gland with lobes 
larger than the terminal phalanges of the thumb. Recently ultrasound has been used to 
establish normal ranges of thyroid volume in iodine-replete areas in 6-12 year old 
children (Zimmermann et al., 2004) and this can be used to describe prevalence of 
goitres more accurately in a population. Thyroid gland size is generally related to 
genetic factors, sex, age, TSH, FT4, smoking, body weight, height, waist-hip ratio, 
body surface area, total body water, fat mass and body fat (Gomez et al., 2000; 
Hansen et al., 2004). In the nonpregnant and pregnant women, size increased with 
BMI (Hansen et al., 2004; Hegedus 1990; Fister et al., 2009). 
 
During pregnancy thyroid volume was inversely correlated with TSH as with the 
general population (Gomez et al., 2000) and positively correlated with TG levels and 
T3/T4 ratio (Glinoer et al., 1990), but there was no correlation with urinary iodine 
concentration (Gomez et al., 2000). There is conflicting evidence as to whether thyroid 
volume increases during pregnancy (Azizi et al., 2003; Berghout and Wiersinga 1998; 
Fister et al., 2009; Nelson et al., 1987; Brander and Kivisaari 1989). The proposed 
reasons why thyroid gland volume increases during pregnancy are due to the increase 
vascularity (Rasmussen et al., 1989; Fister et al., 2009), increase total body water 






and therefore normal ranges of thyroid gland volume need to be established for 
pregnant women.  
 
 
1.2.2. Fetal thyroid function 
 
The lack of thyroid hormones during fetal growth and childhood results in prominent 
abnormalities. This is illustrated in cretinism in an iodine-deficient population, with 
evidence of restricted physical and mental development, reduced muscle tone or 
spastic diplegia, squint, thickened skin, enlarged tongue, protruding abdomen. 
 
There are three phases of fetal thyroid development; Embryogenesis, hypothalamic 
maturation and development of hypothalamic-pituitary-thyroid system control. Human 
studies have shown that the fetal thyroid gland begins to produce thyroxine at 10-12 
weeks gestation (Shepard 1967). However there is conflicting evidence as to the 
gestation at which functional maturation of the fetal pituitary-thyroid axis is achieved. 
Some authors suggest that TSH secretion is responsive to changes in serum FT4 as 
early as 11 weeks (Greenberg et al., 1970) while others suggest that such maturation 
occurs largely during the last half of pregnancy (Fisher et al., 1970; Fisher et al., 1973, 
Fisher et al., 1977). 
 
The amount of thyroid hormones in amniotic fluid was not found to correlate with the 
fetal or maternal thyroid hormone serum levels (Pekonen et al., 1984). After the 
introduction of cordocentesis it became possible to examine the fetal pituitary and 
thyroid development under physiological conditions (Nicolaides et al., 1986). A study 
by Ballabio et al., used cordocentesis samples of 23 women and examined fetal thyroid 
function from 18-31 weeks’ gestation, demonstrating an increase in fetal serum TSH, 
T4 and FT4 throughout gestation. Compared to the maternal serum levels, fetal TSH 
was higher and T4 was lower however FT4 reached maternal levels by 28 weeks 
gestation. The threshold for negative feedback control seems to be set at a higher 
level, however these small number of cases may not be truly representative of 





physiological levels especially that the majority of them were severely anaemic due to 
red cell isoimmunisation (Ballabio et al., 1991).  
 
In another study which included 62 fetuses where cordocentesis was performed for 
prenatal diagnosis and the fetuses were found to be normal, there was a significant 
increase in the concentration fetal serum TSH, TBG, T4, FT4, T3 and FT3 with 
gestation and no association between fetal and maternal thyroid hormones and TSH 
concentrations (Thorpe-Beeston et al., 1991a).  
 
This suggested that the fetal thyroid axis develops independently of the mother’s 
thyroid axis. There was no significant association between fetal TSH, TBG and thyroid 
hormones. Although the total and FT4 concentrations reached adult levels by 36 
weeks’ gestation in this study, the total and FT3 were always less than 50% of mean 
adult concentrations, which possibly reflects the fact that in the fetus the mechanism of 
conversion from T4 to T3 is immature or lacking. Fisher et al., also showed that there 
is 10 fold increase in the ratio of serum T3 to T4 from 30 weeks to 1 month postnatally 
(Fisher et al., 1977). Possible explanations are late maturation of the pituitary thyroid 
axis or rapid deiodination by the placenta. The increase of fetal thyroid hormones with 
no correlation to TSH suggests that the thyroid gland matures independently of TSH, 
and possibly improved transfer via the placenta’ however this was not supported by 
another study (Vulsma et al., 1989). The continued increased of TSH in the 3
rd
 
trimester even with normal FT4 levels may indicated that FT3 is more important for 
negative feedback in the fetus.   
 
 
1.2.3. Transfer of maternal thyroid hormones the fetus 
 
The importance of the maternal thyroid hormones for the fetus were initially 
demonstrated by Morreale de Escobar and colleagues on pregnant rat animal models 
where they performed thyroidectomies on rats and compared thyroid hormone levels in 
the mother and the embryo to those of control rats (Morreale de Escobar et al., 1985). 






viable embryos. They also demonstrated that the weight of the embryotrophoblast in 
the rats with a thyroidectomy was reduced throughout pregnancy compared to those of 
controls and that the weight of individual organs such as brain, liver and lung of the 
fetus was reduced at the end of pregnancy (20 and 21 days gestation) (Morreale de 
Escobar et al., 1985).  
 
It was initially thought that the placenta was impermeable to thyroid hormones until 
early studies have detected T4 and T3 in 9- to 14-day old rat embryos before the onset 
of fetal thyroid gland function (Sweney and Shapiro 1975; Obregon et al., 1984; 
Woods et al 1984). In humans the landmark study by Vulsma et al., which studied 25 
neonates with a complete organification defect or thyroid agenesis and measured their 
cord blood at birth, found T4 levels ranging from 35-70 nmol/l (Vulsma et al., 1989). 
Since then, T4 was found to be present in fetus from as early as 4 weeks gestation 
(Obregon et al., 2007). A study examining the expression of thyroid hormone 
transporters in 110 normal human placentas, showed that mRNA encoding thyroid 
hormone transporters are expressed from 6 weeks and throughout gestation (Loubiere 
et al., 2010). The human fetus is dependent on transplacental delivery of maternal 
thyroid hormones before 16 weeks gestation (Patel et al., 2011).  
 
The placenta acts as a barrier protecting the fetus from changes in maternal thyroid 
function and transfer is carefully regulated by trophoblast cell membrane transporters, 
placental deiodinases D3 and D2. Thyroid hormones are also metabolised in the 
placenta as both D3 and D2 deiodinases are expressed from the first trimester of 
pregnancy and their expression falls as gestation progresses. Placental D3 activity 
however is approximately 200 times that of D2 (Patel et al., 2011), they inactivate T4 to 
rT3 and activate T4 to active T3 respectively. The role of D2 in the placenta is likely 
only for housekeeping purposes whereas D3 prevents excess T4 reaching the fetus. 
 
It has been suggested that the main thyroid hormone binding protein produced and 
expressed in the placenta is transthyretin (TTR) (McKinnon et al., 2005) and that 
maybe is how thyroid hormones are transported in the placenta.  
 






1.3 THYROID DYSFUNCTION 
 
1.3.1.  Clinical hypothyroidism due to iodine deficiency  
 
Worldwide iodine deficiency is an important cause of hypothyroidism and studies have 
shown a correlation between iodine deficiency and raised TSH levels in newborns 
(Delange et al., 1986; Zimmermann et al., 2005). A study conducted in Switzerland 
showed that an increase in iodine concentration in salt by 25% from 15 to 20 mg/kg 
results in an increase in median UIC in pregnant women from 138 µg/L in 1998 to 249 
µg/L in 2004 (p<0.01) and a reduction in number of newborns with TSH >5 mU/L from 
2.9% in 1992-1998 to 1.7% in 1999-2004 (Zimmermann et al., 2005). Studies on rat 
animal models have shown that iodine deficiency does initially result in reduced levels 
of T4 and increased levels of TSH and thyroid volume however T3 levels did not 
change significantly (Minato et al., 2012) and the metabolism of T4 is not altered in an 
iodine deficiency state. It is therefore likely that the level of T3 is maintained by 
preferential biosynthesis of T3 over T4 in the thyroid gland. This seems reasonable as 
T3 is metabolically more active and has fewer iodine atoms. The level of serum T3 was 
only affected when the T4 level was reduced to 5% of normal value (Pedraza et al., 
2006) and serum T3 must decrease before many T3-dependent tissues become T3-
deficient. Thyroid autoregulation is therefore important in adapting to iodine deficiency 
preventing the decrease of T3 in serum and most tissues despite a significant 
reduction of serum T4. However the brain’s supply of thyroid hormones is mainly from 
the conversion of T4 to T3 by its own deiodinase than from circulating T3 and therefore 
a reduction in serum T4 would pose a potential risk to the developing brain (Calvo et 
al., 1990). 
 
The effects of Iodine deficiency on the pregnancy and the fetus have been well 
documented (Gardner 1975) and varied depending on the severity of Iodine deficiency. 
Iodine deficiency causes endemic hypothyroidism as both mother and fetus will be 
deficient throughout the pregnancy whereas sporadic hypothyroidism which is only 






its features include deaf-mutism, short stature, spasticity and profound mental 
retardation. The association between maternal iodine deficiency and 
neurodevelopmental delay in the offspring has been recognised over a 100 years. 
Iodine deficiency is the single most important preventable cause of brain damage 
worldwide (World health Organisation, WHO). People living in areas affected by severe 
iodine deficiency may have an intelligence quotient (IQ) of up to 13.5 points below that 
of those from comparable communities in areas where there is no iodine deficiency 
(Bleichrodt and Born 1994). This mental disability has an immediate effect on child 
learning capacity, women’s health, the quality of life in communities, and economic 
productivity. Therefore universal salt iodization was introduced and is aimed to iodize 
all salt for human and animal consumption to the internationally agreed recommended 
levels.  
 
Studies are now linking iodine deficiency with adverse pregnancy outcomes, recently a 
study examined study examining the effects of iodine supplementation during the 
second half of pregnancy showed that pregnancies supplemented with iodine were 
less likely to deliver preterm and the neonate was less likely to be growth restricted 
(Joshi et al., 2011). Another preliminary study looking at the effects of maternal iodine 
supplementation (300µg) during the first trimester of pregnancy on psychological 
development of infants aged 3 to 18 months (Velasco et al., 2009), demonstrated an 
improved psychometric assessment (higher psychomotor development index, p=0.02 
and behavioural rating score).                                                                                                                                                                                                     
 
 
1.3.2.  Clinical hypothyroidism without iodine deficiency  
 
The prevalence of overt hypothyroidism in pregnancy is 0.3% (Klein et al., 1991). The 
most common cause of hypothyroidism in an iodine sufficient population is HT. HT is a 
cell-mediated immune response that results in the gradual destruction of thyroid tissue 
with characteristically positive anti-TPO and anti-TG antibodies although they don’t 
play a significant role in the pathogenesis. More details in section 1.3.4.  
 





The endocrine society clinical practice guidelines recommend when treating overt 
hypothyroidism the dose of levothyroxine should be titrated aiming for a TSH <2.5 
mIU/L in the 1
st 




 trimesters (De Groot et al., 
2012) or using trimester specific reference ranges established in the laboratory. The 
thyroid function testes should be repeated every 4-6 weeks. 
 
Adverse effect on neurodevelopment in children 
 
The initial mention of non-iodine hypothyroidism measured using serum butanol 
extractable iodine and the effects of this on neuropsychological development of the 
offspring was initially mentioned in 1971 (Man et al., 1971). In 1999 Pop et al., 
measured FT4, TSH and Anti-TPO antibody levels at 12 and 32 weeks gestation in 
220 pregnant women who did not have a history of thyroid disease living in an iodine 
sufficient area and who had a live born which was phenotypically normal with no 
complications such as prematurity, birth weight above 2500 grams and did not develop 
pre-eclampsia. The thyroid function was then correlated with the child’s development at 
10 months of age using the Dutch version of the Bayley Scales of Infant Development 
(Bayley, 1969) performed by a blinded psychologist. The 10 month gestation was used 
to avoid later bias from environmental factors such as psycho-social aspects (Pop et 
al., 1999). In the women with FT4 levels below the 5
th
 (<9.8pmol/l) and 10
th
 
(<10.4pmol/l) percentile at 12 weeks, their offspring scored significantly lower in the 
Bayley psychomotor subscale (mean difference 14.1 and 7.4 respectively) this was not 
evident at 32 weeks gestation. A difference of 10 points on the psychomotor 
development index is equivalent to 1 month delay in development (Bayley, 1969). They 
showed that the lower the FT4 levels the lower the psychomotor development index 
scale (linear regression R 0.46, p=0.03). All the children they assessed had normal T4 
and TSH values one week after birth as examined by the national screening 
programme for congenital hypothyroidism. This was the first study to show that low 
FT4 levels <10
th
 percentile at 12 weeks was associated with an increased risk of 
impaired neurodevelopment in the child at 10 months of age (RR 5.8, 95% CI 1.3-
12.6). This study also demonstrated that women that were Anti-TPO antibody positive 






weeks, 46% of them had FT4 levels below the 10
th
 centile at 12 weeks and therefore 
this might provide an explanation of the result of their previous studies (Pop et al., 
1995, details below) which showed the positive Anti-TPO antibodies at 32 weeks was 
associated with impaired child development at 4.5 years of age (decrease in IQ of 10 
points). 
 
Controversially, screening for subclinical hypothyroidism started after the publication of 
an American study of 25,216 women linking high levels of TSH (combined with lower 
levels of FT4) in the second trimester and lower IQ scores in the offspring (Haddow et 
al 1999). Women were divided into 2 groups, those with TSH levels >99.7
th
 percentile 




 percentile (15 women). Serum T4, 
FT4 and anti-TPO were measured in these 62 women (15 had already been diagnosed 
with hypothyroidism and 14 were on thyroxine) and 124 matched controls. The mean 
FT4 in the 62 affected women was 9.13 pmol/L (vs 12.5 pmol/L in the control group) 
classifying this group as overt rather than subclinical hypothyroidism. The 
neuropsychological testing was performed by 2 blinded psychologist, at 7 and 9 years 
of age at the time of assessment. The average IQ score was 7 points lower and 19% 
of children of women with hypothyroidism had scores <85 vs 5% of the control 
children. The high percentage of anti-thyroid peroxidase antibody positivity (77%) in 
hypothyroid women may indicate that the cause of hypothyroidism in these women is 
chronic autoimmune thyroiditis however the threshold in this study for positivity was low 
(>2 U/mL). Follow up of these women 11 years later identified that 4% of the control 
women were diagnosed with hypothyroidism compared to 64% of those that they 
identified during pregnancy. They advocate for screening as not only will it improve the 
childs IQ score by 4 but also will treat the women early and reduce morbidity as 64% 




Overt hypothyroidism is commonly associated with anovulation due to 
hyperprolactinemia from increasing TRH serum levels. Therefore, pregnancy in 
untreated women is unlikely and if it does occur the risk of miscarriage is high 





(Abalovich et al., 2002). Numerous studies reported on the association of overt 
hypothyroidism and adverse pregnancy outcome; however it seems that with thyroid 
hormone replacement the pregnancy outcome can be good (Greenman et al., 1962; 
Pekonen et al., 1984). The endocrine society clinical practice guidelines state that 
there is good (level A) evidence to show that overt hypothyroidism can have serious 
adverse effects on pregnancy (De Groot et al., 2012). 
 
An early study published in 1962, studied 23 pregnancies with suspected thyroid 
disorder assessed by butanol-extractable iodine (BEI) (normal range for pregnancy 
5.5-10.5 µg/100ml) which is a measure of thyroid function (Greenman et al., 1962). 
The outcome included 1 miscarriage, 2 fetal deaths, 2 neonatal deaths, 5 infants were 
assessed to be severely mentally disabled at about 1 year of age (3 of them were born 
premature, 1 was growth restricted, 1 had a severe heart condition). This study 
however demonstrated that those women who were hypothyroid not on treatment with 
low BEI had much worse outcomes than those who are clinically hypothyroid but with 
normal BEI as well as those with known hypothyroidism on inadequate treatment (BEI 
is low) (Greenman et al., 1962).  
  
Montoro et al., (1981) is one of the earliest reports on the outcome of 11 pregnancies 
with biochemically confirmed hypothyroidism. The thyroid function tests were 
performed across gestation includes FT3, FT4 and TSH and hypothyroidism was 
defined as TSH >5 mU/ml and T4 <4.5 µg/dL. One patient developed PE and IUFD 
occurred at 29 weeks, there was no spontaneous preterm labour, none of the 
neonates weighed <2500g, one baby had Down syndrome otherwise there was no 
developmental delay in milestones in the first 2-3 years (Montoro et al., 1981). Another 
report of 28 pregnancies, 16 diagnosed with overt hypothyroidism, defined as TSH> 10 
mIU/mL and T4 < 4.5 µg/dL (nonpregnant range used); (Davis et al., 1988). Women 
with overt hypothyroidism were more likely to develop PE (44%, 7/16), fetal death 
(19%, 3/16), preterm delivery <37 weeks (mean gestational age 35.2 weeks) however 
most were induced due to PE, 1/16 was spontaneous preterm labour) and have a birth 
weight <2500g (31%, 5/16 pregnancies however 3/16 were due to induced preterm 






restricted at 38 weeks). During repeat pregnancies, 5 of these women where followed 
up and given LT4 and were clinically and biochemically euthyroid throughout, 4 had 
low birth weight infants due to premature rupture of membranes in 3 cases and PE in 1 
case however these women were high risk women to previous premature deliveries 
and still births (Davis et al., 1988). Due to small number in these reports, conclusions 
based on statistical analysis are not informative.  
 
The evidence linking overt hypothyroidism and PE is still not consistent. A prospective 
study of 23 women with overt hypothyroidism (clinically and biochemically) showed an 
increased risk of PE and gestational hypertension, with 22% developing either (vs 
7.6% in the general population, p<0.04). They also were more likely to deliver infants 
<2500g (22 vs 6.8%; p<0.02) this was due to the increased prematurity due to 
gestational hypertension. There was no increase in spontaneous preterm labour. One 
of these women has a still born and developed eclampsia (Leung et al., 1993).  
 
A Finnish study found that women who have overt hypothyroidism in the 1
st
 trimester of 
pregnancy were not at an increased risk of developing PE (1.9% in both groups) 
(Mannisto et al., 2010). This was consistent with a study by Negro et al., which also 
showed no association between hypothyroidism and pregnancy-induced hypertension 
(Negro et al., 2010a). 
 
A retrospective study of 150 pregnancies, with known overt hypothyroidism, on 
levothyroxine were examined to correlate thyroid function at conception with pregnancy  
outcome (Abalovich et al., 2002). These include women with autoimmune thyroid 
disease. Overt was defined as TSH >5 mIU/L and FT4 <4.5 µg/dL and subclinical 
when TSH >5 mIU/L and FT4 within the normal range however both groups were 
combined as the hypothyroid group. At conception 99 were euthyroid, 16 with overt 
hypothyroidism and 35 with subclinical hypothyroidism. The miscarriage rate was 
higher in the hypothyroid group (31.4 vs 4%, p<0.0001) however all the miscarriages 
occurred in those that were treated inadequately. The term delivery rate was lower in 
the hypothyroid group (58.8 vs 84.5%, p=0.18) however the likelyhood of preterm 
delivery is higher if treatment was inadequate (20.8 vs 92.6% term delivery rate). This 





study showed that the adverse outcomes were not related on the severity of the 
disease but on the adequacy of treatment (Abalovich et al., 2002). This study 
highlights the need to monitor these patients carefully throughout pregnancy. 
 
Effects of treatment 
 
A recently published study, however, has looked at the effect of treatment of 
hypothyroid women and the children’s IQ score at 3 years of age (Lazarus et al 2012). 





 weeks) with no history of thyroid disease and randomised them 
into screening group (10,924 women) and control group (10,922 women). A blood 
sample was taken from both groups, the sample was analysed for TSH and FT4 within 
1 week for the screening group and after delivery for the control group. The definition 
of screen positive was TSH > 97.5
TH
 percentile and FT4<2.5
TH
 percentile or both. 
Women that were screen positive were started on 150 micrograms of levothyroxine 
and levels were checked 6 weeks after levothyroxine initiation and at 30 weeks to 
adjust dose as necessary for a target TSH level of 0.1-1.0 mIU/L. The primary 
outcome of the study was the IQ at 3 years of age in women who were screen positive. 
The children were assessed by the Wechsler Preschool and Primary Scale of 
Intelligence, 3
rd
 edition (2003) by a blinded psychologist. Based on the Haddow et al 
(1999) they expected a decrease in the percentage of children with an IQ score less 
than 85 at 7 years of age (5% in the screened vs 15% in the control). In the screened 
group, 4.6% were screen positive and vs 5% in the control group. Treatment in the 
screened group was started at a median gestational age of 13
+3
 weeks. Psychological 
testing was completed in 78.2% in the screened who tested positive and 73.3% in the 
control group who tested positive. The mean standard IQ score was 100 in the control 
and 99.2 (p=0.40) in the screened group. The percentage of children with an IQ <85 
was 12.1% in the screened and 14.1% in the control group. This difference was not 
significant (p=0.39) and there was no association between initial TSH measurement 







American Thyroid Association guidelines stating no evidence for routine screening in 
pregnancy. 
 
1.3.3 Clinical hyperthyroidism 
 
The prevalence rate of overt hyperthyroidism in pregnancy is 0.1-0.4%. Graves’ 
disease is the most common cause of hyperthyroidism in females during the 
reproductive years accounting for 85-90% of causes of overt hyperthyroidism in 
pregnancy (Galofre and Davies 2009). Hyperthyroidism in pregnancy that is not treated 
adequately increases the risk of preeclampsia, congestive heart failure, thyroid storm, 
miscarriage, stillbirth, preterm delivery and placental abruption. Fetal hyperthyroidism 
which occurs in <0.01% of pregnancies may result in tachycardia, fetal goitre, 
accelerated bone maturation, growth retardation, low birth weight and malformations 
(Zimmerman 1999) and is either caused by maternal thyroid hormones or the 
stimulating thyroid receptor antibodies crossing the placenta which have an effect on 
the fetal thyroid gland after 12 weeks gestation (Chan and Mandel 2007; Laurberg et 
al., 2009). Neonatal hyperthyroidism occurs in 5% of newborns to mothers with 
Graves’ disease and persists for 12 weeks as the maternal antibodies have a half-life 
of 3 weeks (Chan and Mandel 2007; Laurberg et al., 2009). 
 
The aim of treatment during pregnancy is maintain FT4 at or just above the upper limit 
of the nonpregnant reference range (De Groot et al., 2012). It is recommended to treat 
using propylthiouracil in the first trimester (to avoid the association of methimazole with 




 trimesters (to 
reduce the risk of liver toxicity with propylthiouracil. If however the patient develops 
adverse reactions to these drugs, or requires high doses or is non adherent with 
treatment and have uncontrolled hyperthyroidism then a subtotal thyroidectomy may 
be indicated in the second trimester. There is no evidence treatment of subclinical 
hyperthyroidism improves pregnancy outcome and can negatively affect fetal outcome 
(De Groot et al., 2012)  
 
A meta-analysis of clinically hyperthyroid patients from 8 studies examining the effect 
of treatment (propylthiouracil and methimazole) on pregnancy outcome showed a 





reduced risk of preterm delivery (RR 0.23, 95% CI 0.1-0.52), PE (RR 0.23, 95% CI 
0.06-0.89) and low birth weight (RR 0.38, 95% CI 0.22-0.66) (Vissenberg et al., 2012). 
 
 
1.3.4. Euthyroid autoimmune thyroiditis 
 
In a survey done on 13,344 disease free individuals in the United States population, 
has shown that anti-TG antibodies were positive in 10.4 +/- 0.5% and anti-TPO 
antibodies in 11.3 +/- 0.4% (Hollowell et al., 2002). Prevalence of antibodies was 
higher in women than men, increases with age, more prevalent in whites (12.3 +/- 
0.5%) than blacks (4.5 +/- 0.3%) (p < 0.001). In this study anti-TPO antibodies were 
significantly associated with hypo- or hyperthyroidism, but anti-TG antibodies were not 
(Hollowell et al., 2002). The overall prevalence of anti-TPO in disease-free females in 
the US was 14.6% and that of anti-TG was 13.8% (Hollowell et al., 2002). In a large 
prospective study of 2227 caucasian pregnant women the prevalence anti-TPO 
antibodies in the euthyroid women is 7.9% (169/2143) (Negro et al., 2007a). Another 
population based cohort of euthyroid pregnant women in Finland described the 
prevalence of anti-TG antibodies to be 3.6% and the prevalence of anti-TPO 
antibodies was 3.0%, lower than previously reported however only women with TSH 
and FT4 within the normal range were included (Mannisto et al., 2012). A Dutch study 
screened 9778 pregnant women and found the prevalence of anti-TPO to be 4.7% 
(Ghassabian et al., 2012). The reason for this discrepancy is due to the fact that the 
cut-off used for positivity varies significantly.  
 
There are some data showing that the higher the level of iodine intake the higher the 
prevalence of thyroid antibodies (Hollowell et al., 2002; Kasagi et al., 2009; Aghini-
Lombardi et al., 1999) and in a population previously iodine-deficient given iodine 
prophylaxis the incidence of thyroid autoimmunity increased 4 fold (Heydarian et al., 
2007). Although one study did link high iodine intake with a higher rate of postpartum 






supplementation is considered safe in pregnancy even if the woman was anti-thyroid 
antibody positive (Antonangeli et al., 2002; Nohr et al., 2000).  
 
The latest endocrine society clinical practical guidelines recommend that autoimmune 
euthyroid women at the early stages of pregnancy are at risk of developing 
hypothyroidism and should therefore be monitored every 4-6 weeks for raised TSH 
above reference range (De Groot et al., 2012). 
 
Adverse effect on neurodevelopment in children  
 
The study by Matsuura and Konishi in 1990 was the first to document that the fetal 
brain development is adversely affected when both mother and fetus are hypothyroid 
due to chronic autoimmune thyroiditis (Matsuura and Konishi 1990). However the data 
regarding the effect of maternal anti-thyroid antibody on the fetal neurodevelopment is 
not consistent. A study by a Danish group measured TSH, FT4, FT3 and Anti-TPO 
(titre >100U/ml) antibodies at 32 weeks gestation and 4 weeks postpartum and 
thereafter at 6 weekly intervals until 34 weeks postpartum in 230 women (Pop et al., 
1995). The child’s development was assessed by the Dutch translation of the 
McCarthy Scales of Childrens Abilities (MSCA). They defined thyroid dysfunction as 
abnormal TSH (normal range 0.14-3.5mU/L) and FT4 (normal range 8.9-18pmol/L), 
and that of subclinical hypothyroidism as high TSH with a normal FT4. They described 
an association between Anti-TPO antibody positivity at 32 weeks gestation and lower 
MSCA assessment scores in 4 of the 6 categories at preschool age, most significantly 
in the cognitive scores with a 10.5 point difference. All the women had normal FT4 and 
TSH levels at 32 weeks gestation. However to correct for any possible confounding 
factors such as maternal depression, they performed a logistic regression analysis and 
demonstrated that Anti-TPO antibodies at 32 weeks gestation, low educational level of 
mother, current major maternal depression, previous episode of depression in mother’s 
life, family history of depression were all factors associated with lower cognitive (GCS) 
score in the offspring. This study has shown that euthyroid women with Anti-TPO 
antibodies is associated with neurodevelopmental delay (Pop et al., 1995). This was 
consistent with a study from China which measured serum TSH, FT4 and anti-TPO 
antibodies in 1268 pregnant women at 16-20 weeks gestation (Li et al., 2010). Patients 





who were euthyroid with positive anti-TPO antibodies had a lower mean intelligence 
score by 10.56 points (p=0.001) and lower mean motor scores by 9.03 (p<0.001) than 
matched controls at 25-30 months of age. Using a multivariate logistic regression 
analysis they found an independent effect of anti-TPO antibodies and increased serum 
TSH on intelligence (OR 6.69, OR 15.63 respectively) and motor scores (OR 9.23, OR 
8.25 respectively).  
 
However, the same group (Pop et al., 1999) then measured Anti-TPO antibodies at 12 
and 32 weeks gestation in 220 pregnant women who did not have a history of thyroid 
disease living in an iodine sufficient area and who had a live born which was 
phenotypically normal with no complications such as prematurity, birth weight above 
2500 grams and did not develop pre-eclampsia and assessed the offspring’s 
psychomotor development at 10 months of age. They showed using multiple logistic 
regression that Anti-TPO antibody levels >100U/ml at 12 and 32 weeks gestation was 
not an independent predictor of the childs psychomotor development at 10 months of 
age.  Some of these women had low FT4 (<10
th
 centile for gestation) and therefore 
were not euthyroid. The cause of discrepancy in results possibly could be due to the 
fact that the study by Pop et al., 1999 examined the offspring at 10 months of age 




We have shown above the association between clinical hypothyroidism with adverse 
pregnancy outcome. These adverse outcomes could be the result of the deficiency of 
thyroid hormones or could be the result of increased prevalence of anti-thyroid 
antibodies in these conditions. The prevalence of these antibodies are also higher in 
infertile women (Poppe and Velkeniers 2003a). A meta-analysis performed to establish 
whether anti-thyroid antibodies are associated with various adverse pregnancy 
outcomes (van den Boogaard et al., 2011) found women that were anti-thyroid 







2.0; Figure 1.5). However, no association was found between the presence of thyroid 
antibodies and the clinical pregnancy rates after IVF (OR 0.67, 95% CI 0.36-1.4). 
Studies are now examining whether anti-thyroid antibody positive euthyroid women 
who managed to get pregnant are at risk of developing adverse pregnancy outcomes. 
 
The first study that linked thyroid autoantibodies to risk of miscarriage showed that in 
552 women who presented in the first trimester of pregnancy, there was an increased 
risk of miscarriage in those with either anti-TPO and anti-TG antibody positivity 
(Stagnaro-Green et al., 1990). The rate of miscarriage is 8.4% in the antibody negative 
women and 17% in the antibody positive women. They also showed that thyroid 
hormone levels are not associated with the rate of miscarriage. Glinoer et al., 1994 
also showed that euthyroid women with positive anti-thyroid antibodies had and 
increased risk of miscarriages (7% vs 3.3%) however due to small numbers this was 
not statistically significant. Important to note is that the rate of premature delivers 
doubled (16% vs 8%, p<0.005) although the level of anti-thyroid antibodies decreased 
during pregnancy by an average of 60% (Glinoer et al., 1994). However this group did 
not use gestation specific normal range of TSH, the upper limit of normal TSH was 4 
mU/L. There results reaffirmed their previous results published in 1991, which 
demonstrated that euthyroid patients with positive anti-thyroid antibodies had an 
increased risk of miscarriage (13.3% vs 3.3%, p< 0.001) (Glinoer et al., 1991). 
Thereafter numerous studies looked at pregnancy loss and preterm delivery in anti-
thyroid antibody positive women examining specific groups such as those experiencing 
recurrent pregnancy loss and undergoing assisted conception. 
 
A summary of the literature concerning anti-thyroid antibodies and miscarriage rate 
was shown and a meta-analysis performed of both case-controlled and longitudinal 
studies from 1990 to 2003 (Prummel et al., 2004, Table 1.2). They found a clear 
association between anti-thyroid antibodies and miscarriage (OR 2.73, 95% CI 2.2-3.4 
in case-control studies; OR 2.30; 95% CI, 1.80–2.95 in longitudinal studies). Some 
possible explanations for this include, the fact that there is a heightened autoimmune 
state rejecting the fetal allograft, or the fact that these antibody positive women were 
slightly older (mean age difference 0.7 +/-1.0 years, p<0.001) or due to thyroid failure 





and higher TSH levels in the antibody positive but euthyroid women (difference 0.81 
+/-0.58, p=0.005).   
 
 
Table 1.2. Meta-analysis of prospective studies analyzing abortion rates among 
women with antithyroid antibodies versus women without antibodies. 
 
Author 
Abortion rate  
OR (95% CI) 
Antibody negative Antibody positive 
Stagnaro-Green et al. 1990 17/100(17 %) 33/392 (8 %) 2.23 (1.19–4.20) 
Glinoer et al. 1991 6/45 (13 %) 20/603 (3 %) 4.48 (1.70–11.81) 
Lejeune et al. 1993 5/23 (22 %) 16/340 (5 %) 5.63 (1.82–17.1) 
Pratt et al. 1993 8/13 (62 %) 12/42 (29 %) 10.0 (2.20–46.5) 
Singh et al. 1995 28/87 (32 %) 49/301 (16 %) 2.44 (1.42–4.20) 
Iijama et al. 1997 13/125 (10 %) 52/951 (5 %) 2.01 (1.06–3.80) 
Kim et al. 1998 4/10 (40 %) 4/35 (11 %) 5.17 (2.72–26.54 
Muller et al. 1999 4/12 (33 %) 8/42 (19 %) 2.13 (0.51–8.87) 
Rushworth et al. 2000 10/24 (42 %) 30/77 (39 %) 1.12 (0.44–2.84) 
Poppe et al. 2003b 9/17 (53 %) 20/87 (23 %) 3.77 (1.34–10.63) 
Total 104/456 (23%) 336/2957 (11%) 2.30 (1.80-2.95) 
 
OR = odds ratio, CI = confidence interval 
 
 
A meta-analysis of subfertile women undergoing IVF, included 4 prospective studies on 
1098 women, showed that anti-thyroid antibodies is associated with a significantly 
higher rate of miscarriage (RR 1.99, 95% CI 1.42-2.79, P<0.001) (Toulis et al., 2010). 
 
Data concerning effect of anti-thyroid antibodies on preterm delivery rate is not 
consistent. A study involving 1179 Japanese women, (lljima et al., 1997) showed that 
women who were anti-TPO or anti-TG positive had similar preterm delivery rates to 
those women who were anti-thyroid antibody negative (4%, 3.1% and 3% respectively) 
however birth weight to women who were anti-TPO antibody positive was significantly 
lower than those who were antibody negative (3021 vs 3110g, p<0.05). In contrast, a 
study conducted on 1500 euthyroid Pakistani women (Ghafoor et al., 2006), showed 
that anti-TPO positivity is associated with a higher preterm delivery rate (26.8 vs 8.0%, 
p<0.01). A large population-based study of 10,990 women, found that anti-thyroid 










that these antibodies maybe a marker for an inflammatory process making women 
susceptible to this complication. However only 9,981 women from the 10,990 were 
euthyroid (Cleary-Goldman 2008). An uncontrolled case series showed that 
autoimmune thyroid disease is associated with preterm delivery (Stagnaro-Green 
2009).  
 
A recent meta-analysis examined the affect of anti-thyroid antibodies on the rate of 
miscarriage and preterm birth (Thangaratinam et al., 2011). This meta-analysis 
included 30 articles with 31 studies (19 cohort and 12 case-control) involving 12,126 
women examined the association between thyroid autoantibodies and miscarriage and 
5 studies with 12 566 women evaluated the association with preterm birth. Analysis of 
the cohort studies showed a >3 fold increase in the OR of miscarriage in the antibody 
positive women (OR 3.90, 95% CI 2.48-6.12; p<0.001). In the case-control studies, the 
OR for miscarriage was 1.80 (95% CI 1.25-2.60; p=0.002). There was a significant 
doubling in the odds of preterm birth with the presence of thyroid autoantibodies (OR 
2.07, 95% CI 1.17-3.68; P=0.01). The mean concentration of serum TSH was 
significantly higher in the antibody positive group with pregnancy loss than the antibody 
negative group (by 0.51 mIU/L, p=0.007). They concluded that the presence of 
maternal thyroid autoantibodies is strongly associated with miscarriage and preterm 
delivery (Thangaratinam et al., 2011).  Another meta-analysis published the same year 
(Negro 2011), selected 23,000 patients showed an association between thyroid 
autoimmunity and preterm delivery (OR 1.67, 95% CI 1.44-1.94, P<0.001). A recent 
study, also showed that euthyroid women positive for thyroid antibodies were at 
increased risk of spontaneous preterm birth < 37 weeks gestation (RR 1.7, 95% CI 
1.1-2.8) (Karakosta et al., 2012) however there was no increased risk of SGA < 10
th
 
centile for GA, including and excluding the preterm births (RR 0.9 and 1.1 
respectively). 
 
A meta-analysis of 11 prospective cohort studies involving 35,467 women found the 
relative risk of preterm delivery compared to the reference group to be 1.41 (95% CI 
1.08-1.84, p=0.011, Figure 1.4). However, on subgroup analysis anti-TPO antibodies 
was associated with a relative risk of 1.69 (95% CI 1.19-2.41, p=0.003) whereas anti-





TG was not associated with an increased risk of preterm delivery (RR 0.88, 95% CI 
0.60-1.29, p=0.513) (He et al., 2012).  
 
There is very little evidence linking thyroid autoimmunity and PE. A Finish study found 
that women who are anti-TPO or anti-TG positive in the 1
st
 trimester of pregnancy were 
not more likely to develop PE (1.9% vs 2.2% and 1.1% respectively) (Mannisto et al., 
2010) and similar results were found in a Greek study were euthyroid antibody positive 
women were in fact less likely to develop gestational hypertension and preeclampsia 




Figure 1.4. Forest plot showing the association between thyroid antibodies and risk of preterm 






A summary of 12 studies reporting on 966 thyroid antibody positive patients and 7331 
controls, demonstrated an increased risk of subfertility (Figure 1.5) and miscarriage in 
patients with thyroid antibodies (OR 3.7, 95% CI 1.8-7.6; Figure 1.6). There was no 
evidence from 5 studies of an increased risk of miscarriage in IVF pregnancies (OR 
1.6, 95% CI 0.76-3.5). However, patients with recurrent miscarriages more often had 




Figure 1.5. Forest plot of Odds Ratios and 95% Confidence Interval of pooled studies 
comparing euthyroid thyroid antibody positive patients with euthyroid antibody negative controls 





Figure 1.6. Forest plot of Odds Ratio’s and 95% Confidence Interval of pooled studies 
comparing euthyroid thyroid antibody positive patients with euthyroid antibody negative controls 
according to the risk of miscarriage (van den Boogaard et al., 2011). 





There was no association with pregnancy-induced hypertension or PE (OR 1.4, 95% 
CI 0.42-4.8). This meta-analysis showed an increased risk of preterm delivery (OR 1.9, 




Figure 1.7. Forest plot of Odds Ratio’s and 95% Confidence Interval of pooled studies 
comparing euthyroid thyroid antibody positive patients with euthyroid antibody negative controls 




Figure 1.8. Forest plot of Odds Ratio’s and 95% Confidence Interval of pooled studies 
comparing (a) patients with subclinical hypothyroidism with euthyroid controls and (b) euthyroid 
thyroid antibody positive patients with euthyroid antibody negative controls according to the risk 







Effects of treatment 
 
In a prospective study of 1074 euthyroid women divided into 3 groups at the first 
antenatal visit, the anti-TPO positive given LT4, the untreated anti-TPO positive and 
the anti-TPO negative. This study confirmed that women who were anti-TPO positive 
had higher TSH (1.7 vs 1.1mIU/L; p<0.05), higher miscarriage rate (13.8 vs 2.4%; 
p<0.01) and higher prematurity rate (22.4 vs 8.2%; p<0.01) than the control group. The 
LT4 treated group compared to the untreated group had lower TSH and higher T4 
levels, lower miscarriage rate (3.5% vs 13.8%; p<0.05) and lower premature delivery 
rate of <37 weeks gestation (7%vs 22.4%; p<0.05) (Negro et al., 2006). It is accepted 
by the authors that the reduced miscarriage rate is not due to LT4 as most 
miscarriages occurred in the first trimester before treatment was started. The same 
group also showed that levothyroxine was not beneficial in a group of women 
undergoing assisted conception (Negro et al., 2005). However, TSH was not measured 
in this study and therefore euthyroidism can not be confirmed. Autoimmunity in infertile 
women is possibly a larger factor in abnormal fertilization, implantation, and placental 
development, therefore LT4 treatment alone may not be sufficient to improve 
outcomes. A meta-analysis of both these studies showed a significant reduction in 
miscarriages using levothyroxine by 52% (OR O.48, 95% CI 0.25-0.92,p=0.03) 
(Thangaratinam et al., 2011). This group recommends the use of LT4 in women who 
have a TSH level > 2 mIU/liter and/or a high titer of anti-thyroid antibodies.  
 
A retrospective study in a unit which routinely screens for thyroid dysfunction in 
pregnancy and treats women with 50 µg of LT4 if TSH >1 mU/L and anti-TPO is 
positive in the first-trimester showed that 49 women on treatment aiming for TSH level 
between 1-2 mU/L had a reduced rate of first-trimester miscarriage compared to the 
non-treated group (16.1% vs 0, p=0.02), however there was no difference in the rate of 
PE, preterm delivery or placental abruption. This study supports universal screening 
and treatment of autoimmune thyroid disease in pregnancy (Lepoutre et al., 2012). 
 
A prospective randomised placebo-controlled study on the use of selenium in anti-TPO 
positive women to prevent postpartum thyroiditis showed a reduction in the risk of 





PPTD (28.6 vs.48.6%, p<0.01) on selenomethionine 200 µg/day starting after 12 
weeks gestation. It seemed to have exerted an anti-inflammatory activity on the thyroid 
gland (Negro et al., 2007b). 
 
 
1.4 SUBCLINICAL HYPOTHYROIDISM 
 
Subclinical hypothyroidism, defined as serum TSH above the upper limit of trimester 
specific reference range with normal serum FT4, is the first sign of mild thyroid 
dysfunction. Women who are anti-thyroid antibody positive are at increased risk of 
subclinical thyroid dysfunction. The prevalence of subclinical hypothyroidism in 
pregnancy is about 2.4% (Klein et al., 1991; Glinoer et al., 1995). Subclinical thyroid 
disease during pregnancy increases the risk of progression into overt thyroid disease 
20 years later (Mannisto et al., 2010). 
 
The endocrine society clinical practice guideline (De Groot et al., 2012), recommends 
treatment of subclinical hypothyroidism who are anti-TPO positive as the potential 
benefits outweigh the potential risk. They state that the evidence for improved obstetric 
outcome is fair level B and for neurological outcome is poor level I. The panel also 
recommends treatment of subclinical hypothyroidism who are anti-TPO negative and the 
evidence for improved obstetric outcome is fair level C and for improved neurological 
outcome is poor level I (De Groot et al., 2012).  
 
 
1.4.1. Adverse pregnancy outcomes 
 
The evidence for overt hypothyroidism causing adverse pregnancy outcomes led us to 
investigate whether subclinical hypothyroidism is also associated with these outcomes. 
Subclinical hypothyroidism was also shown to be associated with infertility and 
hyperprolactinaemia though the evidence is not consistent (Rodondi et al., 2006; 






An early report of 12 pregnancies with subclinical hypothyroidism (TSH> 10 mIU/mL 
and T4 >4.5 µg/dL, nonpregnant range used) (Davis et al., 1988), were at high risk of 
developing PE (17%, 2/12) and have birth weight <2500g (3/12, 2 were growth 
restricted and 1 was delivered preterm/diabetic). One case miscarried at 13 weeks, 
there was no spontaneous preterm labour (Davis et al., 1988).    
 
A prospective trial examining fetal loss in 4123 women who are anti-TPO antibody 
negative with either TSH levels between 2.5 and 5.0 in the 1
st
 trimester or with TSH 
<2.5 and are not hyperthyroid (TSH undetectable and raised FT4) (Negro et al., 
2010b). Women with TSH between 2.5-5.0 had a higher fetal loss rate which included 
miscarriages and stillbirths (6.1 vs 3.6%, p=0.006). However there was no difference in 
the preterm delivery rate before 34 and 37 weeks between the 2 groups (Negro et al., 
2010b). Another study demonstrated the association between fetal loss and TSH levels 
in a cohort of 2497 women (Benhadi et al., 2009). The incidence of fetal loss 
(miscarriages and stillbirths) increases 60% for every doubling in TSH levels (OR 1.6, 
95% CI 1.04-2.47), this strong association was not seen with FT4 serum levels. 
Patients with overt disease were excluded from this study (TSH reference range used 
0.34-5.60 mU/L and FT4 7.5-21.1 pmol/l) (Benhadi et al., 2009). 
 
Subclinical thyroid dysfunction and its association with PE was investigated after 
several case-control studies reported that in patients presenting with the clinical 
features of PE in the third trimester, thyroid function is disturbed with increase in 
maternal serum thyroid stimulating hormone (TSH) and decrease in the levels of 
thyroid hormones (Lao et al., 1988, 1990; Basbug et al., 1999; Khaliq et al., 1999; 
Larijani et al., 2004) or an increase in TSH and normal FT3/FT4 (Kumar et al., 2005). 
Some showed a correlation between TSH and severity of PE (Basbug et al., 1999) and 
in severe cases although the total thyroid hormones levels are lower, the free fraction 
is higher than in controls (Larijani et al., 2004). 
 
A prospective study of 45 women with subclinical hypothyroidism (TSH> 5 mU/ml and 
FT4 between 4.5-13.2, normal range of nonpregnant population) showed an increased 
risk of PE and gestational hypertension, with 15% developing either (vs 7.6% in the 





general population, p<0.01). They were also more likely to deliver infants <2500g (9 vs 
6.8%). The increased prematurity rate was due to induction of labour for gestational 
hypertension (Leung et al., 1993). There was no increase in spontaneous preterm 
labour. 
 
A large population based screening study of 9403 women where TSH was measured 
in the second trimester, defined thyroid deficiency as TSH >6 mU/l  and if so the FT4 
serum measurement was done. This group included both subclinical and overt 
hypothyroidism (the group with TSH 6-9.9 mU/l had a mean FT4 of 11.0 pmol/l and the 
group with TSH >10 mU/l had a mean FT4 of 9.6 pmol/l). The prevalence of TSH >6 
mU/l was 2.2% and > 10 mU/l was 0.4%. The rate of fetal death was significantly 
higher those with TSH >6 mU/l compared to those with TSH <6 mU/l (3.8% vs 0.9%, 
OR 4.4, 95% CI 1.9-9.5), these fetal deaths all occurred after 16-18 weeks. The 
prevalence of antithyroid antibodies however was higher in the thyroid deficiency group 
and so the association can not be attributed to either marker (9% vs 60%, p<0.001). 
However, the risk of the other adverse outcomes was not increased. There was no 
significant difference in mean gestational age at delivery, birth weight and pregnancy 
induced hypertension (Allan et al., 2000). 
 
In a large study of 17,298 patients who attended for prenatal care at or before 20 
weeks gestation, were screened for thyroid dysfunction (Casey et al., 2005) and 404 
were found (2.3%) to have subclinical hypothyroidism (TSH>97.5
th 
centile for 
gestational age and FT4 >0.680 ng/dL). They compared the pregnancy outcome of 




 centile. Placental abruption 
and preterm delivery (birth at or before 34 weeks) were increased in the women with 
subclinical hypothyroidism (RR 3.0, 95% CI 1.1-8.2 for abruption and RR 1.8, 95% CI 
1.1-2.9 for preterm delivery), however risk of developing gestational hypertension or 
PE was not increased. The increased risk of prematurity was still present even when 
excluding women with TSH >10mU/L. The rate of neonates delivered <2500g was not 
increased in those with subclinical hypothyroidism, however the rate admission to 
intensive care and respiratory distress was twice as high (RR 1.8, 95% CI 1.1-2.9 and 





was the same in both groups. The authors speculate that prematurity may be the link 
between  
 
decreased neurodevelopment in women with subclinical hypothyroidism during 
pregnancy. In this study unlike Allan et al., women who had low FT4 were excluded. 
 
However, a screening study involving 10,990 women reported that subclinical 
hypothyroidism (TSH >97.5
th




 centile for 
gestational age) in both the 1
st
 and the 2
nd
 trimester was not associated with increased 
risk for subsequent development of PE, miscarriage, preterm labour, preterm PROM 
and birth weight <2,500g (Cleary-Goldman et al., 2008). Another study found that in 
5505 women with subclinical hypothyroidism (TSH >95
TH
 centile corrected for 
gestation) in the 1
st
 trimester of pregnancy were at significant risk of developing 
chronic hypertension and thyroid disease later on, however there was no significant 
increase in risk of PE (though risk was higher 3.8 vs 1.9%) (Mannisto et al., 2010). 
Similar results were demonstrated in a study in Greece, women with subclinical 
hypothyroidism (TSH above reference range corrected for gestational age) were not at 
an increased risk of developing gestational hypertension and PE (RR 1.1, 95% CI 0.3-
4.1) (Karakosta et al., 2012), spontaneous preterm birth (RR 0.3, 95% CI 0.1-2.4) or 
brith weight <10
th
 centile for gestation age (RR 1.5, 95% CI 0.5-4.4). 
 
Another recent population based study of 24,883 women, examined the rate of 
pregnancy hypertension (includes gestational hypertension, mild PE or severe PE) in 
women who were subclinically hyperthyroid, euthyroid and subclinically hypothyroid 
using the normal range of TSH as 0.03-4.13 mU/L (Wilson et al., 2012). Patients with 
overt disease were excluded from the study (normal range FT4 0.9-2.0 ng/dL). The 
incidence of hypertension in pregnancy was 6.2%, 8.5% and 10.9% in the subclinical 
hyperthyroid, euthyroid and subclinical hypothyroid groups respectively (p=0.016). 
There was a significant association between subclinical hypothyroidism and severe PE 
(OR 1.6, 95% CI 1.1-2.4; p=0.03). 
 
A meta-analysis was performed to establish whether subclinical thyroid function is 
significantly associated with adverse pregnancy outcome (van den Boogaard et al., 





2011). They showed an increases risk of unexplained subfertility (OR 4.0, 95% CI 1.7-
9.8). There was no association with pregnancy-induced hypertension however there 
was a significantly increased risk of PE (OR 1.7, 95% CI 1.1-2.6). There was no 
association with preterm delivery (OR 1.0, 95% CI 0.59-1.8) (Figure x) or birth weight 
<2500g (OR 0.93, 95% CI 0.46-1.9). 
 
 
Nerurodevelopmental delay  
 
 
The only study on biochemically confirmed subclinical hypothyroid patients patients 
and neurodevelopmental delay was a done by group from China, they measured 
serum TSH, FT4 and anti-TPO antibodies in 1268 pregnant women at 16-20 weeks 
gestation (Li et al., 2010). Patients with subclinical hypothyroidism (pregnancy specific 
reference ranges) had 8.88 lower mean intelligence scores (p=0.008) and 9.98 lower 
mean motor scores (p<0.001). Using a multivariate logistic regression analysis they 
found an independent effect of increased serum TSH and anti-TPO antibodies on 




1.4.2 Effect of treatment 
 
The benefits of levothyroixne in women with subclinical thyroid dysfunction, has so far 
been examined only in infertile women, some undergoing ART (Velkeniers et al., 2013; 
Kim et al., 2011). 
 
A randomised prospective case-control study of 64 infertile women with subclinical 
hypothyroidism biochemically and clinically, with TSH > 4.5 mIU/L and mean FT4 was 
1.2 + 0.2 SD were randomised to either LT4 treatment or no treatment (Kim et al., 2011). 
The treatment group were given 50 µg of levothyroxine and they had a higher clinical 
pregnancy rate but did not reach statistical significance, the embryo implantation rate 
was also higher (p= 0.044), there were no miscarriages in the treatment group (0 vs 





The anti-thyroid antibody levels were similar between the pregnant and non pregnant 
groups in the treatment and control group, however the levels were higher in those that 
miscarried in the control group.  
 
 
A meta-analysis of current evidence for subclinical hypothyroidism did not find sufficient 
evidence to advocate for levothyroxine treatment (Vissenberg et al., 2012) however 
another published meta-analysis of the benefits of levothyroxine in women with 
subclinical hypothyroidism undergoing ART (Velkeniers et al., 2013), demonstrated a 
higher delivery rate (RR2.76, 95% CI 1.2-6.44, p=0.018), significantly lowered 
miscarriage rate (RR 0.45, 95% CI 0.24-0.82, p=0.01). There was no available data for 
its use for premature delivery and PE in the ART patients. 
 
1.5 MATERNAL THYROID FUNCTION AND PREGNANCY COMPLICATIONS 
 
1.5.1 Normal pregnancy 
 
Reference ranges derived from non-pregnant individuals are inappropriate because 
pregnancy is associated with profound changes affecting thyroid function. Human 
chorionic gonadotrophin (hCG), whose levels increase during the first 10 weeks of 
pregnancy and subsequently decrease, has thyrotropic properties causing an increase 
in serum T4 and decrease in TSH (Yoshimura and Hershman, 1995). The 
concentration of thyroid binding globulins increases with gestation as a result of 
estrogen stimulation and therefore measurement of the total amount of thyroid 
hormones does not provide an accurate reflection of active free (F) fraction of these 
hormones (Ain et al., 1987; Glinoer, 1997).  
 
Several studies reported reference ranges of thyroid function in early pregnancy (Table 
1.3). However, these studies examined a small number of patients, or the gestational 
range was wide, maternal history of thyroid disease was not recorded, anti-thyroid 
antibodies were either not measured or patients with such antibodies were not 
excluded, or they did not examine serum TSH with both FT3 and FT4 (Smith and Bold 
1983; Chan and Swaminathan, 1988; Leylek et al., 1996; Panesar et al., 2001; Haddow 





et al., 2004; Kurioka et al., 2005; Dashe et al., 2005; Stricker et al., 2007; Casey et al., 
2007; Cotzias et al., 2008; Lambert-Messerlian et al., 2008; Gilbert et al., 2008; 
McElduff et al., 2008; Marwaha et al., 2008; Pearce et al., 2008). 
 
 
1.5.2 Pregnancy in women with hypothyroidism treated with thyroxine 
 
Pregnancy is associated with an approximate 50% increase in demand for thyroid 
hormones which is apparent within the first 16 weeks of gestation (Alexander et al., 
2004). This increase is mainly attributed to the estrogen-driven doubling in thyroxine-
binding globulin concentrations (Glinoer et al., 1990).  
 
In women with pre-existing hypothyroidism treated with levothyroxine the increased 
demands for thyroid hormones in pregnancy should be met by increasing the dose of 
the drug (Alexander et al., 2004; McDougall and Maclin, 1995). Nevertheless, several 
studies have documented that in the first-trimester of pregnancy 30-50% of such 
women may be inadequately treated during this critical period for fetal development 
when the fetal brain is entirely dependent on maternal thyroid hormones (Hallengren et 
al., 2009; McClain et al., 2008; Morreale de Escobar et al., 2000; Contempre et al., 
1993; Burrow et al., 1994). 
 
The evidence for inadequate therapy is based on the biochemical finding of high serum 
thyroid stimulating hormone (TSH) in the presence of normal free thyroxine (FT4) 
(Alexander et al., 2004). However, assessment of thyroid function by TSH and FT4 
alone may be insufficient because it is free tri-iodothyronine (FT3) which is ultimately 
responsible for the control of both metabolic activity and regulation of TSH production 
(Fish et al., 1987).  
 
Under normal circumstances the daily relative production of T3 to T4 by the thyroid 
gland is about 1:9. While the whole source of circulating T4 is the thyroid gland, 80% 
of circulating T3 is derived from peripheral deiodination of T4 (Izumi and Larsen, 1977; 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































exogenous administration of levothyroxine normalization of the serum levels of T4 
would not adequately address the deficiency in the production of T3 by the thyroid 
gland.  
 
Whatever the dose of levothyroxine the serum T4 to T3 ratio will always be elevated 
(Fish et al., 1987; Hennemann et al., 2004). In patients undergoing total thyroidectomy, 
the dose of levothyroxine needed to maintain serum T3 at its normal endogenous pre-
thyroidectomy level results in elevated serum FT4 concentration (Jonklaas et al., 
2008). The symptoms of hypothyroidism in patients treated with levothyroxine are 
abolished only with a dose resulting in supernormal FT4 and subnormal TSH (Toft and 
Beckett, 2003; Saravanan et al., 2002). These results may essentially indicate that 
levothyroxine treatment is successful only when there is normalization of FT3.  
 
1.5.3 Thyroid function in pregnancies resulting in fetal death 
 
Clinical hypothyroidism is associated with subfertility and in those women who conceive 
there is a high risk of miscarriage (60%) and fetal death (Abalovich et al., 2002; 
Glinoer, 1997). A study examining the outcome of pregnancies in women with primary 
hypothyroidism reported that the rate of miscarriage in 16 cases with overt 
hypothyroidism was 60% whereas in 99 women made euthyroid with adequate 
thyroxine treatment there were no miscarriages (Abalovich et al., 2002).
 
In another 
study of 29 pregnant women with overt hypothyroidism the rate of fetal death during 
the second and third trimesters was nine times higher than in 552 euthyroid women 
(Sahu et al., 2010). 
 
In subclinical hypothyroidism, there is contradictory evidence as to whether the rate of 
fetal death is increased or not. A prospective study of 63 pregnant women with 
hypothyroidism on thyroxine replacement reported that the rate of fetal loss at 7-20 
weeks was significantly higher in women with TSH above 4 mU/L than in those with 
TSH at or below 4 mU/L (26.3% vs 6.3%) (Hallengren et al., 2009). Another study 





screening for neural tube and chromosomal defects and reported that the rate of fetal 
death between the time of enrolment and term was significantly higher in women with 
TSH at or above 6 mU/l than in those with TSH below 6 mU/L (3.8% vs 0.9%) (Allan et 
al.,2000).  
 
Two other studies reported a lack of association between subclinical hypothyroidism 
and fetal death. Casey et al, assessed thyroid function in all pregnant women attending 
for routine care in their hospital at or before 20 weeks of gestation (Casey et al., 2005). 
The rate of fetal death between enrolment and delivery was 0.5% in both those with 
TSH at or above the 97.5th percentile and FT4 within the normal range and in those 




 percentiles. Cleary-Goldman et al, assessed 
thyroid function in women undergoing screening for chromosomal defects at 11-13 
weeks (Cleary-Goldman et al., 2008). There were no significant differences in the rates 
of miscarriage before 24 weeks and perinatal death between women with serum TSH 




 percentiles and those TSH at or above the 97.5th 
percentile and FT4 in the normal range (0.4% vs 0.6% and 0% vs 0.3% respectively). 
Possible explanations for the contradictory results of the above studies are firstly, the 
small number of fetal losses in the cases with thyroid deficiency, with only a total of 16 
such losses in the four studies (Hallengren et al., 2009; Allan et al., 2000; Casey et al., 
2005; Cleary-Goldman et al., 2008) and secondly, the timing of thyroid screening in the 
late first trimester or the second trimester when the majority of pregnancy losses had 
already occurred. 
 
There is also controversy as to whether any possible association between subclinical 
hypothyroidism and fetal death is the direct consequence of the metabolic 
derangement or it is mediated by the coexistence of antithyroid antibodies (Stagnaro-
Green and Glinoer 2004; Negro et al., 2007a; Negro et al., 2006). Studies in the first-
trimester reported that the risk of early miscarriage was 2-4 times higher in antithyroid 
antibody-positive compared to antibody-negative women (Stagnaro-Green and Glinoer 
2004). Antithyroid antibodies may exert a direct adverse effect on the pregnancy, they 
may serve as a marker for other autoimmune conditions which cause fetal death, 
women with thyroid autoimmunity may be euthyroid before pregnancy but develop 
subclinical or overt hypothyroidism during the first-trimester or such women suffer 





subfertility and become pregnant at an older age which in itself is associated with 
increased risk of fetal loss. 
 
1.5.4 Thyroid function in pregnancies that develop preeclampsia 
 
Preeclampsia (PE), which affects about 2% of pregnancies, is a major cause of 
maternal and perinatal morbidity and mortality (WHO, 2005; Lewis, 2007; CEMACH, 
2008; Witlin et al., 2000; Irgens et al., 2001). Recent evidence suggests that PE can 
be divided into early-PE requiring delivery before 34 weeks and late-PE with the former 
being associated with a high incidence of fetal growth restriction, whereas in late-PE 
fetal growth is usually normal (Yu et al., 2008). The underlying mechanism for the 
development of PE is thought to be impaired trophoblastic invasion of the maternal 
spiral arteries and their conversion from narrow muscular vessels to wide non-
muscular channels independent of maternal vasomotor control (Brosens et al., 1967; 
Khong et al., 1986; Pijnenborg, 1996). Indirect evidence for impaired placental 
perfusion in pregnancies destined to develop PE has been provided by Doppler studies 
of the uterine arteries which showed increased pulsatility index (PI) which is evident 
from 11-13 weeks of gestation and this increase is particularly marked for early-PE 
(Martin et al., 2001; Plasencia et al., 2007; Poon et al., 2009). Effective first-trimester 
screening for both early-PE and late-PE is provided by a combination of maternal 
demographic characteristics and medical history, uterine artery PI and maternal mean 
arterial pressure (MAP) (Poon et al.,2009).
 
 
Several studies have reported than in patients presenting with the clinical features of 
PE, thyroid function is disturbed with increase in maternal serum thyroid stimulating 
hormone (TSH) and decrease in the levels of thyroid hormones (Lao et al., 1988; Lao 
et al., 1990; Khaliq et al., 1999; Basbug et al., 1999; Larijani et al., 2004; Kumar et al., 
2005). The results of a population based study in which serum TSH was measured in 
women on average 20 years after their first pregnancy highlighted further the 
interrelation between hypothyroidism and PE (Levine et al., 2009b). Women who had 
PE in their first pregnancy were 1.7 times as likely to have increased serum TSH than 





pregnancies had a 5-7 fold increased likelihood for having high TSH. It was postulated 
that the effect of PE on thyroid function during and after pregnancy is mediated by the 
antiangiogenic factor soluble fms-like tyrosine kinase 1 (sFlt-1) which is elevated in 
patients with PE (Levine et al., 2009b). Patients with cancer treated with vascular 
endothelial growth factor inhibitors are at increased risk of developing hypothyroidism 
(Desai et al., 2006; Wolter et al., 2008; Feldman et al., 2009). Studies in mice have 
shown that the administration of sFlt-1 causes a major reduction in thyroid tissue 
capillary density and increased concentrations of TSH (Kamba and McDonald, 2007; 
Kamba et al., 2006). However, the suggestion that PE causes hypothyroidism is at 
least in part contradicted by the finding that women with hypothyroidism have an 
increased risk of developing PE (Echt and Doss, 1963; Davis et al., 1988; Leung et al., 
1993). Consequently, an alternative explanation for the findings of Levine et al, (Levine 
et al., 2009b) is that subclinical hypothyroidism may predispose to the development of 
PE, rather than the other way round. However, a first-trimester screening study 
reported that thyroid hypofunction in early pregnancy was not associated with 
increased risk for subsequent development of PE (Cleary-Goldman et al., 2008). 
 
 
1.5.5 Thyroid function in pregnancies delivering small for gestational age 
neonates 
 
Small-for-gestational age (SGA) neonates, with birth weight below the 5
th
 percentile, 
are at increased risk of perinatal death and handicap. The condition is heterogeneous 
and includes constitutionally small neonates and growth restricted ones due to 
impaired placentation, genetic disease or environmental damage. In normal pregnancy 
the spiral arteries in the placental bed are invaded by trophoblast, which becomes 
incorporated into the vessel wall and replaces the endothelium, muscular layer and 
neural tissue. These physiological changes convert the spiral arteries from narrow 









Impaired trophoblastic invasion and placentation is thought to be the underlying 
mechanism for many cases of preeclampsia (PE) and of impaired fetal growth in the 
absence of PE (Sheppard and Bonnar, 1981; Khong et al., 1986; Pijnenborg et al., 
2006; Brosens et al., 2011). Abnormal placentation is reflected in increased impedance 
to flow in the uterine arteries at 11-13 weeks gestation both in pregnancies that 
subsequently develop PE and to a lesser extent in those delivering SGA neonates in 
the absence of PE (Plasencia et al., 2008; Karagiannis et al., 2011). 
 
The mechanism underlying trophoblast proliferation and invasion is largely unknown 
but there is some evidence implicating thyroid hormones in this process. In-vitro 
studies reported that thyroid hormones receptors are expressed in extravillous human 
trophoblast and thyroid hormones upregulate proliferation and the invasive potential of 
this trophoblast (Barber et al., 2005; Oki et al., 2004). Addition of thyroid hormones to 
an organ culture system of human placental tissue from early pregnancy stimulated the 
production of several placental hormones, including progesterone, human chorionic 
gonadotrophin and estradiol (Maruo et al., 1991). 
 
There is also contradictory evidence that clinical and subclinical hypothyroidism is 
associated with increased risk for both PE and the birth of SGA neonates in the 
absence of PE (Leung et al., 1993; Levine et al., 2009b; Sahu et al., 2010; Blazer et 
al., 2003; Casey et al., 2007; Allan et al., 2000). In a previous study, we reported that 
in pregnancies that develop PE maternal serum TSH at 11-13 weeks’ gestation was 
higher and FT4 was lower than in normotensive controls (Chapter 6). 
 
 
1.5.6 Thyroid function in pregnancies resulting in spontaneous preterm 
delivery 
 
Preterm delivery is the main cause of neonatal death and neurological handicap in 
children (CMACE, 2010; Goldenberg et al., 2008; McCormick MC, 1985). 





pregnancy care. Whilst all births before 37 weeks’ gestation are defined as preterm, 
the vast majority of mortality and morbidity relates to early delivery before 34 weeks.  
 
A review of the literature concluded that both subclinical hypothyroidism and 
autoimmune thyroid disease in euthyroid women are associated with preterm delivery 
(Stagnaro-Green 2009). However, two large screening studies investigating the 
possible association between thyroid dysfunction and preterm delivery reported 
contradictory results. The first study measured serum TSH in 17,298 pregnancies 
attending for routine antenatal care before 20 weeks and reported that in the 404 
women with subclinical hypothyroidism, compared to the euthyroid women, there was a 
2-fold increase in risk of delivery before 34 weeks (4.5 vs 2.5%) (Casey et al. 2005). 
The authors speculated that prematurity may be the link between decreased 
neurodevelopment in the children of women with subclinical hypothyroidism during 
pregnancy (Haddow et al. 1999).
 
In contrast, a second study assessed maternal 
thyroid function in 10,990 pregnancies at 10-13 weeks and reported that the rate of 
delivery before 37 weeks in 240 women with subclinical hypothyroidism was not 
significantly different than in euthyroid pregnancies (5.6 vs. 7.2%) (Cleary-Goldman et 
al. 2008). 
 
These contradictory results may be the consequence of differences between the 
studies in the gestational age defining preterm delivery and the proportion of cases 
with iatrogenic rather than spontaneous preterm delivery which was not specified 
(Casey et al. 2005; Cleary-Goldman et al. 2008).
 
 
An additional factor that may account for contradictory results between studies is the 
distribution of maternal characteristics in the study populations. We have shown that in 
establishing references ranges for maternal thyroid function it is necessary to take into 
account certain maternal characteristics, which affect the measured levels of TSH and 
FT4 (Chapter 3). We have also found that in women with anti-thyroid antibodies, 
compared to the antibody negative group, the median TSH was higher and the median 
FT4 was lower and concluded that in establishing normal ranges of thyroid function it is 
necessary to exclude antibody-positive patients.
  
 





1.5.7 Thyroid function in pregnancies with fetal aneuploidies 
 
Human chorionic gonadotrophin (hCG), which has an identical α-subunit and 
structurally similar ß-subunit to those of TSH, has thyrotropic properties and in early 
pregnancy there is an inverse association between maternal serum levels of TSH and 
hCG (Braunstein et al., 1976. Yoshikawa et al., 1989; Glinoer et al., 1990; Ballabio et 
al., 1991; Yoshimura and Hershman, 1995). Free ß-hCG is an established screening 
marker for trisomy 21 and we demonstrated that ß-hCG mRNA correlates with serum 
hCG levels (Banerjee et al., 2005).  
 
In pregnancies with fetal trisomy 21 the maternal serum concentration of free ß-hCG at 
11-13 weeks’ gestation is on average twice as high as in euploid pregnancies, whereas 
in trisomy 18 the levels are one fifth of normal (Macri et al, 1990; Spencer et al., 1999; 
Tul et al., 1999; Kagan et al., 2008a).  
 
It is therefore anticipated than in aneuploid pregnancies the maternal serum 
concentration of TSH would be altered. However, a case control study of 23 
pregnancies with fetal trisomy 21 and 115 with euploid fetuses at 9-11 weeks reported 
that although in the unaffected pregnancies there was a correlation between serum 
hCG and TSH (r=0.21, p=0.02) there was no significant difference between the 
trisomic and euploid pregnancies in either hCG or TSH (Weinans et al., 2001). This 
may be due to the early gestational age at measurement before the peak of serum 
hCG. In this study no corrections were made for maternal characteristics and 
gestational age that are known to affect the measured concentrations of hCG and 
TSH.  
 
Maternal serum free ß-hCG decreases with gestational age and maternal weight, it is 
decreased in cigarette smokers and in parous women and it is increased in women of 








1.6 OBJECTIVES OF THIS THESIS 
 
The aims of this thesis are: 
 
1. To establish reference ranges of serum TSH, FT3 and FT4 at 11-13 weeks’ 
gestation in a large number of singleton pregnancies with no known thyroid disease 
and in the absence of anti-thyroperoxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) 
antibodies and to examine the effect of maternal characteristics and serum anti-TPO, 
anti-Tg and free ß-hCG on the levels of TSH, FT3 and FT4. 
 
2. To examine pregnant women with hypothyroidism treated by levothyroxine and 
investigate the interrelations between FT3, FT4 and TSH to offer a possible 
explanation for the finding of the coincidence of high serum TSH in the presence of 
normal FT4 in such patients. 
 
3. To investigate the possible association between maternal thyroid dysfunction and 
fetal death by comparing serum TSH, FT4, FT3 and antithyroid antibody levels at 11-
13 weeks’ gestation in pregnancies ending in miscarriage or fetal death with those 
resulting in normal live births. 
 
4. To investigate if the prevalence of maternal thyroid hypofunction at 11-13 weeks of 
gestation is higher in pregnancies that subsequently develop PE and if it is whether 
assessment of thyroid function can improve the prediction of PE provided by a 
combination of factors in the maternal history and the measurements of MAP and 
uterine artery PI. 
 
5. To investigate if the prevalence of maternal thyroid hypofunction at 11-13 weeks’ of 
gestation is higher in pregnancies that subsequently delivered SGA neonates in the 
absence of PE.  
 
6. To estimate the possible association between maternal thyroid dysfunction and 
preterm delivery by comparing anti-thyroid antibody positivity and serum TSH and FT4 
levels at 11-13 weeks’ gestation, after appropriate adjustments for maternal 





characteristics, in pregnancies which subsequently resulted in spontaneous delivery 
before 34 weeks with normal pregnancies delivering after this gestation. 
 
7. To examine the association between maternal serum levels of TSH and hCG in 
trisomy 21, trisomy 18 and euploid pregnancies at 11-13 weeks, assess any 
differences in FT4 and FT3 between the three groups and investigate the potential 
value of TSH in first-trimester screening for aneuploidies. 
 
8. To establish a normal range of serum TSH and FT4 in dichorionic and 





















The study population for this thesis was derived from a prospective screening study for 





 weeks’ gestation.  
 
The maternal serum concentrations of FT3, FT4, TSH, anti-TPO and anti-Tg were 
measured by immunoassay using direct, chemiluminometric technology. 
 
Maternal thyroid function was examined in: 
 Singleton pregnancies with normal outcome 
 Singleton pregnancies resulting in miscarriage or fetal death 
 Singleton pregnancies resulting in preeclampsia 
 Singleton pregnancies resulting in spontaneous early preterm delivery 
 Singleton pregnancies resulting in delivery of small for gestational age neonates 
 Singleton pregnancies with fetal aneuploidies 
 Singleton pregnancies with maternal hypothyroidism treated with thyroxine 
 Dichorionic and monochorionic twins 
 
Thyroid function in each pregnancy group was compared to that in singleton 
pregnancies with normal outcome. 
 





2.1 STUDY POPULATION 
 
The study population for this thesis was derived from a prospective screening study for 





 weeks’ gestation.  
 
2.1.1 Screening protocol 
 




 weeks’ gestation, the following steps are carried out. 
First, we record maternal characteristics and medical history, secondly, we measure 
the mean arterial pressure (MAP), thirdly, we perform an ultrasound scan and fourthly, 
we obtain maternal blood. 
 
Maternal history and characteristics 
 
Patients are asked to complete a questionnaire on maternal age, racial origin 
(Caucasian, Afro-Caribbean, South Asian, East Asian and mixed), method of 
conception (spontaneous or assisted conception requiring the use of ovulation drugs), 
cigarette smoking during pregnancy (yes or no), history of any medical condition 
including hypothyroidism or hyperthyroidism (yes or no), any medication including 
thyroxine or antithyroid drugs (yes or no) and obstetric history including parity (parous 
or nulliparous if no previous pregnancies at or after 24 weeks) and previous pregnancy 
with PE (yes or no).  
 
The questionnaire is then reviewed by a doctor together with the patient and the 





Mean arterial pressure 
 
The MAP is measured by automated devices (3BTO-A2, Microlife, Taipei, Taiwan) 
(Poon et al., 2009c). The pressure is measured in both arms simultaneously and a 




series of recordings are made at 1-minute intervals until variations between 
consecutive readings fall within 10 mmHg in systolic blood pressure and 6 mmHg in 
diastolic blood pressure in both arms. When this point of stability is reached we 
calculate the MAP of each arm as the average of the last two stable measurements 




An ultrasound scan is carried out transabdominally and in cases when adequate 
examination is not possible the scan is performed transvaginally. The objectives of the 
scan are: firstly, to confirm gestational age from the measurement of the fetal crown-
rump length (CRL) [Robinson], secondly, to diagnose any major fetal abnormalities 
and thirdly, to measure fetal nuchal translucency thickness (NT) (Snijders et al., 1998). 
Additionally, the uterine artery PI is measured (Poon et al., 2009a). Essentially, 
transabdominal ultrasound and colour flow mapping is used to identify each uterine 
artery, pulsed wave Doppler is performed to measure the PI in the left and right 
arteries and the one with the lowest PI is recorded. 
 
In twin pregnancies gestational age is calculated from the measurement of the fetal 
CRL [13] of the bigger twin. Chorionicity is determined from the presence or absence 
of the lambda sign [14]. 
 
Maternal blood sampling 
 
Maternal blood was collected for measurement of serum free ß-hCG and PAPP-A 
(DELFIA EXPRESS analyzer, PerkinElmer, Waltham, USA) as part of screening for 
chromosomal abnormalities by a combination of fetal NT and serum biochemistry 
(Kagan et al., 2008b).  
 
Additional blood was collected for research and the separated plasma and serum are 
stored at -80
0
C for subsequent biochemical analysis. Written informed consent is 
obtained from the women agreeing to participate in the study, which was approved by 
King’s College Hospital Ethics Committee. 







Data on pregnancy outcome were collected from the hospital maternity records or the 
general medical practitioners of the women. 
 
2.1.2  Study groups 
 
During the study period (March 2006 to December 2006) we screened 4,852 singleton 




 weeks. This population was used for deriving 
normal ranges and identifying subgroups with pregnancy complications. In some of the 
pregnancy complication groups, we identified additional cases from our screened 
population between January 2007 and October 2008. In the selection of the number of 
patients screened, a pragmatic view was undertaken that this number would contain 
sufficient cases of each of the pregnancy complications investigated by the thesis to 




The study group included 4,318 of the 4,852 singleton pregnancies examined between 
March and December 2006. The inclusion criteria were pregnancies with no history of 
thyroid disease, which did not develop preeclampsia and resulted in live birth after 34 
weeks of phenotypically normal neonates with birth weight above the 5
th
 centile (13).  
 
In this group there were 726 (16.8%) pregnancies in which the concentration of one or 
both antithyroid antibodies was 60 U/mL or more. Normal ranges for TSH, FT3 and 





Thyroid function at 11-13 weeks was examined in 164 singleton pregnancies from 




women who reported that they had hypothyroidism before pregnancy and they were 
receiving treatement with thyroxine. 
 
The 164 cases included 69 from the screening study of 4,852 pregnancies between 
March and December 2006 and an additional of 95 cases examined between January 
2007 and October 2008. 
 
Miscarriage or fetal death 
 
Thyroid function at 11-13 weeks was examined in 202 singleton pregnancies that 
subsequently resulted in miscarriage or fetal death.  
 
The 202 cases included 87 from the screening study of 4,852 pregnancies between 
March and December 2006 and an additional of 115 cases examined between January 




Thyroid function at 11-13 weeks was examined in 102 singleton pregnancies with no 
history of thyroid disease, resulting in spontaneous preterm delivery before 34 weeks’ 
gestation of phenotypically normal neonates. The 102 cases included 51 from the 
screening study of 4,852 pregnancies between March and December 2006 and an 




Thyroid function at 11-13 weeks was examined in 102 singleton pregnancies with no 
history of thyroid disease, resulting in preeclampsia. These cases were part of the 
4,852 pregnancies examined between March and December 2006 
 
Small for gestational age 
 
Thyroid function at 11-13 weeks was examined in 212 singleton pregnancies with no 





history of thyroid disease, which did not develop PE and resulted in live birth of 
phenotypically normal neonates with birth weight below the 5th percentile for 
gestational age 
    
The 212 cases included 197 from the screening study of 4,852 pregnancies between 
March and December 2006 and an additional of 15 cases examined between January 




Thyroid function at 11-13 weeks was examined in 30 singleton pregnancies with fetal 
trisomy 21, 25 with fetal trisomy 18 and 2 with paternally derived triploidy. The 
diagnosis of aneuloidy was made by chorionic villus sampling after first-trimester 




The study group included 235 twin pregnancies with no history of thyroid disease, 
which did not develop pre-eclampsia and resulted in live birth at or after 33 weeks of 
phenotypically normal neonates with birth weight above the 5
th
 centile. Additionally, we 
examined 19 cases that developed severe twin-twin-transfusion syndrome (TTTS) 
requiring endoscopic laser surgery [17]. The pregnancies were examined between 
March 2006 and March 2011. 
 
 
2.2 SAMPLE ANALYSIS 
 
The maternal serum concentrations of FT3, FT4, TSH, anti-TPO and anti-Tg were 
measured by immunoassay using direct, chemiluminometric technology (Siemens 
Advia Centaur assays, Siemens Healthcare Diagnostics Ltd, Surrey, UK). 
 
 




Details of TSH assay 
 
The Adiva Centaur TSH assay used is an immunometric or non-competitive third 
generation assay where the analyte is reacted with an excess of labelled antibody as 
illustrated below. It has an improved limit of detection (0.003 mIU/L) compared to the 
first (0.1 mIU/L) and second (0.01 mIU/L) generation assay due to the use of 
antibodies with greater affinity for TSH, this also means using as little sample volume 
as possible (100µL).  
 
The assay used is a sandwich assay with anti-TSH antibodies bound to it on either side 
on different sites and hence it is called non-competitive, this is possible since TSH is a 
large polypeptide analyte relative to the FT4 and FT3 nonpeptide hormones. 
 
              Ab1 +Ag +Ab2*                   Ab1AgAb2* + Ab1 + Ab2* 
                  Initial state                             Final state         
 
Ab1 = capture antibody; Ab2* = labelled antibody; Ag = Analyte (TSH) 
 
The assay components include the reagent which is an acridinium ester (AE) labelled 
monoclonal mouse anti-TSH antibody (Ab2*) and the fluorescein-labelled anti-TSH 
antibody (Ab1) which bind to different sites of the TSH. Once these antibodies are 
added to sample, all the TSH molecules should attach to these antibodies on either 
side forming a ‘sandwich’. Then to remove any unbound AE-labelled antibody a solid 
phase separation method is used, the sample is added to solid phase-bound anti-
Fluorescein antibody which is attached to a magnetic bead and when the magnet is 
turned on the TSH molecules will then attach to the bottom of the tube. Then, 
aspiration of the liquid phase occurs followed by washing the solid phase with buffer 
twice to ensure completeness of separation and to reduce any non-specific binding. 
Then the magnet is turned off to re-suspend the magnetic particles, this is an 
exceptionally rapid and efficient separation method. Then using chemiluminescence of 
the AE label that produces a flash of intense light means you can measure low 
concentrations of TSH due to greater sensitivity and a wider working range. The assay 





is demonstrated in figure 2.1. The signal detected is directly proportional to the 




Figure 2.1. Constituents of the TSH Adiva Centaur assay. Taken from Siemens Healthcare 
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Details of FT4 and FT3 assays 
 
These free hormones are non-peptide hormones were measured by competitive 
immunoassay methods where the analyte in the sample competes with labelled analyte 
for the binding sites on a limited amount of antibody as illustrated below. The 
competition for binding sites must occur by ensuring that the amount of antibody is 
insufficient to bind all the labelled analyte. When equilibrium is reached, the amount of 
labelled analyte bound to the antibody will be inversely related to the amount unlabelled 
analyte in the sample. In determining the label in the bound fraction, this will provide a 
measure of the amount of analyte in the sample by using a calibration curve. 
     
        Ag +Ag* +Ab                          AgAb + Ag*Ab + Ag* 
             Initial state                                  Final state         
 
 
Ag/Ag* = Free hormone/labelled free homone; Ab = antibody 
 
The Advia Centaur FT4 and FT3 assays are one step analogue rapid, simple and high 
through put assays. There is minimal interference from autoantibodies such as the 
Rheumatoid factor and heterophilic antibodies and no serum protein interferences.  
                       
The FT4 Adiva Centaur assay is a competitive labelled analogue assay with a single 
incubation step (figure 2.3). The sample (25µL) is incubated with solid phase-coupled 
rabbit anti-T4 antibody (300µL) and AE-labelled T4 analogue (100µL). The AE-labelled 
T4 analogue is sufficiently similar to FT4 to bind the anti-T4 antibody, but is sufficiently 
dissimilar to prevent binding to serum binding proteins (figure 2.4). The solid phase 
separation method used is a paramagnetic particle attached to antibody and therefore 
a magnetic field and a buffer are used to remove excess labelled-T4.   
 
Once an equilibrium is reached with both FT4 and labelled-T4 competing for the solid 
phase rabbit anti-T4 antibody, the excess unbound labelled-T4 is removed as 
described above. The higher the concentration of FT4 the less labelled-T4 is bound to 





the solid phase rabbit anti-T4 antibody and therefore the less the signal. The graph plot 
between the signal and FT4 concentration has a sigmoid shape and therefore the 
assay is inaccurate at FT4 concentration <1.3  and >50 pmol/L as shown in figure 2.5. 
 
Figure 2.3. Constituents of the FT4 Adiva Centaur assay. Taken from Siemens Healthcare 
Diagnostics, Frimley, Surrey UK.  
 
 
Figure 2.4. This figure demonstrates the competition for binding between the AE-labelled T4 
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Figure 2.5. Graph showing chemiluminescence on y-axis and FT4 in pmol/L on x-axis. 
 
The FT3 Adiva Centaur assay is also competitive assay with a single incubation step. 
The sample is incubated with abundant AE-labelled T3 antibody and the analogue 
diiodothyronine-bovine gamma globulin complex (T2-BGG). The serum FT3 and the 
analogue compete to bind to the AE-labelled antibody. The analogue is coupled to 
magnetic particles in solid-phase, the unbound AE-labelled T3 antibody will therefore 
bind to the analogue with magnetic particles and produce a signal (figure 2.6). This 
assay is also not adversely affected by the presence of abnormal concentrations of 
thyroid binding proteins. 
Solid phase coupled
T2-BGG analogue 
AE- labelled antibodies FT3 in serum
SIGNAL
 
Figure 2.6. Constituents of the FT3 Adiva Centaur assay.  
 
The higher the concentration of FT3 in the serum the lower the amount of analogue 
that binds to the labelled antibody and therefore the lower the signal produced. The 
graph is also sigmoid shaped similar to that of FT4, and therefore this assay is 
inaccurate at measuring FT3 levels <0.3 and >30 pmol/L as shown in figure 2.7.  
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                             0.3                        30      [FT3]           
Figure 2.7. Graph showing chemiluminescence signal on y-axis and FT3 concentration in 
pmol/L on x-axis. 
 
Details of Anti-TPO and anti-TG assays 
 
The ADVIA Centaur anti-TPO assay is also a competitive immunoassay using 
chemiluminescent technology. Autoantibody against thyroid peroxidase in the patient 
sample competes with monoclonal mouse anti-TPO antibody covalently coupled to 
paramagnetic particles in the Solid Phase for a limited amount of human TPO 
complexed with acridinium ester-labeled monoclonal mouse anti-TPO antibody in the 









Figure 2.8. Competitive immunoassay for anti-TPO assay. Taken from Siemens Healthcare 
Diagnostics, Frimley, Surrey UK.  
 




The ADVIA Centaur anti-Tg assay is a competitive immunoassay using direct, 
chemiluminescent technology. Autoantibody against thyroglobulin in the patient sample 
competes with polyclonal human anti-Tg antibody bound to polyclonal goat anti-human 
antibody covalently coupled to paramagnetic particles in the Solid Phase for a limited 
amount acridinium ester-labeled human thyroglobulin in the Lite Reagent as shown in 
figure 2.9. 
 
In both assays there is an inverse relationship exists between the amount of anti-TPO 
and anti-Tg present in the patient sample and the amount of relative light units (RLUs) 
detected by the system. The cutoff used for positivity for both anti-TPO and anti-TG in 














Figure 2.9. Competitive immunoassay for anti-Tg assay. Taken from Siemens Healthcare 
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Figure 2.10. Graphs showing the inverse relationship between the signal in relative light units (y-
axis) and level of anti-TPO antibody (left) and anti-TG antibody (right) on the the x-axis in U/ml. 
In our study 60 U/ml was the cutoff for positivity in both antibodies. 
 
 
The minimum detectable concentrations of FT3, FT4, TSH, anti-TPO and anti-Tg are 
shown in Table 2.1. The intra-assay coefficients of variation (SD/mean x100) are 
summarised in Table 2.2. If the serum concentration of anti-TPO and anti-Tg was less 
than 60 U/mL, which was the manufacturer’s reference limit, the patients were 
considered to be antibody negative. 
 
Table 2.1. Minimum detectable concentrations of thyroid hormones and antibodies. 
 Minimum detectable concentration 
Free triiodothyronine (FT3) 0.3 pmol/L 
Free Thyroxine (FT4) 1.3 pmol/L 
Thyroid stimulating hormone (TSH) 0.003 mIU/L 
Anti thyroid peroxidase antibody (anti-TPO) 15 U/mL 
Anti thyroglobulin antibody (anti-Tg)  30 U/mL 
 
Table 2.2. Intra-assay coefficient of variation of thyroid hormones and antibodies. 
 Intra-assay coefficient of variation 
Free triiodothyronine (FT3)  
   Concentration 2.9 pmol/L 3.08% 
   Concentration 6.6 pmol/L 2.35% 
   Concentration 14.2 pmol/L 2.47% 
Free Thyroxine (FT4)  
   Concentration 6.1 pmol/L 4.69% 
   Concentration 13.9 pmol/L 2.31% 
   Concentration 39.9 pmol/L 2.22% 
Thyroid stimulating hormone (TSH)  
   Concentration 0.74 mIU/L 2.48% 
   Concentration 5.65 mIU/L 2.44% 
   Concentration 18.98 mIU/L 2.41% 
Anti thyroid peroxidase antibody (anti-TPO)  
   Concentration 1.70 U/mL 7.93% 
   Concentration 10.01 U/mL 4.54% 
   Concentration 14.95 U/mL 6.26% 
Anti thyroglobulin antibody (anti-Tg)   
   Concentration 62 U/mL 5.5% 
   Concentration 333 U/mL 2.9% 
 






2.3 STATISTICAL ANALYSIS  
 
The characteristics of the various study groups were compared by Mann Whitney test 
for continuous variables and Fisher’s exact test or Chi-square test for categorical 
variables.  
 
Intially TSH, FT3 and FT4 was checked for normality by the Kolmogorov-Smirnov test. 
This compares whether the scores in the sample set to a normally distributed set of 
scores with the same mean and standard deviation. If the test is not significant 
(p>0.05) then there is no significant difference from a normal distribution and therefore 
probably normally distributed. If there is a significant difference p<0.05, then it is not 
normally distributed. However in large samples size such as ours, a small deviation 
from normality can be statistically significant, but this deviation may not be significant 
enough to require a statistical procedure that we apply to the data, and therefore we 
plotted the data graphically as it is important to visually assess the extent of non-
normality. 
 
In the normal pregnancy group serum TSH, FT3 and FT4 were transformed to make 
their distribution Gaussian. Multiple regression analysis was then used to determine if 
gestational age at screening, maternal age, BMI, racial origin and method of 
conception were significant predictors of the transformed TSH, FT3 and FT4.  
 
The measured values of TSH, FT3 and FT4 in each were expressed as multiples of the 
expected median (MoM) of normal. Comparison of TSH MoM, FT3 MoM and FT4 MoM 
between each pregnancy group was by Kruskal-Wallis test with post-hoc Bonferroni 
correction (critical statistical significance p<0.0167). The proportion of cases with serum 
TSH above the 97.5
th
 centile and serum FT3 and FT4 below the 2.5
th
 centile in each 
group were compared using the Chi-square test with post-hoc Bonferroni correction. 
 
Regression analysis was used to determine the significance of the inter-relations 
between serum TSH, FT3 and FT4 and free ß-hCG.  






Gaussian distribution.  
 
The Gaussian distribution is a symmetric bell-shaped curve, a normal distribution 
where the mean, median and mode are the same.  
 
Wilcoxon rank-sum test 
 
The Wilcoxon rank-sum test is a nonparametric test used to compare 2 groups where 
the data is not normally distributed (test for normality is explained above), equivalent of 
the Student’s t-test for normally distributed data.   
 
This test ranks the data, so the lowest value is given a number 1, second lowest is 2 
and so on, if there is no difference between the 2 groups then you would expect to find 
a similar number of low and high ranks in the 2 groups, and if you add up all the ranks 
then one would expect to find the summed total of ranks in each group to be the same. 
If they are different then the following calculation is made:  the test statistic (Ws) is the 
lowest of these sums and to determine if the difference is significant, the mean (Ws) 
and standard error (SEWs) is calculated: 
 
Ws = n1(n1 + n2 +1)/2 
Where n1 is the sample size for group 1 and n2 is the sample size for group 2. 
 
SEWs = Sqrt n1n2(n1+n2+1)/12 
 
Then we can convert these values into a z-score: 
 
z = Ws –Ws/SEWs 
 
If the z score >1.96 ignoring the minus sign then the test is significant at p<0.05 so 
there is a significant difference between the 2 groups. 
 




Mann Whitney test  
 
The Mann Whitney U test is the nonparametric equivalent of the Student’s t-test as the 
t-test can be biased when the assumption of normality of distribution is not met. This 
test is calculated in a similar way to the Wilcoxon rank-sum test but uses a U score: 
 
U= n1n2 + N1(N1+1)/2 – R1 
 
Where n1 and n2 are the sample sizes, and R1 is the sum of ranks for group 1. The 
output will also give a p value to determine whether there is a significant difference. 
 
Pearson’s Chi-square test  
 
The Chi-squared test is a nonparametric test to examine if there is a difference in 
proportions between two or more groups. It is used when the data compared is 
categorical and it approximates the p-value. The larger the sample size the better the 
approximation becomes. The Pearson’s Chi-square (x
2








where i represents the rows in the contingencey table and j represents the columns 
and modelij = expected frequency = row total x column total/total number of 
observations 
 
The df is calculated as (r – 1)(c - 1) where r is number of rows and c is the number of 
columns and for each degree of freedom there is critical value at which p<0.05. If the 
observed value was bigger than the critical value then there was a significant 
relationship between the 2 variables 
 
Fisher’s exact test 
 
The Fisher’s exact test is a nonparametric test used also for catergorical variables 
giving an exact p-value. It is used when the sample size is small so using the Chi-





squared test is insufficient as it is an approximate p-value. It is often used when the 
expected frequency in each cell is <5 and therefore the sampling distribution is too 




The Kruskal-Wallis test is the nonparametric equivalent of the one-way analysis of 
variance (ANOVA) when comparing more the two samples that are independent and not 
normally distributed. It is similar to the Mann-Whitney test where all the scores are 
ranked in order. The smallest values is given a rank 1, next highest is 2 and so on 
ignoring what group these scores belong to. Then all the scores are put back to their 
original groups and the ranks are summed up for each group and given a value Ri where i 
is used to denote the particular group. Then the statistic H is calculated by: 
 
Where N is the total sample size, ni is the sample size for each particular group 
 
The value of H has a special kind of distribution known as the Chi-squared distribution 
and the degree of freedom is one minus the number of groups. 
 
The output of SPSS names H as Chi-squared due to its distribution, df (represents 
degrees of freedom) and the significance (p value). If Monte Carlo significance <0.05 
then there is a statistically significant difference between the groups however it does 
not tell us exactly where the difference lies. To examine where the difference lies one 
needs to do multiple Mann-Whitney test however that will increase the Type 1 error 
and therefore a post-hoc Bonferroni correction is used. 
 
post-hoc Bonferroni correction 
 
This post-hoc Bonferroni correction is used for parametric and nonparametric data to 
adjust the significance level of the p-value when comparing more than 2 groups. In 
nonparametric data where multiple Mann-Whitney tests are made when there are > 2 




groups, this would increase the type 1 error and therefore to correct for that so the type 
1 error does not increase >0.05 we adjust the cut off for significance by the number of 




Regression analysis is when we fit a model to our data and use it to predict values of 
the dependent vaiable (DV) from one or more independent variables (IVs). It is a way 
of predicting an outcome variable from one predictor variable (simple regression) or 
several predictor variables (multiple regression). 
 
Linear regression analysis is a statistical model where one variable is dependent on the 
other and when plotted on Cartesian axes where x is the predictor variable and y is the 
dependent variable, a straight line forms. The strength of correlation is determined by 
Pearson correlation coefficient r.  
 
Linear regression: Yi = β0 + β1 xi + εi 
The coefficients (the β0 = y intercept of the line, β1 = gradient of the straight line ) and 
the noise terms ε1  
 
The ‘line of best fit’ is the one with the least difference between the observed data 
points and the line also called the method of least squares (SS = sum of squares), 
however this does not assess the goodness to fit or how this model is a better predictor 
than ‘our best guess’. R
2 
represents the amount of variance the outcome variable can 
be explained by the model (SSM) relative to how much variation there was to explain in 




 = SSM/ SST 
 
In simple regression, Pearson’s correlation coefficient is the square root of R
2
 and that 
gives us an overall fit of the regression model. The F-ratio represents how much the 
model has improved the prediction of the outcome compared to the level of inaccuracy 
of the model and is calculated by dividing the average sum of squares (also called 





mean squares MS= SS/df) of the model (MSM) by the residual mean squares (MSR): 
 
F-ratio = MSM/MSR 
A good model would have a large F-ration at least >1. 
 
The t-statistic tests the null hypothesis that the coefficient of a predictor variable is 0 
and therefore the gradient of the regression line is also 0. The test tells us whether the 
b-value is different from 0 relative to the variation in b-value across samples.  
 
t = bobserved – bexpected/SEb 
 
bexpected here is 0, therefore 
 
t = bobserved /SEb 
 
The df which is calculated as N-p-1 (N is total sample size, p is the number of 
predictors, linear regression df = N - 2) determines the distribution and significance of 
the t-statistic. If p<0.05 then b is significantly different from 0 and therefore the 
predictor makes a significant contribution to predicting the outcome. 
  
Multiple regression analysis is a statistical model used when there are multiple 
predictor variables x1, x2,x3 and one dependent variable y.  
 
Multiple regression: Yi = β0 + β1 (x1)i + β2 (x2)i + β3 (x3)i + … + βK (xK)i + εi 
















Objective: To establish normal ranges of maternal serum thyroid stimulating hormone 
(TSH), free thyroxine (FT4) and free tri-iodothyronine (FT3) at 11-13 weeks of 
gestation. 
 
Methods: Maternal serum concentrations of FT3, FT4, TSH, anti-thyroperoxidase (anti-
TPO) and anti-thyroglobulin (anti-Tg) antibodies were measured at 11-13 weeks. 
Normal ranges were constructed from the data of singleton pregnancies with no 
antithyroid antibodies resulting in live birth after 34 weeks of phenotypically normal 
neonates with birth weight above the 5th centile. Adjustments were made for maternal 
characteristics found by multiple regression analysis to affect the levels of TSH, FT3 
and FT4. 
 
Results: 3,592 of the 4,318 pregnancies examined were antibody negative and in this 
group serum TSH increased whereas FT3 and FT4 decreased with gestation and all 
three were lower in Afro-Caribbean than in Caucasian women. Serum FT3 and FT4 
decreased but TSH did not change significantly with maternal age, TSH and FT3 
increased whereas FT4 decreased with body mass index, TSH decreased whereas FT3 
and FT4 increased with serum free ß-hCG. In the antibody positive group, compared to 
the negative group, median TSH was higher and median FT3 and FT4 were lower.  
 









This chapter is based on: Ashoor G, Kametas NA, Akolekar R, Guisado J and Nicolaides KH 
(2010) Maternal thyroid function at 11-13 weeks of gestation. Fetal Diagn Ther, 27:156-63. 
 
 










Screening for thyroid disease in early pregnancy is hindered by the lack of appropriate 
reference ranges of thyroid function (see Chapter 1.5). Previous studies reporting 
reference ranges of thyroid function in early pregnancy examined a small number of 
patients, or the gestational range was wide, maternal history of thyroid disease was not 
recorded, anti-thyroid antibodies were either not measured or patients with such 
antibodies were not excluded, or they did not examine serum TSH with both FT3 and 




The aims of this chapter are to establish reference ranges of serum TSH, FT3 and FT4 
at 11-13 weeks’ gestation in a large number of singleton pregnancies with no known 
thyroid disease and in the absence of anti-thyroperoxidase (anti-TPO) and anti-
thyroglobulin (anti-Tg) antibodies and to examine the effect of maternal characteristics 
and serum anti-TPO, anti-Tg and free ß-hCG on the levels of TSH, FT3 and FT4. 
 
 
3.2 PATIENTS AND METHODS 
 
The study design and overall study population are described in Chapter 2. 
 
In this study we retrospectively measured the maternal serum concentrations of FT3, 
FT4, TSH, anti-TPO and anti-Tg at 11-13 weeks in 4,318 pregnancies resulting in live 
birth of phenotypically normal neonates born after 34 weeks’ gestation in the absence 









Sample analysis  
 
The maternal serum concentrations of FT3, FT4 and TSH were measured by 




The characteristics of the antibody positive and negative groups were compared by 
Mann Whitney test for continuous variables and Fisher’s exact test or Chi-square test 
for categorical variables.  
 
In the antibody negative group, serum TSH, FT3 and FT4 were not normally 
distributed. After logarithmic transformation the distributions of FT3 and FT4 were 
Gaussian (Figure 3.1). However, log10 TSH remained negatively skewed therefore 
square root () transformation was applied (Figure 3.1). Multiple regression analysis 
was then used to determine if gestational age at screening, maternal age, BMI, racial 
origin and method of conception were significant predictors of  TSH, log10 FT3, log10 
FT4.  
 
The observed values of TSH, FT3 and FT4 were expressed as multiples of the expected 
median (MoM) of normal. Regression analysis was also used to determine the 
significance of the inter-relations between serum TSH, FT3 and FT4 and free ß-hCG. 
Comparison of TSH MoM, FT3 MoM and FT4 MoM between the antibody positive and 
antibody negative groups was by Kruskal-Wallis test with post-hoc Bonferroni correction 
(critical statistical significance p<0.0167).  
 
The proportion of cases with serum TSH above the 97.5th percentile and serum FT3 
and FT4 below the 2.5th percentile in the antibody positive and negative groups were 
compared using the Chi-square test with post-hoc Bonferroni correction.  
 
 






The statistical software package SPSS 16.0 (SPSS Inc.,Chicago, IL), Medcalc for 
windows, version 9.6.2.0 (MedCalc Software, Mariakerke, Belgium) and XLSTAT-Pro 




The patient characteristics of the hypothyroid group with the normal pregnancy group 
(Chapter 3) are compared in Table 4.1. In the hypothyroid group, compared to the 
normal group, the maternal age was higher, there was a higher prevalence of 
Caucasian women and a higher prevalence of women who conceived after the use of 
ovulation induction drugs. 
 
 
Table 4.1. Maternal demographic characteristics in the hypothyroid and normal groups. 
 
 
Comparison between hypothyorid and normal groups was by Chi square or Fisher exact test for 









In 3,592 of the 4,318 pregnancies examined the serum concentration of anti-TPO and 
anti-Tg was less than 60 U/mL and in 726 (16.8%) the concentration of one or both 
antibodies was 60 U/mL or more. The patient characteristics of the antibody negative 
and antibody positive groups are compared in Table 3.1. In the antibody positive group, 
the mean maternal age was increased and there was a higher proportion of Caucasian 
and South Asian women. 
 
 























































































































Reference range of serum FT3, FT4 and TSH 
 
In the antibody negative group the distribution of  TSH, log10 FT3 and log10 FT4 
approximated a Gaussian normality (Figure 3.1).  
 
Multiple regression analysis demonstrated that there were significant contributions to the 
level of TSH, FT3 and FT4 from maternal characteristics (Table 3.2). Serum TSH 
increased whereas FT3 and FT4 decreased with gestational age and all three were lower 
in Afro-Caribbean than in Caucasian women (Figure 3.2). Serum FT3 and FT4 
decreased but TSH did not change significantly with maternal age. Serum TSH and FT3 
increased whereas FT4 decreased with body mass index. The 50th, 95th, 97.5th, 5th and 










* Comparisons by Chi-square test with post-hoc Bonferroni correction for categorical variables 







Maternal age in years, median (IQR) 32.2 (27.9-36.0) 33.2 (29.3-36.7)* 
Body mass index in Kg/m2, median (IQR) 24.7 (22.2-27.9) 24.5 (22.3 -28.2) 
Crown-rump length in mm, median (IQR) 63.5 (59.0-68.7) 63.6 (58.9 -68.8) 
Racial origin   
   Caucasian, n (%) 2543 (70.8) 582 (80.2)* 
   Afro-Caribbean, n (%) 708 (19.7) 52 (7.0)* 
   South Asian, n (%) 148 (4.1) 63 (8.7)* 
   East Asian, n (%) 57 (1.6) 13 (1.8) 
   Mixed, n (%) 136 (3.8) 17 (2.3) 
Conception   
   Spontaneous, n (%) 3491 (97.2) 699 (96.3) 
   Ovulation drugs, n (%) 101 (2.8) 27 (3.7) 






There were significant associations between TSH MoM with FT4 MoM (r= -0.176, 
p<0.0001) and FT3 MoM (r= -0.107, p<0.0001) and between FT3 MoM and FT4 MoM 
(r=0.547, p<0.0001). There were significant associations between free ß-hCG MoM with 
TSH MoM (r= -0.156, p<0.0001), with FT3 MoM (r=0.135, p<0.0001) and with FT4 MoM 
(r=0.134, p<0.0001).  
 
Table 3.2. Contribution of maternal and fetal characteristics to  TSH, log10 FT4 and 
log10 FT3 demonstrated by multiple regression analysis. 
 
Characteristics Coefficient Standard error P value 
Sqrt TSH    
Gestational age (weeks) 0.034864 0.012 0.0042 
Body mass index (Kg/m2) 0.002811 0.001 0.0002 
Black racial origin -0.182494 0.016 <0.0001 
Asian racial origin -0.133563 0.032 <0.0001 
Oriental racial origin -0.162253 0.050 0.0013 
Log10 FT4 
Gestational age (weeks) -0.006395 0.002 0.0026 
Maternal age (years) -0.000518 0.0002 0.005 
Body mass index (Kg/m2) -0.001280 0.0002 <0.0001 
Black racial origin -0.010828 0.003 <0.0001 
Asian racial origin 0.011146 0.004 <0.0001 
Oriental racial origin 0.018198 0.009 0.038 
Log10 FT3 
Gestational age (weeks) -0.004332 0.002 0.032 
Maternal age (years) -0.001165 0.0001 <0.0001 
Body mass index (Kg/m2) 0.001138 0.0002 <0.0001 





Serum TSH, FT3 and FT4 in the antibody positive group 
 
In 726 (16.8%) of the 4,318 pregnancies the concentration of one or both anti-TPO and 
anti-Tg was 60 U/mL or more. In 308 (7.1%) both antibodies were positive, in 133 
(3.1%) only anti-TPO was positive and in 285 (6.6%) only anti-Tg was positive. The 
prevalence of antibody positivity was higher in Caucasian (582 of 3125, 18.6%) than 
Afro-Caribbean women (51 of 759, 6.7%; p<0.0001). 
 
In the antibody positive group, compared to the antibody negative group, the median 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.2. Reference range of maternal serum TSH with gestational age in Caucasian 





Table 3.4. Comparison of the antibody positive and antibody negative groups for 
median TSH, FT3 and FT4 and proportion of cases with TSH above the 97.5th 




Comparisons between each antibody group with no antibody group by Chi-square test with post-hoc 
Bonferroni correction for categorical variables and by Kruskal-Wallis with post-hoc Bonferroni correction 
for continuous variables.  
 
 










Thyroid stimulating hormone 
Median MoM 1.01 1.53* 1.30* 1.80* 
>97.5th centile, n (%) 89 (2.5%) 17 (12.8%)* 24 (8.4%)* 76 (24.7%)* 
Free thyroxine 
Median MoM 0.99 0.98 1.01 0.96* 
<2.5th centile, n (%) 89 (2.5%) 5 (3.8%) 9 (3.2%) 14 (4.5%) 
Free triiodothyronine 
Median MoM 0.99 0.98* 0.98 0.97* 


















































Serum TSH was above the 97.5th percentile in 2.5% of the antibody negative group 
and increased to 5.3% (3 of 57) in the group with anti-TPO of 60-100 IU/mL, 15.1% (28 
of 186) in the group with anti-TPO of 101-500 IU/mL and 31.3% (62 of 198) in the 
group with anti-TPO of more than 500 IU/mL. The respective values in the anti-Tg 





This chapter has established normal ranges of maternal serum TSH, FT3 and FT4 at 
11-13 weeks’ gestation. We excluded pregnancies complicated by miscarriage or fetal 
death, fetal growth restriction, preeclampsia and preterm delivery because of the 
reported association between these pregnancy complications and clinical or subclinical 
hypothyroidism (Leung et al., 1993; Allan et al., 2000; Casey et al., 2005). We also 
excluded pregnancies with known thyroid disease and those with anti-thyroid 
antibodies.  
 
We chose 11-13 weeks because this is the gestation at which pregnant women attend 
maternity units for their first antenatal visit. At this visit an ultrasound scan is carried out 
to determine the number of fetuses, confirm the gestation, exclude major defects and 
measure the fetal nuchal translucency thickness which in combination with maternal 
serum free ß-hCG and PAPP-A is used for effective screening of aneuploidies. 
Consequently, this is the likely gestation for screening for thyroid disease in pregnancy 
should such screening be accepted as a necessary part of routine antenatal care 
because it would be important to identify and treat hypothyroidism as early in 
pregnancy as possible.  
 
Multiple regression analysis demonstrated that in our antithyroid antibody-negative 
normal pregnancies maternal characteristics and gestational age affect the serum 
concentrations of TSH, FT3 and FT4. Consequently, in establishing normal ranges we 
made adjustments for these factors by using the same multiple of the median 
approach as in the analysis of other metabolites, such as serum free ß-hCG. Previous 





studies on maternal thyroid function in pregnancy have not made such adjustments 
and the observed differences in reported results may be a consequence of differences 
in maternal characteristics of the study populations, such as racial origin, age and body 
mass index. (Table 1.5; Smith et al, 1983; Chan et al., 1988; Leylek et al., 1996; 
Panesar et al., 2001; Haddow  et al., 2004; Kurioka  et al., 2005; Dashe  et al., 2005; 
Stricker  et al., 2007; Casey  et al., 2007; Cotzias  et al., 2008; Gilbert  et al., 2008; 
Lambert-Messerlian  et al., 2008; McElduff and Morris, 2008; Marwaha  et al., 2008; 
Pearce  et al., 2008). Other possible factors contributing to the differences in results 
are the inclusion of patients with or without antithyroid antibodies, gestational age 
distribution of the pregnancies and reagents used for the assays.   
 
Serum TSH increased and FT3 and FT4 decreased with gestational age within the 
narrow range of 11-13 weeks and this is likely to be the consequence of the thyrotropic 
properties of hCG whose concentration decreases with gestation. The finding that 
serum FT3 and FT4 decrease with maternal age, suggests that the function of the 
thyroid gland declines with age. A large study in non-pregnant individuals reported an 
age-related increase in both the mean serum TSH concentration and in the percentage  
 
of people with high serum TSH concentration (>4.5 mIU/L) (Hollowell et al., 2002). The 
finding that serum TSH increases and FT4 decreases with body mass index is 
compatible with the association between clinical and subclinical hypothyroidism with 
increased insulin resistance and the metabolic syndrome (Ruhla et al., 2010; Verma et 
al., 2008). We can not offer an explanation for the finding that FT3 increases with body 
mass index. 
 
In women of Afro-Caribbean racial origin the serum concentration of both TSH and the 
thyroid hormones is lower than in Caucasian women. The results suggest that the 
pituitary-hypothalamus-thyroid gland axis in Afro-Caribbeans is set at a different level 
than in Caucasians but the underlying mechanism is uncertain. The finding of lower 
serum TSH in Afro-Caribbeans compared to Caucasians has also been reported in 
previous studies in both pregnant women and in non-pregnant individuals (Hollowell et 







In about 10% of our population there were detectable anti-TPO antibodies and this 
prevalence is similar to the 5-15% rate reported in previous studies in the first trimester 
of pregnancy (Haddow et al., 2004; Stricker et al., 2007; Lambert-Messerlian et al., 
2008; McElduff et al., 2008; Marwaha et al., 2008; Pearce et al., 2008). In 14% of our 
population there were anti-Tg antibodies and this prevalence is higher than the 3-9% 
rate reported in previous studies (Lambert-Messerlian et al., 2008; McElduff et al., 
2008; Marwaha et al., 2008). 
 
The finding of lower antibody positivity in Afro-Caribbeans compared to Caucasians 
has also been reported in previous studies in both pregnant women and in non-
pregnant individuals (Hollowell et al., 2002; La'ulu and Roberts, 2007). In the antibody 
positive group, compared to the antibody negative group, the median TSH was higher 
and the median FT3 and FT4 were lower. This effect was observed for both anti-TPO 
and anti-Tg antibodies in contrast to a report in non-pregnant individuals that anti-Tg 
antibodies in the absence of anti-TPO does not affect thyroid function (Hollowell et al., 
2002).  
 
In the antibody positive group the percentage of cases with TSH values above the 
97.5th percentile increased with the serum antibody concentration. A previous study 
reported that the majority of antibody-positive women with subclinical hypothyroidism 
during pregnancy will develop clinical hypothyroidism within the subsequent 10 years 
(Haddow et al., 1999). Consequently, in establishing normal ranges of thyroid function 





The chapter established normal ranges for maternal thyroid function at 11-13 weeks’ 
gestation after adjustment for maternal characteristics which affect the measured 
serum concentrations of TSH, FT3 and FT4. These ranges will form the basis for the 
study of thyroid function in pathological pregnancies and the investigation of the 
consequences of subclinical hypothyroidism. 





Chapter 4  Thyroid function in pregnancies of women with 









Objective: The aim of this study in pregnant women with hypothyroidism treated by 
levothyroxine is to examine the interrelations between thyroid stimulating hormone 
(TSH), free thyroxine (FT4) and free tri-iodothyronine (FT3) and offer a possible 
explanation for the common finding of the coincidence of high serum TSH in the 
presence of normal FT4 in such patients. 
 
Methods: This was a retrospective cross sectional study. Maternal serum 
concentrations of FT3, FT4 and TSH were measured at 11-13 weeks in 164 singleton 
pregnancies from women with hypothyroidism before pregnancy receiving treatement 
with thyroxine. The values were compared to the results in 4,318 normal singleton 
pregnancies. 
 
Results: In the hypothyroid group, compared to the normal group, there was an 
increase in median TSH (1.990 vs 1.007 MoM) and FT4 (1.052 vs 0.992 MoM) and 
decrease in FT3 (0.901 vs 0.991 MoM). In both the hypothyroid and unaffected groups 
there were significant associations between TSH and FT4, TSH and FT3 and between 
FT3 and FT4. In 65 (39.6%) cases serum FT4 was above the 2.5th centile but either 
TSH was above the 97.5th centile and / or FT3 was below the 2.5th centile. 
 
Conclusions: In a high proportion of pregnant women with hypothyroidism treated with 
levothyroxine there is evidence of persistent hypothyroidism because the treatment is 












This chapter is based on: Ashoor G, Rotas M, Maiz N, Kametas NA and Nicolaides KH (2010) 
Maternal Thyroid Function at 11-13 Weeks of Gestation in Women with Hypothyroidism Treated 
by Thyroxine. Fetal Diagn Ther, 28:22-27. 
 










Pregnancy is associated with an approximate 50% increase in demand for thyroid 
hormones which is mainly attributed to the estrogen-driven doubling in thyroxine-
binding globulin concentrations (see Chapter 1.2). In women with pre-existing 
hypothyroidism treated with levothyroxine the increased demands for thyroid hormones 
in pregnancy should be met by increasing the dose of the drug, but several studies 
have documented that in the first-trimester of pregnancy 30-50% of such women may 
be inadequately treated (see Chapter 1.5). The evidence for inadequate therapy is 
based on the biochemical finding of high TSH in the presence of normal FT4, but 
assessment of thyroid function by TSH and FT4 alone may be insufficient because it is 
FT3 which is ultimately responsible for the control of both metabolic activity and 




The aim of this chapter in pregnant women with hypothyroidism treated by 
levothyroxine is to examine the interrelations between FT3, FT4 and TSH and offer a 
possible explanation for the finding of the coincidence of high serum TSH in the 
presence of normal FT4 in such patients. 
 
 
4.2 PATIENTS AND METHODS 
 
The study design and overall study population are described in Chapter 2. 
 
In this study we measured the maternal serum concentrations of FT3, FT4, TSH, anti-
TPO and anti-Tg at 11-13 weeks in 164 singleton pregnancies from women who 
reported that they had hypothyroidism before pregnancy and they were receiving  





treatement with thyroxine. The values were compared to the results of 4,318 normal 
singleton pregnancies with no history of thyroid disease, which did not develop PE and 
resulted in live birth after 34 weeks of phenotypically normal neonates with birth weight 
above the 5th centile (Chapter 3). The normal pregnancy group included 726 (16.8%) 
pregnancies in which the concentration of one or both antithyroid antibodies was 60 
U/mL or more. Normal ranges for TSH, FT3 and FT4 were derived from the study of 




The maternal serum concentrations of FT3, FT4 and TSH were measured by 




The characteristics of the hypothyroid group with the group used for the construction of 
normal ranges were compared by Mann Whitney test for continuous variables and 
Fisher’s exact test or Chi-square test for categorical variables. The measured 
concentrations of FT3, FT4 and TSH were converted to multiples of the expected 
normal median (MoM) corrected for gestational age and maternal age, racial origin and 
body mass index.  
 
The hypothyroid and normal groups were compared for median TSH MoM, FT3 MoM 
and FT4 MoM using the Mann Whitney test and for the proportion of cases with serum 
TSH above the 97.5th percentile and serum FT3 and FT4 below the 2,5th percentile by 
the Chi-square test. In the hypothyroid group regression analysis was also used to 
determine the significance of the interrelations between TSH MoM, FT3 MoM and FT4 
MoM. 
 
The statistical software packages SPSS 15.0 (SPSS Inc.,Chicago, IL) was used for the 
data analyses. 
 










The patient characteristics of the hypothyroid group with the normal pregnancy group 
(Chapter 3) are compared in Table 4.1. In the hypothyroid group, compared to the 
normal group, the maternal age was higher, there was a higher prevalence of 
Caucasian women and a higher prevalence of women who conceived after the use of 
ovulation induction drugs. 
 
 
Table 4.1. Maternal demographic characteristics in the hypothyroid and normal groups. 
 
Maternal variables Normal (n=3,592) Hypothyroid (n=164) 
Maternal age in yrs (median, IQR) 32.2 (28.0-36.0) 35.4 (23.6-42.9)* 
Body mass index in Kg/m2, median (IQR) 24.7 (22.2-27.9) 24.9 (19.2-41.0) 
Racial origin   
   Caucasian, n (%) 2,543 (70.8) 134 (81.7)** 
   Afro-Caribbean, n (%) 708 (19.7) 12 (7.3) 
   Indian or Pakistani, n (%) 148 (4.1) 11 (6.7) 
   Chinese or Japanese, n (%) 57 (1.6) 4 (2.4) 
   Mixed, n (%) 136 (3.8) 3 (1.8) 
Parity   
   Nulliparous, n (%) 1684 (46.9) 64 (39.0) 
   Parous, n (%)  1908 (53.1) 100 (61.0) 
Cigarette smoker, n (%) 322 (9.0) 10 (6.1) 
Conception by ovulation drugs 101 (2.8) 11 (6.7)* 
 
Comparison between hypothyorid and normal groups was by Chi square or Fisher exact test for 
categorical variables and Mann Whitney-U test for continuous variables. *p<0.001, 
 
 
In the hypothyroid group, compared to the normal group, the median TSH MoM and 
FT4 MoM was increased whereas the median FT3 MoM was decreased (Table 4.2). 
The serum TSH was above the 97th percentile in 48 (29.3%) of the 164 cases, the FT3 
was below the 2.5th percentile in 49 (29.9%) cases and the FT4 was below the 2.5th 
percentile in 6 (3.7%) cases (Figure 4.1). In all cases of low FT4, the serum TSH was 
above the 97.5th percentile. In 25 (52.1%) of the cases with low FT3, the serum TSH 
was above the 97.5th percentile.  





On the basis of their serum TSH, FT4 and FT3 levels the 164 patients fell into one of 
five groups: 
 93 (56.7%) patients with serum TSH below the 97.5th percentile and both FT4 
and FT3 above the 2.5th percentiles. 
 6 (3.7%) patients with TSH above the 97.5th percentile and both FT4 and FT3 
below the 2.5th percentiles. 
 20 (12.2%) cases with TSH above the 97.5th percentile, FT3 below the 2.5th 
percentile and FT4 above the 2.5th percentile. 
 22 (13.4%) cases with TSH above the 97.5th percentile and both FT4 and FT3 
above the 2.5th percentiles. 
 23 (14.0%) cases with FT3 below the 2.5th percentile, TSH below the 97.5th 
percentile and FT4 above the 2.5th percentile 
 
Table 4.2. Maternal serum thyroid stimulating hormone, free thyroxine and free tri-
iodothyronine values in the hypothyroid and normal groups 
 
Comparison between each hypothyroid and normal groups was by Chi square or Fisher exact 
test for categorical variables and Mann Whitney-U test for continuous variables. **p<0.0001 
 
In both the hypothyroid and normal groups, there were significant associations between 
TSH and FT4, TSH and FT3 and between FT3 and FT4 (Table 4.3, Figure 4.2). 
 
Table 4.3. Correlations between serum thyroid stimulating hormone, free thyroxine and 
free tri-iodothyronine values in the hypothyroid and normal groups. 
 
 Normal Hypothyroid 
Correlations r P r p 
TSH with FT3 -0.182 <0.0001 -0.550 <0.0001 
TSH with FT4 -0.245 <0.0001 -0.474 <0.0001 
FT3 with FT4 0.476 <0.0001 0.452 <0.0001 
 Normal (n=3592) Hypothyroid (n=164) 
Thyroid stimulating hormone 
     MoM (median, IQR) 1.007 (0.608-1.511) 1.990 (0.793-3.467)** 
     mIU/L (median, IQR) 1.096 (0.670-1.665) 2.435 (0.942-3.982)** 
     MoM >97.5 centile (%) 89 (2.5) 48 (29.3)** 
     MoM <2.5 centile (%) 89 (2.5) 5 (3.0) 
Free thyroxine 
     MoM (median, IQR) 0.992 (0.908-1.086) 1.052 (0.938-1.202)** 
     pmol/L (median, IQR) 14.9 (13.6-16.3) 15.8 (14.0-17.9)** 
     MoM >97.5 centile (%) 89 (2.5) 13 (7.9)** 
     MoM <2.5 centile (%) 89 (2.5) 6 (3.7) 
Tri-iodothyronine 
     MoM (median, IQR) 0.991 (0.935-1.059) 0.901 (0.818-0.957)** 
     pmol/L (median, IQR) 4.6 (4.4-5.0) 4.2 (3.8-4.5)** 
     MoM >97.5 centile (%) 89 (2.5) 4 (2.4) 
     MoM <2.5 centile (%) 89 (2.5) 49 (29.9)** 

























Figure 4.1. Relationship between maternal serum thyroid stimulating hormone (TSH) free tri-
idothyronine (FT3) and free thyroxine (FT4) and in multiples of the expected normal median 
(MoM) at 11-13 weeks of gestation in pregnancies with pre-existing hypothyroidism treated with 
levothyroxine. The vertical lines represent the 2.5th and 97.5th percentiles of the normal ranges 





















Figure 4.2. Relationship between maternal serum free tri-idothyronine (FT3) and free thyroxine 
(FT4) and in multiples of the expected normal median (MoM) at 11-13 weeks of gestation in 
pregnancies with pre-existing hypothyroidism treated with levothyroxine. The interrupted lines 
represent the 2.5th centiles of the normal ranges for FT3 and FT4. 




































































































































































































In normal group of 4,318 pregnancies, 726 (16.8%) were positive for one or both 
antithyroid antibodies (chapter 3). In this study of pregnancies with hypothyroidism 
treated with thyroxine the prevalence of antithyroid antibody positivity was increased to 
73.2% (Table 4.4). 
 
 
Table 4.4. Prevalence of antithyroid antibody positivity in the pregnancies with 










This study has assessed thyroid function at the first obstetric visit at 11-13 weeks of 
gestation in women with known hypothyroidism diagnosed before pregnancy and 
receiving levothyroxine. In the hypothyroid group, compared to the unaffected group, 
there was a higher incidence of Caucasian women and the median maternal age was 
increased. These results are compatible with those of previous studies in non-pregnant 
individuals (Hueston and Pearson, 2004; Sawin et al., 1985; Okamura et al., 1989). 
The finding that in the hypothyroid group there was a higher incidence of women who 
conceived after the use of ovulation induction drugs is compatible with the knowledge 
that hypothyroidism is associated with impaired ovulation (Raber et al., 2003; Joshi et 
al., 1993). In the hypothyroid group the prevalence of antithyroid antibodies was 




Anti-TPO Anti-Tg Both Either 
Hypothyroid 164 107 (65.2%)* 97 (59.1%)* 84 (51.2%)* 120 (73.2%)* 
Unaffected 4318 441 (10.2%) 593 (13.7%) 308 (7.1%) 726 (16.8%) 





developed countries autoimmune thyroiditis is the most common cause of 
hypothyroidism, especially in women of childbearing age (Hollowell et al., 2002). 
  
In the women with hypothyroidism treated with levothyroxine, there was a good inter-
correlation between serum FT4, FT3 and TSH but the median FT4 and TSH were 
increased, whereas the median FT3 was decreased. On the basis of their individual 
results about 55% of the patients were biochemically euthyroid with normal serum TSH 
and normal or high FT4 and FT3. In the remaining 45% at least one of the three 
biochemical tests was suggestive of persistent hypothyroidism. There was a small 
group with low FT4 and FT3 and high TSH. In a much larger group, serum FT4 was 
normal or increased, but either TSH was high and / or FT3 was low. These findings 
raise the question as to whether the objective in the treatment of hypothyroidism in 
pregnancy should be to normalize TSH or FT4 or FT3. 
 
In non-pregnant individuals with overt hypothyroidism, levothyroxine treatment is 
successful in abolishing their symptoms only with a dose resulting in supernormal FT4 
and subnormal TSH (Toft and Beckett, 2003; Saravanan et al., 2002). These results 
may essentially indicate that the treatment is only successful when there is 
normalization of FT3. Many of the symptoms of hypothyroidism, such as fatigue, 
constipation, weight gain, hair loss, dry skin and carpal tunnel syndrome, are common 
in normal pregnancy making it impossible to rely on such symptoms for monitoring 
success of treatment. In the management of pregnant women with hypothyroidism, it is 
recommended that the same approach should be used as in non-pregnant individuals 
where the objective of treatment is normalization of TSH (ACOG, 2002). However, 
such recommendation is not based on scientific evidence that in women with 
hypothyroidism treated with levothyroxine and normal serum FT4 pregnancy outcome 
is better in those with normal TSH than in those with high TSH. Indeed there is an 
inherent contradiction in the recommendation for the need to normalise TSH because 
the same professional body recommends against screening for subclinical 
hypothyroidism (high TSH with normal FT4) since there is no evidence that 
identification and treatment of women with this condition improves maternal or infant 
outcomes (ACOG, 2007). 





Our study was a retrospective cross sectional one of patients examined in a university 
hospital clinic. We did not aim to examine the relation between our findings and the 
dose of levothyroxine, patient compliance, expertise of treating physicians or the 
interval between ingestion of the drug and blood sampling.  
 
The findings provide a snapshot view of thyroid profile in early pregnancy in women 
with hypothyroidism treated with levothyroxine. We found that although the level of 
serum FT4 was invariably normal or increased in a high proportion of cases there was 
high TSH and low FT3, high TSH and normal FT3 or normal TSH and low FT3. 
Consequently, if the objective in the treatment of hypothyroidism in pregnancy is to 
normalize the levels of the biologically active FT3 it is not useful to monitor the levels of 
FT4 but it is essential to measure the levels of both TSH and FT3. 
 
Recommendations on whether the objective in the treatment of hypothyroidism in 
pregnancy is to normalize TSH and / or FT3 rather than FT4 should ultimately be 
based on the results of major prospective studies examining the differential incidence 
of adverse pregnancy outcomes in the groups with low FT3 and normal TSH and FT4 
and in those with high TSH and normal FT4 and FT3 compared to those in which all 





In a high proportion of pregnant women with hypothyroidism treated with levothyroxine 
there is evidence of persistent hypothyroidism because the treatment is inadequate in 

















Background: Studies have shown that overt hypothyroidism is associated with a 
substantial risk of miscarriage. There is controversy as to whether subclinical 
hypothyroidism has the same effect and whether such effect is mediated by the 
presence of anti-thyroid antibodies. Our hypothesis is that maternal thyroid function in 
the first-trimester is altered in pregnancies ending in miscarriage or fetal death. 
Methods: Thyroid stimulating hormone (TSH), free thyroxine (FT4), free 
triiodothyronine (FT3), anti-thyroperoxidase (anti-TPO) antibody and anti-thyroglobulin 
(anti-TG) antibody at 11-13 weeks of gestation were measured in 202 singleton 
pregnancies that subsequently resulted in miscarriage or fetal death and the values 
were compared to the results of 4,318 normal pregnancies. 
Results: In the fetal loss group, compared to the normal group, there was an increase 
in median TSH multiple of the normal median (1.133 vs 1.007 MoM), decrease in 
median FT4 MoM (0.958 vs 0.992 MoM) and increase in the incidence of TSH above 
the 97.5th percentile 5.9% vs 2.5%) and FT4 below the 2.5th percentile (5.0% vs 2.5%). 
Logistic regression analysis demonstrated that in the prediction of fetal loss there were 
significant contributions from FT4 MoM, maternal Afro-Caribbean racial origin, history 
of chronic hypertension and use of ovulation drugs. The prevalence of antithyroid 
antibody positivity was not significantly different in the fetal loss group compared to that 
of normal pregnancies (15.3% vs 16.8%). 




This chapter is based on: Ashoor G, Maiz N, Rotas M, Jawdat F and Nicolaides KH (2010) 
Maternal Thyroid Function at 11 to 13 Weeks of Gestation and Subsequent Fetal Death Thyroid, 
20:989-93. 
 









Clinical hypothyroidism is associated with a high risk of miscarriage and fetal death, but 
in subclinical hypothyroidism there is contradictory evidence as to whether the rate of 
fetal death is increased or not (see Chapter 1.5). There is also controversy as to 
whether any possible association between subclinical hypothyroidism and fetal death is 
the direct consequence of the metabolic derangement or it is mediated by the 




The aim of this chapter was to investigate further the possible association between 
maternal thyroid dysfunction and fetal death in the second and third trimesters by 
comparing serum TSH, FT4, FT3 and antithyroid antibody levels at 11-13 weeks’ 
gestation in pregnancies ending in miscarriage or fetal death with those resulting in 
normal live births. 
 
5.2 PATIENTS AND METHODS 
 
The study design and overall study population are described in Chapter 2. 
 
In this study we retrospectively measured the maternal serum concentrations of FT3, 
FT4, TSH, anti-TPO and anti-Tg at 11-13 weeks in 202 singleton pregnancies that 
subsequently resulted in miscarriage or fetal death (fetal loss group). The values were 
compared to the results of the normal outcome group of 4,318 singleton pregnancies 
with no history of thyroid disease, which did not develop pre-eclampsia and resulted in 
live birth after 34 weeks of phenotypically normal neonates with birth weight above the 
5th centile (Chaper 3). The normal outcome group included 726 (16.8%) pregnancies in 







The maternal serum concentrations of FT3, FT4 and TSH were measured by 




The characteristics of the fetal loss and unaffected groups were compared by Mann 
Whitney test for continuous variables and Fisher’s exact test or Chi-square test for 
categorical variables. The measured concentrations of FT3, FT4 and TSH were 
converted to MoMs corrected for gestational age, maternal age, racial origin and body 
mass index (Chapter 3).  
 
Comparison of TSH MoM, FT3 MoM and FT4 MoM between fetal loss and normal 
groups was by Mann Whitney-U test, with post-hoc Bonferroni correction (critical 
statistical significance p<0.0167). Logistic regression analysis was used to determine if 
maternal factors, TSH MoM and FT4 MoM had a significant contribution in predicting 
fetal loss. The performance of screening was determined by receiver operating 
characteristic (ROC) curves (Zweig and Campbell, 1993).  
 
In the fetal loss and unaffected groups the Chi-square test was used to compare the 
proportion of cases with anti-TPO and anti-Tg antibodies and those with serum TSH 
above the 97.5th percentile and serum FT3 and FT4 below the 2.5th percentile. 
 





The gestational age distribution at the time of miscarriage or the diagnosis of fetal 
death in the fetal loss group is shown in Figure 5.1. The patient characteristics of the 
fetal loss and unaffected groups are compared in Table 5.1. In the fetal loss group, 





compared to the unaffected group, the median BMI was higher and there was a higher 
prevalence of Afro-Caribbean women, and women who conceived after receiving 






















Figure 5.1. Gestational age distribution of miscarriage or fetal death 
 
 







Gestation at sampling in wks (median, IQR) 12.4 (12.3-12.9) 12.4 (12.3-13.0) 
Gestation at delivery in wks (median, IQR) 40.0 (39.0-40.9) 21.0 (17.7-25.7)** 
Maternal age in yrs (median, IQR) 32.2 (28.0-36.0) 32.7 (26.1-36.8) 
Body mass index in Kg/m2, median (IQR) 24.7 (22.2-27.9) 26.9 (23.0-31.2)** 
Racial origin   
   White, n (%) 2,543 (70.8) 87 (43.1) 
   Black, n (%) 708 (19.7) 101 (50.0)** 
   Indian or Pakistani, n (%) 148 (4.1) 6 (3.0) 
   Chinese or Japanese, n (%) 57 (1.6) 1 (0.5) 
   Mixed, n (%) 136 (3.8) 7 (3.5) 
Parity   
   Nulliparous, n (%) 1684 (46.9) 97 (48.0) 
   Parous, n (%) 1908 (53.1)) 105 (52.0) 
Cigarette smoker, n (%) 322 (9.0) 17 (8.4) 
Conception by ovulation drugs, n (%) 101 (2.8) 31 (15.3)** 
 
Comparison between fetal loss and normal groups was by Chi square or Fisher exact test for 
categorical variables and Mann Whitney-U test for continuous variables. *p<0.05, ** p<0.0001 
 
































In the fetal loss group, compared to the normal group, the median TSH MoM was 
increased and the median FT3 MoM, and FT4 MoM were decreased (Table 5.2). 
Linear regression analysis in the fetal loss group showed that there was no significant 
association between the gestation at fetal loss and TSH MoM (p=0.654), FT3 MoM 
(p=0.411) and FT4 MoM (p=0.917). In the fetal loss group serum TSH was above the 
97.5th percentile of the normal range in 12 (5.9%) cases and the serum FT4 was below 




Table 5.2. Thyroid stimulating hormone, free thyroxine and free triiodothyronine values 
in the fetal loss and normal groups. 
 
 
Comparison between the fetal loss and normal groups was by Chi square or Fisher exact test for 




Multiple logistic regression analysis demonstrated that in the prediction of fetal loss 
there were significant contributions from Afro-Caribbean racial origin (OR 4.102, 95% 
CI 3.003-5.603, p<0.001), use of ovulation drugs (OR 8.238, 95% CI 5.210-13.028, 
p<0.001), BMI (OR 1.028, 95% CI 1.000- 1.057, p=0.05), and log FT4 MoM (OR 0.011, 
95% CI 0.001-0.104, p<0.001), but not TSH MoM (p=0.208). If in the regression FT4 
MoM is not included then TSH MoM becomes significant. This is presumably the 





Thyroid stimulating hormone 
     MoM (median, IQR) 1.007 (0.608-1.511) 1.133 (0.639-1.621)* 
     mIU/L (median, IQR) 1.096 (0.670-1.665) 1.127 (0.638-1.714) 
     MoM >97.5 centile (%) 89 (2.5) 12 (5.9)* 
Free thyroxine 
     MoM (median, IQR) 0.992 (0.908-1.086) 0.958 (0.864-1.048)** 
     pmol/L (median, IQR) 14.9 (13.6-16.3) 14.0 (12.8-15.5)** 
     MoM <2.5 centile (%) 89 (2.5) 10 (5.0)* 
Free triiodothyronine  
     MoM (median, IQR) 0.991 (0.935-1.059) 0.979 (0.931-1.054) 
     pmol/L (median, IQR) 4.6 (4.4-5.0) 4.6 (4.3-4.9) 
     MoM <2.5 centile (%) 89 (2.5) 8 (4.0) 





associations between TSH and FT3, TSH and FT4 and FT3 and FT4 in both the fetal 
loss and unaffected groups are shown in Table 5.3. 
 
 
Table 5.3. Correlations between thyroid stimulating hormone TSH), free thyroxine 
(FT4) and free triiodothyronine (FT3) in the normal and fetal loss groups. 
 
 Normal Fetal loss 
Correlations r p r p 
     
TSH with FT3 -0.182 <0.0001 -0.609 <0.0001 
TSH with FT4 -0.245 <0.0001 -0.697 <0.0001 





In the normal group 726 (16.8%) of the 4,318 pregnancies were positive for one or 
both antithyroid antibodies (Chapter 3). In this study of pregnancies complicated by 
fetal loss, the prevalence of antithyroid antibody positivity was not significantly different 
(Table 5.4). 
 




Anti-TPO = anti-thyroperoxidase antibody, anti-TG = anti-thyroglobulin antibody 






This study has demonstrated that in pregnancies resulting in miscarriage or fetal death 
during the second and third trimesters, compared to those with normal outcome, the 
Pregnancy n 
Antibody positive 
Anti-TPO Anti-Tg Both Either 
Normal 4318 441 (10.2%) 593 (13.7%) 308 (7.1%) 726 (16.8%) 




median maternal serum concentration of TSH is increased and FT4 is decreased and 
the incidence of high TSH and low FT4 is increased. In contrast, there were no 
significant differences between the groups in the median concentration of FT3 or in the 
incidence of antithyroid antibody positivity. 
 
In the fetal loss group, compared to the normal outcome group, more women were of 
Afro-Caribbean racial origin, the median maternal BMI was higher and more 
pregnancies were conceived after ovulation induction. These findings are compatible 
with the results of previous studies on the rates of second-trimester miscarriage and 
fetal death. Willinger et al., examined the stillbirth hazard in 5,138,122 singleton 
pregnancies from the National Center of Health Statistics and reported that in Black, 
compared to White women, the risk of fetal death at 20-23 weeks was 2.75 times 
higher and the risk of death at 39-40 weeks was 1.57 times higher (Willinger et al., 
2009).  
 
Obesity is associated with an increased risk of several adverse outcomes. A 
systematic review reported that the rate of pregnancy loss before 20 weeks of 
gestation increases with maternal BMI (Metwally et al., 2008). Similarly, a population-
based cohort study demonstrated that the rate of late fetal death increases with 
maternal BMI (Cnattingius et al., 1998).  
 
There is a scarcity of reports on the outcome of pregnancies conceived after the use of 
ovulation induction drugs without in-vitro fertilization. Whether pregnancies conceived 
through assisted reproductive technology (ART) are at an increased risk of loss is 
inconclusive, and data on maternal age-, ART type-, and gestational age-specific risk 
of loss are limited. Farr et al, examined the outcome of 148,494 ART pregnancies and 
reported that the overall risk of pregnancy loss was 29% and the risk in both groups 
increased with maternal age. The risk of pregnancy loss in singletons after 
confirmation of a fetal heartbeat was about 15% which is slightly higher than in 
naturally conceived pregnancies. The risk of fetal loss was 3.4% after 12 weeks of 
gestation and 1.2% after 20 weeks (Farr, et al., 2007). 
 
 





In our study, the incidence of high TSH and/or low FT4 in the fetal loss group was 
higher than in the normal outcome group. The contradictory results of previous reports 
concerning the association between subclinical hypothyroidism and fetal death may be 
a consequence of the small number of cases of fetal loss in the hypothyroid group and 
methodological differences between the studies. The two studies reporting an increase 
in fetal loss in women with high TSH did not provide data on FT4 which may have been 
normal or decreased (Sahu et al., 2010; Hallengren et al., 2009). In contrast, the 
studies reporting no significant difference in fetal loss between the high and low TSH 
groups included only women with normal FT4 (Casey et al., 2005; Cleary-Goldman et 
al., 2008). 
 
The incidence of antithyroid antibody positivity for either anti-TPO or anti-Tg in the fetal 
loss group was not higher than in the normal outcome group. We have previously 
reported that in the antibody positive group, compared to the antibody negative group, 
the median TSH was higher and the median FT3 and FT4 were lower and this effect 
was observed for both anti-TPO and anti-Tg antibodies (Chapter 3).  
 
Our findings do not support the hypothesis that antithyroid antibodies exert a direct 
toxic effect on the pregnancy leading to fetal loss however the mechanism of fetal loss 
in the first trimester may be different to fetal losses in the second and third trimester. It 
is likely that the previously reported association between antithyroid autoimmunity and 
fetal loss (Stagnaro-Green and Glinoer 2004), may be mediated by an underlying 
thyroid dysfunction. A study of euthyroid patients undergoing assisted reproduction 
technologies (ART) reported that the pregnancy and delivery rates were not different in 
the anti-TPO antibody positive and negative groups (Negro et al., 2007a). However, 
the antibody positive women who failed to become pregnant or miscarried had higher 
TSH levels before ART than in those with a normal outcome. Another study examined 
whether anti-TPO antibody positive patients have an increased risk of miscarriage and 
if this can be reduced by levothyroxine treatment (Negro et al., 2006). They reported 
that the miscarriage rate in anti-TPO antibody positive women with no treatment 




positive women treated with levothyroxine starting from the first-trimester (2.4%) 
(Negro et al., 2006).  
 
The strengths of our study are firstly, examination of a large number of pregnancies 
resulting in miscarriage or fetal death, secondly, assessment of confounding factors in 
the prediction of fetal loss, including maternal characteristics and method of 
conception, thirdly, use of normal ranges of thyroid function corrected for maternal 
characteristics, including age, racial origin and BMI (Chapter 3), and fourthly, 
assessment of thyroid function in the first-trimester of pregnancy providing the option 
for therapeutic interventions in future studies to determine if the incidence of fetal loss 
can be reduced.  
 
A retrospective study of pregnancies in women with primary hypothyroidism treated 
with levothyroxine reported that the miscarriage rate in those that at the time of 
conception had overt or subclinical hypothyroidism was about 65%, whereas in the 
euthyroid group there were no miscarriages (Abalovich et al., 2002). The extent to 
which the fetal loss rate during the second and third-trimesters can be reduced by the 
treatment of women diagnosed with hypothyroidism at 11-13 weeks remains to be 
determined. The limitation of this study is that it does not include early miscarriages 





There are multiple causes of miscarriage and fetal death during the second and third 
trimesters of pregnancy. This study has demonstrated that previously undiagnosed 
hypothyroidism diagnosed at 11-13 weeks of gestation may be a contributing factor to 
about 5% of subsequent fetal losses. The extent to which the diagnosis of subclinical 
hypothyroidism and appropriate therapy can prevent fetal loss and the cost-
effectiveness of such strategy remain to be determined.  
















Objective To determine if maternal thyroid function in the first-trimester is altered in 
pregnancies that subsequently develop preeclampsia (PE). 
 
Methods Mean arterial pressure (MAP), uterine artery pulsatility index (PI) and 
maternal serum thyroid stimulating hormone (TSH), free thyroxine (FT4) and free 
triiodothyronine (FT3) at 11-13 weeks of gestation were measured in 102 singleton 
pregnancies that subsequently developed PE and the values were compared to the 
results of 4,318 normal pregnancies. 
 
Results In both the PE group that required delivery before 34 weeks (early-PE) and the 
late-PE group, compared to the unaffected group, the median MAP multiple of the 
normal median (MoM) and uterine artery PI MoM were significantly increased. In late-
PE but not in early-PE, compared to the unaffected group, the median TSH MoM was 
significantly increased and the median FT4 MoM was decreased. Logistic regression 
analysis demonstrated that TSH MoM provided a significant contribution in the 
prediction of late-PE.  
 
Conclusions: Impaired thyroid function may predispose to the development of late-PE 
and measurement of maternal serum TSH can improve the prediction of late-PE 
provided by a combination of factors in the maternal history and the measurements of 






This chapter is based on: Ashoor G, Maiz N, Rotas M, Kametas NA and Nicolaides KH (2010) 
Maternal thyroid function at 11 to 13 weeks of gestation and subsequent development of 









Preeclampsia (PE), which affects about 2% of pregnancies, can be divided into early-
PE requiring delivery before 34 weeks and late-PE with the former being associated 
with a high incidence of fetal growth restriction, whereas in late-PE fetal growth is 
usually normal (see Chapter 1.5). Effective first-trimester screening for both early-PE 
and late-PE is provided by a combination of maternal demographic characteristics and 
medical history, uterine artery PI and maternal mean arterial pressure (MAP) (Poon et 
al., 2009). Several studies have reported than in patients presenting with the clinical 
features of PE, thyroid function is disturbed with increase in maternal serum TSH and 
decrease in the levels of thyroid hormones (see Chapter 1.5). There is also 
contradictory evidence as to whether PE causes hypothyroidism or subclinical 
hypothyroidism predispose to the development of PE, rather than the other way round 




The aims of this study are to investigate further if the prevalence of maternal thyroid 
hypofunction at 11-13 weeks of gestation is higher in pregnancies that subsequently 
develop PE and if it is whether assessment of thyroid function can improve the 
prediction of PE provided by a combination of factors in the maternal history and the 
measurements of MAP and uterine artery PI. 
 
 
6.2 PATIENTS AND METHODS 
 
The study design and overall study population are described in Chapter 2. 
 
In this study we measured the maternal serum concentrations of free triiodothyronine 
(FT3), free thyroxine (FT4), TSH, anti-thyroperoxidase (TPO) and anti-thyroglobulin 
(Tg) at 11-13 weeks in 102 singleton pregnancies that subsequently developed PE. 





None of the PE patients had a history of thyroid disease. The values were compared to 
the results of our normal group of 4,318 singleton pregnancies with no history of 
thyroid disease, which did not develop PE and resulted in live birth after 34 weeks of 
phenotypically normal neonates with birth weight above the 5th centile (Chapter 3). The 
normal group included 726 (16.8%) pregnancies in which the concentration of one or 
both antithyroid antibodies was 60 U/mL or more. Normal ranges for TSH, FT3 and 
FT4 were derived from the study of the 3,592 pregnancies with no antithyroid 




The definition of PE was that of the International Society for the Study of Hypertension 
in Pregnancy (Davey and MacGillivray, 1988). The diastolic blood pressure should be 
90 mmHg or more on at least two occasions four hours apart developing after 20 
weeks of gestation in previously normotensive women. In addition there should be 
proteinuria of 300 mg or more in 24 hours or two readings of at least ++ on dipstick 
analysis of midstream or catheter urine specimens if no 24-hour collection is available. 
In PE superimposed on chronic hypertension significant proteinuria (as defined above) 
should develop after 20 weeks of gestation in women with known chronic hypertension 
(history of hypertension before conception or the presence of hypertension at the 




The maternal serum concentrations of FT3, FT4 and TSH were measured by 




The characteristics of the early-PE, late-PE and the unaffected group used for the 
construction of normal ranges were compared by Mann Whitney test for continuous 




measured MAP and uterine artery L-PI were converted to multiples of the expected 
normal median (MoM) corrected for fetal CRL, maternal age, BMI or weight, smoking, 
parity, racial origin and method of conception as previously described (Poon et al., 
2009). Similarly, the measured concentrations of FT3, FT4 and TSH were converted to 
MoMs corrected for gestational age, maternal age, racial origin and body mass index 
(Chapter 3).  
 
Comparison of MAP MoM, uterine artery L-PI MoM, TSH MoM, FT3 MoM and FT4 
MoM between early-PE, late-PE and the unaffected group was by Mann Whitney-U 
test, with post-hoc Bonferroni correction (critical statistical significance p<0.025). The 
risks for early-PE and late-PE based on combinations of maternal factors, MAP and 
uterine artery L-PI were determined as previously described and were then 
logarithmically transformed (Poon et al., 2009). Logistic regression analysis was used 
to determine if the log transformed risk based on maternal factors, MAP and uterine 
artery L-PI and TSH MoM had a significant contribution in predicting early-PE and late-
PE. The performance of screening was determined by receiver operating characteristic 
(ROC) curves. 
 
In the early-PE, late-PE and unaffected groups the Chi-square test was used to 
compare the proportion of cases with anti-TPO and anti-Tg antibodies and those with 
serum TSH above the 97.5th centile and serum FT3 and FT4 below the 2.5th centile.  
 
The statistical software packages SPSS 16.0 (SPSS Inc.,Chicago, IL) and Medcalc 





The patient characteristics of the early-PE, late-PE and normal groups are compared 
in Table 6.1. In both the early-PE and late-PE groups, compared to the normal group, 
there was a higher prevalence of Afro-Caribbean women, chronic hypertensives and 
women with a personal or family history of PE. In women that developed late-PE the 
BMI was increased.  
 













Gestation at sampling in wks (median, IQR) 12.4 (12.3-12.9) 12.7 (12.1-13.1) 12.4 (12.1-12.7) 
Gestation at delivery in wks (median, IQR) 40.0 (39.0-40.9) 32.4 (29.1-33.2)* 38.6 (37.3-39.9)* 
Maternal age in yrs (median, IQR) 32.2 (28.0-36.0) 29.5 (23.7-34.9) 32.3 (27.4-37.2) 
Body mass index in Kg/m2, median (IQR) 24.7 (22.2-27.9) 25.1 (22.5-30.8) 27.8 (23.7-31.2)* 
Racial origin    
   White, n (%) 2,543 (70.8) 9 (36.0) 34 (44.2) 
   Black, n (%) 708 (19.7) 13 (52.0)* 34 (44.2)* 
   South Asian, n (%) 148 (4.1) 1 (4.0) 3 (3.9) 
   East Asian, n (%) 57 (1.6) 0 2 (2.6) 
   Mixed, n (%) 136 (3.8) 2 (8.0) 4 (5.2) 
Parity    
   Nulliparous, n (%) 1684 (46.9) 12 (48.0) 44 (57.1) 
   Parous – no previous preeclampsia, n (%) 1818 (50.6) 8 (32.0) 20 (26.0)* 
   Parous – previous preeclampsia, n (%) 90 (2.5) 5 (20.0)* 13 (16.9)* 
Cigarette smoker, n (%) 322 (9.0) 1 (4.0) 5 (6.5) 
Family history of preeclampsia, n (%) 128 (3.6) 5 (20.0)* 9 (11.7)* 
Conception by ovulation drugs, n (%) 101 (2.8) 2 (8.0) 5 (6.5) 
Chronic hypertension, n (%) 38 (1.1) 3 (12.0)* 5 (6.6%)* 
 
Comparison between each hypertensive disorder group and unaffected was by Chi square or 
Fisher exact test for categorical variables and Mann Whitney-U test for continuous variables, 
both with post-hoc Bonferroni correction (critical statistical significance p<0.025): *p<0.025, 
IQR: interquartile range 
 
 
In both the early-PE and late-PE groups, compared to the normal group, the median 
MAP MoM and uterine artery L-PI MoM were significantly increased (Table 6.2). In late-
PE but not in early-PE, compared to the unaffected group, the median TSH MoM was 
significantly increased and the median FT4 MoM was decreased. In late PE the 
proportion of cases with high TSH, low FT4 or low FT3 was higher than in the controls 
(Table 6.2, Figure 6.1). 
 
Regression analysis demonstrated that in the PE group there were no significant 
associations between TSH MoM and uterine artery L-PI MoM (p=0.315), or between 
TSH MoM and MAP MoM (p=0.533).  
 
Logistic regression analysis demonstrated that in the prediction of late-PE there were 
significant contributions from TSH MoM to the prediction from the combination of 
maternal factors, uterine artery L-PI and MAP. The areas under the ROC curves and 





Table 6.2. Mean arterial pressure, uterine artery lowest pulsatility index L-PI) and 
maternal serum thyroid stimulating hormone, free thyroxine and free triiodothyronine in 
the normal group and in those who subsequently developed early and late 
preeclampsia. 
 
 Normal Early preeclampsia Late preeclampsia 
Mean arterial pressure    
     MoM (median, IQR) 0.98 (0.93-1.04) 1.06 (1.01-1.15)** 1.07 (1.00-1.13)** 
     mmHg (median, IQR) 84.67 (79.83-89.5) 91.3 (88.0-101.9) 94.4 (87.0-99.5) 
Uterine artery L-PI    
     MoM (median, IQR) 1.01 (0.82-1.22) 1.54 (1.17-1.64)** 1.20 (0.87-1.50)* 
     units (median, IQR) 1.41 (1.14-1.71) 2.10 (1.67-2.34) 1.68 (1.21-2.13) 
Thyroid stimulating hormone    
     MoM (median, IQR) 1.007 (0.608-1.511) 1.08 (0.556-1.781) 1.390 (0.708-2.122)* 
     m IU/L (median, IQR) 1.096 (0.670-1.665) 1.094 (0.500-1.583) 1.357 (0.730-2.346) 
     >97.5 centile (%) 89 (2.5) 2 (8.0) 10 (13.0)* 
Free thyroxine    
     MoM (median, IQR) 0.992 (0.908-1.086) 0.966 (0.868-1.043) 0.951 (0.843-1.052)* 
     Pmol/L (median, IQR) 14.9 (13.6-16.3) 14.1 (13.1-15.5) 14.0 (12.4-15.6) 
     % <2.5 centile (%) 89 (2.5) 1 (4.0) 6 (7.8)* 
Free triiodothyronine    
     MoM (median, IQR) 0.991 (0.935-1.059) 0.954 (0.881-1.054) 1.010 (0.934-1.064) 
     Pmol/L (median, IQR) 4.6 (4.4-5.0) 4.5 (4.1-5.0) 4.7 (4.4-5.0) 
     % <2.5 centile (%) 89 (2.5) 2 (8.0) 6 (7.8)* 
 
Comparison between each hypertensive disorder group and unaffected was by Chi square or 
Fisher exact test for categorical variables and Mann Whitney-U test for continuous variables, 
both with post-hoc Bonferroni correction (critical statistical significance p<0.025): *p<0.025, 
**<0.001 






In normal pregnancy 726 (16.8%) of the 4,318 pregnancies were positive for one or 
both antithyroid antibodies, 308 (7.1%) were positive for both, 285 (6.6%) were positive 
for anti-Tg only and 133 (3.1%) were positive for anti-TPO antibody (Chapter 3). 
 
In this study of pregnancies complicated by PE the prevalence of antithyroid antibody 
positivity was not significantly increased; in late-PE 11 (14.3%) of the 77 pregnancies 





had positive antibodies, 6 (7.8%) were positive for both, 4 (5.2%) were positive for anti-
Tg and 1 (1.3%) was positive for anti-TPO; in early-PE 3 (12.0%) of the 25 
pregnancies (p=0.687) were positive for both antibodies, 2 (8%) were anti-Tg positive 





Figure 6.1. Relationship between maternal serum thyroid stimulating hormone (TSH) and free 
thyroxine (FT4) and free triidothyronine (FT3) in multiples of the expected normal median (MoM) 
at 11-13 weeks of gestation in pregnancies that subsequently developed preeclampsia. The 
vertical lines represent the 2.5th and 97.5th centiles of the normal ranges for FT4 and FT3 and 




Table 6.3. Performance of screening for late preeclampsia by maternal factors only, 
TSH MoM, a combination of maternal factors with TSH MoM, a combination of 













Figure 6.1. Relationship between maternal serum thyroid stimulating hormone (TSH) and free 
thyroxine (FT4) and free triidothyronine (FT3) in multiples of the expected normal median (MoM) 
at 11-13 weeks of gestation in pregnancies that subsequently developed preeclampsia. The 
vertical lines represent the 2.5th and 97.5th centiles of the normal ranges for FT4 and FT3 and 






The findings of this study demonstrate an association between impaired maternal 
thyroid function at 11-13 weeks and subsequent development of late PE. High serum 
TSH was observed in 5 times as many with late-PE compared with those who did not 








































































































mechanisms because the prevalence of antithyroid antibodies was not higher in the PE 
than in the non-PE group. A study of 5505 patients examining early pregnancy serum 
samples for thyroid function reported that in the group with subclinical hypothyroidism 
the incidence of subsequent development of PE was higher than in the euthyroid group 
(3.8 vs 1.9%) but this difference did not reach statistical significance (Mannisto et al., 
2010). Another first trimester screening study involving 10990 patients reported that 
the subclinical hypothyroidism group was not associated with the development of PE 
but the reported prevalence of PE in this study was only 1% (Cleary-Goldman et al., 
2008). These studies did not report separately their findings of early and late PE 





Table 6.3. Performance of screening for late preeclampsia by maternal factors only, 
TSH MoM, a combination of maternal factors with TSH MoM, a combination of 
maternal factors, lowest uterine artery pulsatility index (L-PI) and mean arterial 





Area under receiver operating characteristic curve (95% CI) 
Late preeclampsia 
Maternal risk factor 0.785  (0.770-0.799) 
TSH MoM 0.603 (0.586-0.621) 
Maternal risk factor plus  
   TSH 0.793 (0.778-0.807) 
   MAP, uterine artery L-PI 0.856 (0.843-0.868) 
   All markers 0.860 (0.848-0.872) 
 
Detection rate (%) for fixed false positive rate (95% CI) 
5% 10% 
Maternal risk factor 27.5  (17.5-39.6) 37.7 (26.3-50.2) 
TSH MoM 21.7 (12.7-33.3) 27.5  (17.5-39.6) 
Maternal risk factor plus   
   TSH 36.2 (25.0-48.7) 47.8 (35.6-60.2) 
   MAP, uterine artery L-PI 39.1 (27.6-51.6) 53.6 (41.2-65.7) 
   All markers 43.5 (31.6-56.0) 59.4 (46.9-71.1) 
 





Our results raise the possibility that the findings of the population based study in which 
serum TSH was measured in women 20 years after their pregnancies and found to be 
higher in those who had developed PE (Levine et al., 2009b), may merely reflect a 
preexisting thyroid dysfunction that preceded their pregnancies. Another population 
based cohort with follow up for 20 years reported that thyroid dysfunction in early 
pregnancy was not associated with the development of PE but those with subclinical 
hypothyroidism were at increased risk of developing overt hypothyroidism in the long 
term (Mannisto et al., 2010).  
 
The study has confirmed the association between the development of PE and factors 
in the maternal history and the measurements of MAP and uterine artery PI (Poon et 
al., 2009). Increased risk for both early-PE and late-PE was observed in women of 
Black racial origin and those with a family or personal history of PE and chronic 
hypertension. Late-PE was also associated with increased BMI. In both early-PE and 
late-PE, MAP and uterine artery PI were increased but the increase in PI was more 
pronounced in those with early-PE. Impaired thyroid function was more pronounced in 
pregnancies that developed late-PE than early-PE.  
 
The strengths of this study are firstly, examination of a large number of appropriately 
documented cases of PE and normal controls, secondly, assessment of confounding 
factors in the prediction of PE, including maternal history, MAP and uterine artery PI, 
thirdly, use of normal ranges of thyroid function corrected for maternal characteristics, 
including age, racial origin and body mass index (Chapter 3), and fourthly, assessment 
of thyroid function in the first-trimester of pregnancy providing the option for 
therapeutic interventions in future studies to determine if the incidence of PE can be 
reduced. The weakness of the study was its cross-sectional nature, which did not allow 
longitudinal assessment of thyroid function from early pregnancy to the development of 
PE.  
 
There is extensive evidence that the underlying mechanism for early-PE is impaired 
trophoblastic invasion of the maternal spiral arteries, reduced placental perfusion and 




contrast, in late-PE placental perfusion and fetal growth are often normal and the main 
pathophysiological processes resemble those of the metabolic syndrome with an 
increase in adipose tissue and impaired glucose and lipid metabolism (Witlin et al., 
2000; Poon et al., 2009; Moldenhauer et al., 2003; Egbor et al., 2006; Vatten et al., 
2004; D’Anna et al., 2006). The association between hypothyroidism and late-PE may 
be mediated by the well described role of thyroid hormones in glucose homeostasis 
and in the synthesis, metabolism and mobilization of lipids (Chidakel et al., 2005; 
Duntas, 2002; Pearce, 2004). Hypothyroidism may also play a direct role in causing 
pregnancy hypertension because thyroid hormones act directly on peripheral arterioles 
to cause dilation (Dernellis and Panaretou, 2002). Studies in non-pregnant individuals 
reported that hypothyroidism is associated with an increase in peripheral resistance 
due to increased arterial wall thickness (Giannattasio et al., 1997) and endothelial 
dysfunction (Virdis et al., 2009). This can be reversed by treatment with thyroid 





Measurement of maternal serum TSH can improve the prediction of late-PE provided 
by a combination of factors in the maternal history and the measurements of MAP and 
uterine artery PI. The ability to predict in very early pregnancy those women at high-
risk for PE might decrease maternal and fetal morbidity through closer surveillance by 
physicians experienced or specialized in high-risk obstetrics, as well as delivery at 
tertiary care centres (Levine and Lindheimer, 2009a). Effective identification of the 
high-risk group can also be useful for future studies investigating the potential role of 
pharmacological interventions starting from the first-trimester to reduce the prevalence 
of the disease.  
 






Chapter 7  Thyroid function in pregnancies delivering 








Background:  Studies have shown that altered thyroid function in early pregnancy may 
affect normal placental development and hence fetal growth. Our hypothesis is that 
maternal thyroid function in the first trimester is altered in pregnancies that 
subsequently deliver small for gestational age neonates (SGA). 
 
Methods: Maternal serum thyroid stimulating hormone (TSH), free thyroxine (FT4) and 
free triiodothyronine (FT3) were measured at 11+0-13+6 weeks’ gestation in 212 
singleton pregnancies with no history of thyroid disease that subsequently delivered 
SGA neonates and the values were compared to the results of 3,598 normal 
pregnancies delivering neonates with birth weight above the 5th percentile for 
gestation. 
 
Results: There were no significant differences between the normal and SGA group in 
median multiple of the median (MoM) TSH (1.07 vs 1.061 MoM), FT4 (0.992 vs 1.010 
MoM) and FT3 (0.991 vs 0.990 MoM). 
 
Conclusion: In women with no history of thyroid disease delivering SGA neonates 
thyroid function during the first trimester of pregnancy is not significantly different from 






This chapter is based on: Karagiannis G, Ashoor G, Maiz N, Jawdat F and Nicolaides KH (2011) 
Maternal thyroid function at eleven to thirteen weeks of gestation and subsequent delivery of 
small for gestational age neonates. Thyroid, 21:1127-31. 






7.1.1 Background  
 
Small-for-gestational age (SGA) neonates, with birthweight below the 5th percentile, is 
heterogeneous and includes constitutionally small neonates and growth restricted ones 
due to impaired placentation, genetic disease or environmental damage. Impaired 
trophoblastic invasion and placentation is thought to be the underlying mechanism for 
many cases of preeclampsia (PE) and of impaired fetal growth in the absence of PE  
(see Chapter 1.5). The mechanism underlying trophoblast proliferation and invasion is 
largely unknown but there is some evidence implicating thyroid hormones in this 
process (Maruo et al., 1991; Barber et al., 2005; Oki et al., 2004). There is also 
contradictory evidence that clinical and subclinical hypothyroidism is associated with 





The aim of this study is to investigate further if the prevalence of maternal thyroid 
hypofunction at 11-13 weeks’ of gestation is higher in pregnancies that subsequently 
delivered SGA neonates in the absence of PE.  
 
 
7.2 PATIENTS AND METHODS 
 
The study design and overall study population are described in Chapter 2. 
 
In this study we measured the maternal serum concentrations of TSH, FT3 and FT4 at 
11-13 weeks in 212 singleton pregnancies with no history of thyroid disease, which did 
not develop PE and resulted in live birth of phenotypically normal neonates with birth 
weight below the 5th percentile for gestational age (SGA group, Figure 7.1) (Poon et al., 
2011b). 






At presentation none of the women had overt hypothyroidism or hyperthyroidism. The 
values were compared to those in 3,592 singleton pregnancies with no history of 
thyroid disease, which did not develop PE and resulted in live birth after 34 weeks of 




The maternal serum concentrations of FT3, FT4 and TSH were measured by 
















Figure 7.1. Distribution of birth weight of the small for gestational age fetuses (black dots) 
plotted on the reference range of birth weight for gestational age (median, 5th and 95th 





The characteristics of the SGA group with the unaffected group were compared by 
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Mann Whitney test for continuous variables and Fisher’s exact test or Chi-square test 
for categorical variables. The measured concentrations of FT3, FT4 and TSH were 
converted to multiples of the expected normal median (MoM) corrected for gestational 
age and maternal age, racial origin and BMI (Chapter 3).  
 
The SGA and unaffected groups were compared for median TSH MoM, FT3 MoM and 
FT4 MoM using the Mann Whitney test and for the proportion of cases with serum TSH 
above the 97.5th percentile and serum FT3 and FT4 below the 2,5th percentile by the 
Chi-square test. Regression analysis was also used to determine the significance of 
the interrelations between TSH MoM, FT3 MoM and FT4 MoM. 
 






The patient characteristics of the SGA and unaffected groups are compared in Table 
7.1. In the SGA group the maternal age and BMI were lower and the prevalence of 
African and South Asian women, cigarette smokers and those with chronic 
hypertension was higher. 
 
 
In the SGA group, compared to the unaffected group, the median TSH MoM, FT3 MoM 
and FT4 MoM were not significantly different (Table 7.2) and there was no significant 
association between the gestational age at delivery and TSH MoM (p=0.662), FT3 
MoM (p=0.538) and FT4 MoM (p=0.543).  
 
The significance of the associations between TSH, FT3 and FT4 in the unaffected and 











Table 7.1. Maternal demographic characteristics in the small and not-small for 
gestational age groups. 
 
Variables 
Not small for gestation  
(n=3,592) 
Small for gestation 
(n=212) 
Gestation: sampling in wks (median, IQR) 12.4 (12.3-12.9) 12.4 (12.1-12.9) 
Gestation: delivery in wks (median, IQR) 40.0 (39.0-40.9) 39.6 (38.2-40.9)* 
Maternal age in yrs (median, IQR) 32.2 (28.0-36.0) 31.0 (25.1-35.7)* 
Body mass index in Kg/m2, median (IQR) 24.7 (22.2-27.9) 23.1 (21.1-26.4)** 
Ancestral origin   
   Caucasian, n (%) 2,543 (70.8) 124 (58.5) 
   African, n (%) 708 (19.7) 58 (27.4)* 
   South Asian, n (%) 148 (4.1) 26 (7.5)** 
   East Asian, n (%) 57 (1.6) 3 (1.4) 
   Mixed, n (%) 136 (3.8) 11 (5.2) 
Parity   
   Nulliparous, n (%) 1684 (46.9) 130 (61.3) 
    Parous, n (%) 1908 (53.1) 82 (38.7)** 
Cigarette smoker, n (%) 322 (9.0) 45 (21.2)** 
Conception by ovulation drugs 101 (2.8) 5 (2.4) 
Chronic hypertension 38 (1.1) 9 (4.2)* 
 
Comparison between the two groups was by Chi square or Fisher exact test for categorical 





Table 7.2. Maternal serum TSH, FT3, FT4 values in the small and not-small for 
gestational age groups. 
 
 
Comparison between the the two groups was by Chi square or Fisher exact test for categorical 
variables and Mann Whitney-U test for continuous variables. *p<0.05, 
 
 Not small for gestation  
(n=3592) 
Small for gestation 
(n=212) 
Thyroid stimulating hormone 
     MoM (median, IQR) 1.007 (0.608-1.511) 1.061 (0.651-1.562) 
     mIU/L (median, IQR) 1.096 (0.670-1.665) 1.107 (0.690-1.687) 
     MoM >97.5 centile (%) 89 (2.5) 10 (4.7) 
Free thyroxine 
     MoM (median, IQR) 0.992 (0.908-1.086) 1.010 (0.919-1.090) 
     pmol/L (median, IQR) 14.9 (13.6-16.3) 15.2 (13.7-16.4) 
     MoM <2.5 centile (%) 89 (2.5) 6 (2.8) 
Free triiodothyronine 
     MoM (median, IQR) 0.991 (0.935-1.059) 0.990 (0.940-1.063) 
     pmol/L (median, IQR) 4.6 (4.4-5.0) 4.7 (4.4-5.0) 
     MoM <2.5 centile (%) 89 (2.5) 4 (1.9) 





Table 7.3. Associations between TSH, FT3 and FT4 in the unaffected and small for 
gestational age groups. 
 
 Unaffected Small for gestational age 
Correlations r p r p 
     
TSH with FT3 -0.182 <0.0001 -0.259 <0.0001 
TSH with FT4 -0.245 <0.0001 -0.133 0.052 






The findings of this study indicate that in pregnancies delivering SGA neonates, 
maternal thyroid function at 11-13 weeks gestation is not significantly different from 
those delivering appropriately grown neonates and there is no evidence that in the 
SGA group the incidence of impaired thyroid function is increased. 
 
A previous screening study in which maternal thyroid function was assessed at 15-18 
weeks’ gestation reported that there was no significant difference in mean birth weight 
between euthyroid pregnancies and those with subclinical hypothyroidism (Allan et al., 
2000). In contrast, a case control study reported that the mean birth weight in 
pregnancies with subclinical hypothyroidism was significantly lower than in euthyroid 
controls (Blazer et al., 2003).  
 
Another screening study before 20 weeks reported that the incidence of neonates with 
birth weight below 2.5 Kg was not significantly different between euthyroid pregnancies 
and those with subclinical hypothyroidism (Casey et al., 2007). However, use of mean 
birth weight or a cut-off in birth weight without appropriate adjustments for gestational 
age are not appropriate for the investigation of thyroid function on fetal growth.  
 
The strengths of our study are firstly, examination of a large number of appropriately 
documented cases of SGA and normal controls, secondly, comparison of the SGA and 
non-SGA groups after adjustment of the results of thyroid function test for those 
factors found to affect measurements in normal pregnancies, including  gestational 





age, maternal age, racial origin and BMI (Chapter 3), and thirdly, assessment of 
thyroid function in the first-trimester of pregnancy providing the option for therapeutic 
interventions in future studies to determine if the incidence of SGA can be reduced. 
The weakness of the study was its cross-sectional nature, which did not allow 
longitudinal assessment of thyroid function from early pregnancy to the development of 
SGA.  
 
The findings that firstly, SGA is not associated with maternal thyroid hypofunction and 
secondly, there is no correlation between gestational age at delivery and TSH, FT3 or 
FT4 suggest that the results of in vitro studies concerning the role of thyroid hormones 
on trophoblast proliferation and invasion (Barber et al., 2005; Oki et al., 2004) may not 
be clinically relevant. Histological studies reported that impaired placentation is 
observed in all cases of PE with or without SGA and in about half of pregnancies with 
SGA in the absence of PE (Brosens et al., 1977). However, Doppler studies of the 
uterine arteries documented that the prevalence of high impedance to flow in 
pregnancies with PE depends on the gestational age at the onset of the disease. The 
uterine artery pulsatility index (PI) was above the 95th percentile in 82% of those that 
developed PE requiring delivery before 34 weeks (early-PE) and in 40% of those 
delivering at or after 34 weeks (late-PE) (Yu et al., 2008). Similarly, in SGA without PE 
high PI was observed in 44% of those that delivered before 34 weeks and in 10% of 
those delivering at or after 34 weeks.  
 
Although the basis of the possible association between hypothyroidism, PE and SGA 
was the suggested role of thyroid hormones in promoting placentation and 
trophoblastic invasion, we previously found that thyroid hypofunction is observed in 
pregnancies developing late- rather than early-PE (Chapter 6).  
 
We therefore suggested that the association is unlikely to be mediated by impaired 
trophoblastic invasion but rather by a metabolic derangement with increased insulin 
resistance, which is thought to underlie late-PE (Egbor et al., 2006; Moldenhauer et al., 
2003; Kaaja et al., 1999; Bosio et al., 1999; D'Anna et al., 2006).  
 






In pregnancies delivering SGA neonates maternal thyroid function at 11-13 weeks’ 
gestation is not impaired. Consequently, irrespective of the possible effect of thyroid 
hormones on placentation, in women with no history of thyroid disease, thyroid function 
does not have a significant contribution to the prevalence of SGA neonates. 






Chapter 8 Thyroid function in pregnancies resulting in 








Objective: To estimate the possible association between spontaneous early preterm 
delivery and maternal thyroid dysfunction in early pregnancy. 
 
Methods: Maternal serum concentrations of thyroid-stimulating hormone (TSH), free 
triiodothyronine (FT3), free thyroxine (FT4), anti-thyroperoxidase (anti-TPO) and anti-
thyroglobulin (anti-Tg) antibodies at 11-13 weeks’ gestation were compared in 102 
singleton pregnancies resulting in spontaneous delivery before 34 weeks and 4,318 
normal pregnancies delivering after this gestation. 
 
Results: In the preterm delivery group, compared to the normal outcome group, there 
was no significant difference in anti-thyroid antibody positivity (16.7 vs. 16.8%). In the 
anti-thyroid antibody negative pregnancies in the preterm delivery group, compared to 
the normal outcome group, the median FT3 multiple of the normal median (MoM) and 
FT4 MoM were reduced (0.97 and 0.94 vs. 0.99 MoM, p<0.05 and p<0.001, 
respectively) but the median TSH MoM was not significantly different (0.99 vs. 1.01 
MoM, p=0.331).  
 
Conclusions: In pregnancies resulting in spontaneous early preterm delivery there is no 
evidence of increased prevalence of anti-thyroid antibody positivity or maternal thyroid 














This chapter is based on: Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH 2011 Maternal 











Preterm delivery is the leading cause of perinatal death and there is contradictory 
evidence that both subclinical hypothyroidism and autoimmune thyroid disease in 




The aim of this study is to estimate the possible association between maternal thyroid 
dysfunction and preterm delivery by comparing anti-thyroid antibody positivity and 
serum TSH, FT3 and FT4 levels at 11-13 weeks’ gestation, after appropriate 
adjustments for maternal characteristics, in pregnancies which subsequently resulted 
in spontaneous delivery before 34 weeks with normal pregnancies delivering after this 
gestation. 
 
8.2 PATIENTS AND METHODS 
 
The study design and overall study population are described in Chapter 2. 
 
In this study we retrospectively examined maternal thyroid function and anti-thyroid 
antibodies at 11-13 weeks in 102 singleton pregnancies with no history of thyroid 
disease, resulting in spontaneous preterm delivery before 34 weeks’ gestation of 
phenotypically normal neonates (preterm delivery group).  
 
The values were compared to those of 4,318 normal singleton pregnancies with no 
history of thyroid disease, resulting in live birth after 34 weeks of phenotypically normal 
neonates (normal outcome group) (Chapter 3). Pregnancies complicated by 
preeclampsia were excluded from both the preterm delivery and normal outcome 
groups. 
 







The maternal serum concentrations of FT3, FT4 and TSH were measured by 




Comparison between the preterm delivery and normal outcome groups was by χ2-test 
or Fisher’s exact test for categorical variables and by Mann Whitney test for continuous 
variables. In the anti-thyroid antibody negative pregnancies (anti-TPO and anti-Tg level 
of less than 60 U/mL) the measured concentrations of FT3, FT4 and TSH were 
logarithmically transformed. However, log10 TSH remained negatively skewed therefore 
square root ( ) transformation was applied. Histograms and probability plots showed 
that the distributions of  TSH, logFT3 and logFT4 were normal. The values were then 
expressed as multiples of the expected normal median (MoM) corrected for gestational 
age and maternal age, racial origin and body mass index. 
 
The preterm delivery and normal outcome groups were compared for median TSH 
MoM, FT3 MoM and FT4 MoM and prevalence of anti-thyroid antibodies. Pearson 
correlation was used to determine the significance of the interrelations of  TSH MoM 
with log10 FT3 MoM and log10 FT4 MoM. Non parametric Spearman’s correlation 
coefficient was used to estimate the association between  TSH MoM, log10 FT3 MoM 
and log10 FT4 MoM with gestational age at delivery in the preterm delivery group. 
 
The statistical software package PASW statistics 18.0 (SPSS Inc.,Chicago, IL) was 




The patient characteristics of the preterm delivery and normal outcome groups are 




women of African racial origin and those conceiving after ovulation induction.  
In the preterm delivery group, compared to the normal outcome group, there was no 
significant difference in anti-thyroid antibody positivity (Table 8.2). In the anti-thyroid 
antibody negative pregnancies in the preterm delivery group, compared to the normal 
outcome pregnancies, the median FT4 MoM and FT3 MoM were reduced (p<0.05 and 
p<0.001, respectively) but the median TSH MoM was not significantly different 
(p=0.331; Figure 8.1, Table 8.3). 
 
Table 8.1. Characteristics of the spontaneous preterm delivery and normal outcome 
groups. 
 
Comparison between the spontaneous preterm delivery and the normal outcome groups was by 
Chi square or Fisher exact test for categorical variables and t- test for continuous variables. 
*p<0.05, **p<0.0001 
 




In the preterm delivery group serum TSH was above the 95th percentile of the normal 






Gestation at sampling in wks (median, IQR) 12.4 (12.3-12.9) 12.6 (12.3-13.0) 
Gestation at delivery in wks (median, IQR) 40.2 (39.2-41.0) 31.4 (29.4-33.0)** 
Maternal age in yrs (median, IQR) 32.4 (28.2-36.1) 32.2 (26.8-36.2) 
Body mass index in Kg/m2, median (IQR) 24.6 (22.3-27.9) 25.0 (21.8-28.1) 
Racial origin   
   Caucasian, n (%) 3,125 (72.4) 60 (58.8) 
   African, n (%) 759 (17.6) 31 (30.4)* 
   Indian or Pakistani, n (%) 211 (4.9) 6 (5.9) 
   Chinese or Japanese, n (%) 70 (1.6) 0 
   Mixed, n (%) 153 (3.5) 5 (4.9) 
Parity   
   Nulliparous, n (%) 2,046 (47.4) 46 (45.1) 
   Parous, n (%) 2,272 (52.6) 56 (54.9) 
Cigarette smoker, n (%) 361 (8.4) 13 (12.7) 
Conception by ovulation drugs 128 (3.0) 9 (8.8)* 
Outcome group n 
Antibody positive 
Anti-TPO Anti-Tg Both Either 
Normal outcome 4,318 441 (10.2%) 593 (13.7%) 308 (7.1%) 726 (16.8%) 
Preterm delivery 102 12 (11.8%) 10 (9.8%) 5 (4.9%) 17 (16.7%) 





(8.2%) and 8 (9.4%) cases, respectively and they were not significantly different from 
the normal outcome group (p=0.128, p=0.202 and p=0.077, respectively). 
 
Table 8.3. Maternal serum thyroid-stimulating hormone free triiodothyronine and free 
thyroxine in the spontaneous preterm delivery and normal outcome groups. 
 
Comparison between the spontaneous preterm delivery and the normal outcome groups was by 














Figure 8.1. Relationship between maternal serum thyroid stimulating hormone (TSH) and free 
thyroxine (FT4) in multiples of the expected normal median (MoM) at 11-13 weeks of gestation 
in pregnancies that subsequently resulted in spontaneous delivery before 34 weeks. The vertical 
lines represent the 5th and 95th centiles of the normal ranges for FT4 and the interrupted 
horizontal lines the 95th centile for TSH. 
 





 MoM (median, IQR) 1.01 (0.61-1.51) 0.99 (0.57-1.42) 
 mIU/L (median, IQR) 1.10 (0.67-1.67) 0.99 (0.56-1.51) 
   
Free thyroxine 
 MoM (median, IQR) 0.99 (0.91-1.09) 0.94 (0.84-1.03)** 
 pmol/L (median, IQR) 14.90 (13.60-16.30) 14.10 (12.45-15.35)** 
   
Free triiodothyronine   
 MoM (median, IQR) 0.99 (0.93-1.06) 0.97 (0.91-1.05)* 






















































There were significant associations between  TSH MoM and log10 FT3 MoM in the 
normal outcome group (r=-0.182, p<0.0001) but not in the preterm delivery group (r=-
0.205, p=0.060). There were significant associations between  TSH MoM and log10 
FT4 MoM log10 in both the preterm delivery (r=-0.329, p=0.002) and normal outcome 
(r=-0.245, p<0.0001) groups. In the preterm delivery group there was no significant 
association between gestation at delivery and  TSH MoM (r=-0.053, p= 0.629), or 






The findings of this study demonstrate that in pregnancies resulting in spontaneous 
early preterm delivery there is no evidence of increased prevalence of anti-thyroid 
antibody positivity or maternal thyroid dysfunction at 11-13 weeks. 
 
Preterm birth is the leading cause of perinatal death and handicap in children and the 
vast majority of mortality and morbidity relates to early delivery before 34 weeks 
(Saigal et al. 2008; Centre for Maternal and Child Enquiries, 2010). Delivery before 34 
weeks occurs in about 2% of singleton pregnancies and in two-thirds of the cases this 
is due to spontaneous onset of labor or preterm prelabor rupture of membranes and in 
the other one-third it is iatrogenic, mainly due to preeclampsia (Celik et al. 2008). 
Consequently, in investigating the possible association maternal thyroid dysfunction 
and preterm delivery we firstly, excluded cases of iatrogenic preterm delivery and 
secondly, selected those delivering before 34 than 37 weeks because they have a 
worse pregnancy outcome.  
 
A previous study of 28 pregnancies delivering before 32 weeks reported that at 15 
weeks’ gestation the maternal serum TSH was above the 97.5th centile in a 
significantly higher proportion of cases than in 124 pregnancies delivering at term (14 
vs 6%) (Stagnaro-Green et al. 2005). However, in this study 64% of the cases with 
early preterm delivery had hypertensive disorders of pregnancy and it is therefore 





uncertain whether it is spontaneous preterm delivery or hypertensive disease that is 
associated with thyroid dysfunction. 
 
In women of African racial origin the rate of spontaneous early preterm delivery was 
higher than in Caucasians. This is compatible with the results of previous studies. 
National statistics in the USA demonstrate that the risk of preterm delivery in women of 
African racial origin is 1.6 times higher than in Caucasians (Mathews and MacDorman, 
2008). Similarly, a population-based study of 585,291 singleton pregnancies from 
North London, UK, reported that after correcting for other confounders the risk of 
spontaneous delivery before 37 weeks was higher by 1.6 times for women of African 
racial origin compared to Caucasians (Balchin et al. 2007). As for the association 
between preterm delivery and the use of ovulation induction drugs some studies 
suggest a method-related cause and others that infertility rather than its treatment is 
the cause because infertile women being older are more likely to suffer from chronic 
medical conditions (Wang et al. 2005; Filicori et al. 2005; Blickstein, 2006).  
 
The prevalence of anti-thyroid antibody positivity in women with spontaneous early 
preterm delivery was not higher than in those with normal pregnancy outcome. This 
finding is in agreement with the results of a screening study for anti-thyroid antibodies 
in early pregnancy which found that the rate of preterm delivery was not significantly 
different between the antibody positive and negative pregnancies (IIjima et al.1997). In 
contrast, some studies reported that the rate of preterm delivery in euthyroid women 
with anti-Tg and / or anti-TPO antibodies was 2-3 times higher than in women with no 
anti-thyroid antibodies (Glinoer et al.1994; Ghafoor et al. 2006). Additionally, a study of 
euthyroid women positive for anti-TPO antibodies reported that the administration of 
levothyroxine during pregnancy, compared to no treatment, was associated with 
significant reduction in the rate of preterm delivery (7% vs 22%) (Negro et al. 2006).  
 
Serum TSH was not higher in the preterm delivery group than in the normal outcome 
group. This finding is compatible with the results of a screening study in 9,404 
pregnancies at 15-18 weeks which reported that there was no significant difference in 




TSH below 6 mU/L (Allan et al. 2000). The results are also compatible with the findings 
of the first-trimester screening study of Cleary-Goldman et al. (2008), where the rate of 
delivery before 37 weeks in women with subclinical hypothyroidism was not 
significantly different than in euthyroid pregnancies. In contrast, the screening study of 
Casey et al. (2005), in which thyroid function was assessed before 20 weeks’ 
gestation, reported that in women with subclinical hypothyroidism there was a doubling 
in the rate of delivery before 34 weeks. 
 
In the spontaneous early preterm delivery group the median serum FT3 and FT4 
concentration was reduced but the incidence of FT3 and FT4 below the 5th centile was 
not significantly different from the incidence in the normal outcome group. In both the 
studies of Cleary-Goldman et al. (2008) and Casey et al. (2007), isolated maternal 
hypothyroxinemia, defined by TSH between the 2.5th and 97.5th percentiles and FT4 
below the 2.5th percentile, was not associated with increased risk of preterm delivery. 
 
The strengths of our study are firstly, distinction between spontaneous and iatrogenic 
preterm delivery, secondly, adjustment of measured concentrations of serum TSH, 
FT3 and FT4 for the maternal factors known to affect these measurements and thirdly, 





We found that there is no significant difference between the preterm delivery and 
normal outcome groups in the prevalence of anti-thyroid antibody positivity, subclinical 
hypothyroidism or isolated hypothyroxinaemia. It is therefore unlikely that maternal 
thyroid dysfunction at 11-13 weeks has an important contribution to the overall 
prevalence of spontaneous early preterm delivery.  However, the design of our study 
does not allow conclusions to be drawn as to whether anti-thyroid antibody positivity, 
subclinical hypothyroidism or isolated hypothyroxinaemia in early pregnancy increase 
the risk for subsequent spontaneous early preterm delivery. 






Chapter 9  Thyroid function in pregnancies with fetal  








Objective: To examine the association between maternal serum levels of thyroid 
stimulating hormone (TSH) and free ß human chorionic gonadotrophin (free ß-hCG), in 
trisomy 21, trisomy 18 and euploid pregnancies at 11-13 weeks and investigate the 
potential value of TSH in first-trimester screening for aneuploidies. 
 
Methods: Maternal serum TSH and free ß-hCG levels at 11-13 weeks in 25 trisomy 21 
and 25 trisomy 18 pregnancies were compared with levels in 3,592 unaffected 
pregnancies. Only women with no history of thyroid disease and negative for 
antithyroid antibodies were included. 
 
Results: Serum TSH in the trisomy 21 pregnancies was lower [0.76 multiples of the 
normal median (MoM), interquartile range (IQR) 0.46-1.09 MoM] and in trisomy 18 it 
was higher (1.25 MoM, IQR 0.88-1.98 MoM) than in unaffected pregnancies (1.01 
MoM IQR 0.61-1.51 MoM). There were significant associations between TSH and free 
ß-hCG in the unaffected pregnancies (r=-0.214, p<0.0001), but not in those with 
trisomy 21 (r=-0.157, p=0.452) or trisomy 18 (r=-0.176, p=0.401). 
 
Conclusions: hCG rather than TSH may be the primary thyrotropic factor in early 
pregnancy. Measurement of TSH does not improve the performance of screening for 
trisomies 21 and 18 provided by nuchal translucency, free ß-hCG and pregnancy 
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In early pregnancy there is an inverse association between maternal serum levels of 
human chorionic gonadotrophin (hCG) and thyroid stimulating hormone (TSH) (see 
Chapter 1.5). In pregnancies with fetal trisomy 21 the maternal serum concentration of 
free ß-hCG at 11-13 weeks’ gestation is on average twice as high as in euploid 
pregnancies, whereas in trisomy 18 the levels are one fifth of normal (Macri et al, 
1990; Spencer et al., 1999; Tul et al., 1999; Kagan et al., 2008a). It is therefore 
anticipated than in aneuploid pregnancies the maternal serum concentration of TSH 
would be altered. However, a case control study of pregnancies at 9-11 weeks’ 
gestation reported that there was no significant difference between trisomy 21 and 
euploid pregnancies in either hCG or TSH (Weinans et al., 2001). However, in this 
study no corrections were made for maternal characteristics and gestational age that 




The aim of this study is to examine further the association between maternal serum 
levels of TSH and hCG in trisomy 21, trisomy 18 and euploid pregnancies at 11-13 
weeks, assess any differences in free thyroxine (FT4) and free triiodothyronine (FT3) 
between the three groups and investigate the potential value of TSH in first-trimester 
screening for aneuploidies. 
 
9.2 PATIENTS AND METHODS 
 
The study design and overall study population are described in Chapter 2. 
 
In this study we retrospectively examined maternal thyroid function at 11-13 weeks in 
30 pregnancies with fetal trisomy 21, 25 with fetal trisomy 18 and 2 with paternally 
derived triploidy. The diagnosis of aneuloidy was made by chorionic villus sampling 





after first-trimester combined screening. In 5 of the trisomy 21 cases the maternal 
serum concentration of anti-TPO and/or anti-Tg was more than 60 U/mL and these 
cases were excluded from further analysis because their values were above the 
manufacturer’s reference limit.  
 
The values of FT3, FT4 and TSH in the 25 cases of trisomy 21, 25 cases of trisomy 18 
and 2 with triploidy were compared to the results of 3,592 antithyroid antibody-negative 
singleton pregnancies with no history of thyroid disease, which resulted in live birth 







The maternal serum concentrations of FT3, FT4 and TSH were measured by 




The characteristics of the trisomy 21, trisomy 18 and unaffected groups were 
compared by one-way ANOVA test, followed by Bonferroni post-hoc test if equal 
variances or Tamhane post-hoc test if unequal variances, for continuous variables and 
Fisher’s exact test or Chi-square test followed by Bonferroni post-hoc test for 
categorical variables.  
 
The measured concentrations of FT3, FT4 and TSH were converted to MoMs 
corrected for gestational age, maternal age, racial origin and body mass index 
(Chapter 3). Similarly, the measured concentration of maternal serum free ß-hCG was 
MoMs corrected for fetal CRL, maternal weight, smoking status, racial origin, parity 
and method of conception (Kagan et al., 2008b).
 
Comparison of TSH MoM, FT3 MoM 
and FT4 MoM between aneuploid and unaffected groups was by one-way ANOVA test, 
followed by Bonferroni post-hoc test if equal variances or Tamhane post-hoc test if 






inter-relations between serum square root () TSH MoM, Log10 FT3 MoM, Log10 FT4 
MoM Log10 PAPP-A MoM and Log10 free ß-hCG MoM. 
 
The added value of including thyroid function markers in aneuploidy screening was 
estimated by standard modeling techniques (Royston and Thompson, 1992).  The 
model parameters - means, standard deviations and correlation coefficients and 
maternal age distribution - were derived directly from the study data.  Trisomy 21 
detection rates were estimated for fixed 3% and 5% false-positive rates; trisomy 18 rates 
for 0.5% and 1%.      
 
The statistical software packages PASW statistics 18.0 (SPSS Inc.,Chicago, IL) was 





The maternal characteristics and results of first-trimester combined screening for 
aneuploidies in trisomy 21, trisomy 18 and unaffected pregnancies are compared in 
Table 9.1. In both the trisomy 21 and trisomy 18 groups, compared to the unaffected 
group, maternal age and fetal NT thickness were higher and serum PAPP-A was 
lower. Serum free ß-hCG in trisomy 21 was increased and in trisomy 18 it was 
decreased. 
 
Serum TSH in the trisomy 21 pregnancies was lower and in trisomy 18 it was higher 
than in unaffected pregnancies (Table 9.2). There were no significant differences 
between the groups in serum FT4 but in trisomy 18 pregnancies FT3 was significantly 
reduced. In the unaffected pregnancies, but not in those with trisomy 21 or trisomy 18, 
there were significant intercorrelations between TSH, free ß-hCG, FT3 and FT4 (Table 
9.3). 
 
None of the thyroid function markers increased the model predicted detection rates for 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































0.8%.  The increase in detection for trisomy 18 was at most 0.2%. The Mahalinobis 
distance for the decrease in TSH MoM values in trisomy 21 was 0.46 and for the 
increase in trisomy 18 was 0.37.  
 
In the two cases of paternally derived fetal triploidy the gestational age was 13 weeks 
and the fetal CRL was 63.5 mm and 73.7 mm, respectively. The maternal serum free 
ß-hCG was 7.51 and 6.77 MoM, the levels of TSH were undetectable and both FT3 




Table 9.2. Maternal thyroid function in trisomy 21, trisomy 18 and unaffected 
pregnancies. 
 
Comparison between each aneuploid group and the unaffected pregnancies was by ANOVA  
test for categorical both with post-hoc Bonferroni test for free thyroxine and post-hoc Tamhane 




Table 9.3. Pearson correlation between square root ( ) TSH MoM, Log FT4 MoM and 









Thyroid stimulating hormone 
     MoM (median, IQR) 1.01 (0.61-1.51) 0.76 (0.46-1.09)* 1.25 (0.88-1.98)* 
     m IU/L (median, IQR) 1.10 (0.67-1.67) 0.85 (0.49-1.22)* 1.46 (1.03-2.11)* 
Free thyroxine 
     MoM (median, IQR) 0.99 (0.91-1.09) 1.04 (0.91-1.23) 0.97 (0.83-1.03) 
     Pmol/L (median, IQR) 14.9 (13.6-16.3) 15.4 (13.5-18.2) 14.4 (12.2-15.4) 
Free triiodothyronine 
     MoM (median, IQR) 0.99 (0.93-1.06) 1.02 (0.97-1.18) 0.95 (0.91-1.00)* 







Correlations r p r P r p 
 TSH MoM with Log FT4 MoM -0.245 <0.0001 0.106 0.613 -0.111 0.596 
 TSH MoM with Log FT3 MoM -0.182 <0.0001 -0.307 0.135 0.238 0.251 
Log FT4 MoM with Log FT3 MoM 0.476 <0.0001 0.376 0.064 0.359 0.078 
Log β-hCG MoM with  TSH MoM -0.214 <0.0001 -0.157 0.452 -0.176 0.401 
Log β-hCG MoM with Log FT4 MoM 0.124 <0.0001 0.252 0.223 -0.015 0.944 
Log β-hCG MoM with Log FT3 MoM 0.104 <0.0001 0.205 0.325 -0.093 0.658 







This study has demonstrated that in euploid pregnancies there is a weak inverse 
association between free ß-hCG MoM and TSH MoM. In trisomy 21 pregnancies free 
ß-hCG is increased and TSH is decreased and in trisomy 18 pregnancies free ß-hCG 
is decreased and TSH is increased.  
 
In first trimester screening for aneuploidy the observed decrease in TSH MoM values 
in trisomy 21 and the increase in trisomy 18 pregnancies had only modest 
discriminatory value, which was about half that of AFP which is the weakest current 
marker.  Moreover, the negative correlation between free ß-hCG and TSH means that 
the use of both markers in screening will effectively decrease the Mahalinobis 
distances. This is reflected in the lack of any model predicted additional detection if 
TSH was added to current first trimester screening protocols.   
 
The finding of an inverse association between free ß-hCG MoM and TSH MoM is 
compatible with the known thyrotropic properties of hCG (Braunstein and Hershman, 
1976; Pekonen et al., 1988; Glinoer et al., 1990; Ballabio et al., 1991). In pregnancy 
there is a mirror image between TSH and hCG levels with high hCG and low TSH at 8-
14 weeks and subsequent increase in TSH during the second and third trimesters 
coinciding with the decline in hCG (Glinoer et al., 1990). Pregnancy is associated with 
an approximate 50% increase in demand for thyroid hormones which is apparent within 
the first 16 weeks of gestation and is mainly attributed to the estrogen-driven doubling 
in thyroxine-binding globulin concentrations (Glinoer et al., 1990; Alexander et al., 
2004). Consequently, the increased demands for maternal thyroid hormones of early 
pregnancy are under the influence of the placenta rather than the maternal pituitary 
gland. It could even be postulated that the otherwise unknown role of hCG resides in 
its thyrotropic properties at this critical stage of development when the fetal 
requirements for thyroid hormones are entirely dependent on the mother. Although the 
fetal thyroid gland begins to produce thyroid hormones from as early as 11 weeks of 
gestation (Shepard, 1967) functional maturation of the fetal pituitary-thyroid axis occurs 








In this study we measured the screening marker free ß-hCG which is not a hormonally 
active molecule but its levels reflect those of the hormonally active intact hCG 
molecule. This interrelation between hCG and TSH maintains normal FT3 and FT4 
levels and this is reflected in trisomy 21 pregnancies where despite doubling in free ß-
hCG levels, FT3 and FT4 were not significantly different from euploid pregnancies.  
 
However, in cases of very high levels in free ß-hCG, as observed in our two cases of 
androgenic triploidy, serum FT3 and FT4 were increased with complete suppression of 
TSH production. The opposite was true in the case of trisomy 18 where very low levels 
of free ß-hCG were accompanied by an increase in TSH but the level of FT3 was 
reduced. Although the level of FT4 was also lower than in euploid pregnancies the 
difference was not significant. These data provide further support to the hypothesis 
that hCG rather than TSH may be the primary thyrotropic factor in early pregnancy. 
Although serum TSH is altered in pregnancies with fetal trisomies 21 and 18 this 
measurement does not improve the performance of screening for these aneuploidies 






The data of this study provide further support to the hypothesis that hCG rather than 
TSH may be the primary thyrotropic factor in early pregnancy. Although serum TSH is 
altered in pregnancies with fetal trisomies 21 and 18 this measurement does not 
improve the performance of screening for these aneuploidies provided by nuchal 
translucency, free ß-hCG and pregnancy associated plasma protein-A. 
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Objective: To establish reference ranges of maternal serum thyroid stimulating 
hormone (TSH), free thyroxine (FT4) and free triiodothyronine (FT3) at 11-13 weeks’ 
gestation in twin pregnancy. 
 
Methods: This was a case series of 177 dichorionic and 58 monochorionic twin 
pregnancies with normal outcome and 19 monochorionic pregnancies complicated by 
severe twin-to-twin transfusion syndrome (TTTS). Maternal serum concentrations of 
TSH, FT3, FT4, anti-thyroperoxidase and anti-thyroglobulin antibodies were measured 
at 11-13 weeks’ gestation. The measured TSH, FT3 and FT4 were converted to 
multiple of median (MoM) of normal singleton pregnancy and MoM values in the 
different groups were compared.  
 
Results: In the antithyroid antibody negative twin pregnancies with normal outcome, 
compared to singletons, serum TSH MoM was lower (median 0.62, IQR 0.16-1.18 vs. 
1.01, IQR 0.61-1.51; P<0.0001), FT3 MoM and FT4 MoM were not significantly 
different (FT3: median 0.99, IQR 0.90-1.06 vs. 0.99, IQR 0.94-1.06; p=0.132; FT4: 
median 0.98, IQR 0.91-1.08 vs. 0.99, IQR 0.91-1.09; P=0.975) and free ß-hCG MoM 
was higher (median 1.91, IQR 1.33-2.59 vs. 0.98, IQR 0.66-1.50; P<0.0001). In the 
antibody-positive group (n=37), compared to the negative group (n=198), the median 
TSH was higher but FT4, FT3 and free ß-hCG were not significantly different. In the 
TTTS group, compared to normal twin pregnancies, TSH, FT4, FT3 and free ß-hCG 
were not significantly different.  
 
Conclusion: In twins, compared to singleton pregnancies, TSH is lower but FT3 and 










This chapter is based on: Ashoor G, Muto O, Poon LCY, Muhaisen M and Nicolaides KH (2013) 










A study in 132 twin pregnancies, compared to 13,599 singletons, reported that serum 
TSH is lower (Dashe et al., 2005). This has been attributed to the higher levels of 
human chorionic gonadotrophin (hCG) in twins, which stimulates thyroid hormone 




The aim of this study is to establish a normal range of serum TSH, FT3 and FT4 in 
dichorionic and monochorionic twins at 11-13 weeks’ gestation and compare the 
values to singleton pregnancies. 
 
 
10.2 PATIENTS AND METHODS 
 
The study design and overall study population are described in Chapter 2. 
 
This was a case series of Dichorionic and monochorionic twin pregnancies attending 
for their routine first hospital visit in pregnancy held at 11-13 weeks’ gestation 
(Sepulveda et al., 1996). The inclusion criteria were: twin pregnancies with live fetuses 
at 11-13 weeks, delivery of live births at or after 33 weeks’ gestation.  
 
We excluded cases with: maternal history of hypothyroidism or hyperthyroidism, fetal 
abnormalities, preeclampsia and small for gestational age neonates with birth weight 
below the 5th percentile of our normal range for gestation (Poon et al., 2011b). These 
criteria were met by 235 cases with available serum for analysis (normal group). 
Additionally, we examined 19 cases that developed severe twin-twin-transfusion 
syndrome (TTTS) requiring endoscopic laser surgery (Ville et al., 1998). None of the 
women suffered from hyperemesis gravidarum at the time of testing. 
 









The maternal serum concentrations of FT3, FT4 and TSH were measured by 




The characteristics of the dichorionic and monochorionic twins were compared by the 
Mann-Whitney-U test for continuous variables and Fisher’s exact test or chi-square 
test for categorical variables.  
 
The measured serum TSH, FT3 and FT4 in the twins with normal outcome were 
converted to MoM of normal singleton pregnancy, corrected for gestational age, 
maternal age, BMI and racial origin as previously described (Chapter 3). The limitation 
with this statistical approach is the assumption that the effects of maternal 
characteristics such as age, race and BMI on thyroid functions are the same in twins 
as in singleton pregnancy. In the antibody-negative group, regression analysis was 
used to determine if twinning was a significant predictor of square-root TSH MoM, log10 
FT3 MoM and log10 FT4 MoM. These transformations of square-root for TSH and log10 
for FT3 and FT4 were used to achieve Gaussian normality of the distributions (Chapter 
3). The observed values of TSH, FT3 and FT4 were then expressed as MoM for 
normal twin pregnancy. Similarly MoM values were also calculated for the TTTS group. 
 
Regression analysis was used to determine the significance of the inter-relations 
between serum TSH, FT3, FT4 and free -hCG. Comparison of TSH MoM, FT3 MoM 
and FT4 MoM between the antibody-positive and antibody-negative groups was done 
by the Kruskal-Wallis test with post hoc Bonferroni correction (critical statistical 
significance p<0.0167). Similarly, the normal outcome group was compared with the 







The proportion of cases with serum TSH above the 97.5th percentile, serum FT3 and 
FT4 below the 2.5th percentile in the antibody-positive and -negative groups were 
compared using the chi-square test with post hoc Bonferroni correction. 
 
The statistical software package SPSS 20.0 (SPSS Inc., Chicago, Ill., USA) was used 




In the 235 twin pregnancies with normal outcome there were 177 (75.3%) with 
dichorionic and 58 (24.7%) with monochorionic twins (Table 10.1).  
 
 
Table 10.1. Comparison of maternal characteristics in dichorionic and monochorionic 
twin pregnancies with normal outcome. 
 





Median maternal age, years (IQR) 33.7 (29.7-36.8) 33.6 (28.9-36.7) 0.801 
Median body mass index, kg/m2 (IQR) 25.3 (23.0-29.3) 24.4 (21.9-28.3) 0.178 
Median gestational age, week (IQR) 13.0 (12.6-13.5) 13.0 (12.6-13.5) 0.912 
Racial origin    
   Caucasian, n (%) 136 (76.8) 45 (77.6) 1.000 
   African, n (%) 30 (16.9) 5 (8.6) 0.141 
   South Asian, n (%) 6 (3.4) 5 (8.6) 0.145 
   East Asian, n (%) 1 (0.6) 0 (0.0) 1.000 
   Mixed, n (%) 4 (2.3) 3 (5.2) 0.368 
Conception    
   Spontaneous, n (%) 88 (49.7) 30 (51.7) 0.880 
   Assisted, n (%) 89 (51.3) 28 (48.3) 0.880 
Antibody negative, n (%) 152 (85.9) 46 (79.3) 0.298 
Antibody positive, n (%) 25 (14.1) 12 (20.7) 0.298 
IQR = Interquartile range. * Comparisons by chi-square test for categorical variables and by 
Mann-Whitney U test for continuous variables (P < 0.05). 
 
In 198 (84.3%) of the 235 pregnancies the serum concentration of anti-TPO and anti-
Tg was <60 U/mL and in 37 (15.7%) the concentration of one or both antibodies was 
>60 U/mL. In 17 (7.2%) both antibodies were positive, in 12 (5.1%) only anti-TPO was 
positive and in 8 (3.4%) only anti-Tg was positive. The prevalence of antibody positivity 
was not significantly different between dichorionic (25 of 177, 14.1%) and 
monochorionic twins (12 of 58, 20.7%; P=0.298). 
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Antithyroid antibody negative twin pregnancies with normal outcome   
In the antithyroid antibody negative twin pregnancies with normal outcome, compared 
to singletons, serum TSH MoM was lower (median 0.62, IQR 0.16-1.18 vs. 1.01, IQR 
0.61-1.51; P<0.0001; Figures 10.1 and 10.2), FT3 MoM and FT4 MoM were not 
significantly different (FT3: median 0.99, IQR 0.90-1.06 vs. 0.99, IQR 0.94-1.06; 
p=0.132; FT4: median 0.98, IQR 0.91-1.08 vs. 0.99, IQR 0.91-1.09; P=0.975; Figure 
10.2) and free ß-hCG MoM was higher (median 1.91, IQR 1.33-2.59 vs. 0.98, IQR 

















Figure 10.1.  Maternal serum thyroid stimulating hormone concentration of twin pregnancies in 
Caucasian (left) and African (right) women plotted on the normal ranges (2.5th, 50th, 97.5th 
percentile) of singleton pregnancies (red lines) and twin pregnancies (black lines). 
 
Regression analysis demonstrated that twinning, but not chorionicity (TSH: P=0.722; 
FT3: P=0.578; FT4: P=0.911), had significant contribution to the level of TSH but not 






















































































































































































































































Expected square-root TSH MoM = 0.999933 (s.e. 0.006139) + [-0.211140 (s.e. 
0.026860) if twin pregnancy]; R2=0.016, P<0.0001 
 
Expected log10 free T3 MoM = 0.000000 (s.e. 0.000783) + [-0.001131 (s.e. 0.003426) if 
twin pregnancy]; R2=0.000, P=0.741 
 
Expected log10 free T4 MoM = 0.000000 (s.e. 0.001076) + [0.003856 (s.e. 0.004708) if 
twin pregnancy]; R2=0.000, P=0.413 
 
The observed values of TSH, FT3 and FT4 were then expressed as MoM for normal 
twin pregnancy. The 50th, 95th, 97.5th, 5th and 2.5th percentiles of serum TSH, FT3 and 
















Figure 10.2. Box-whisker plots of the multiples of median (MoM) thyroid stimulating hormone 
and free thyroxine in singleton and twin pregnancies. 
 
In dichorionic twins, compared to monochorionic twins, there were no significant 
differences in TSH MoM (median 0.98, IQR 0.28-1.29 vs. 1.13, IQR 0.23-2.22; 
P=0.856), FT3 MoM (median 0.99, IQR 0.90-1.03 vs. 1.00, IQR 0.96-1.10; P=0.052), 
FT4 MoM (median 0.98, IQR 0.91-1.08 vs. 1.01, IQR 0.94-1.06; P=0.537) or free ß-














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































There was a significant correlation between log10 TSH MoM and log10 FT4 MoM (r=-
0.487, P<0.0001) and log10 FT3 MoM (r=-0.502, P<0.0001) and log10 free -hCG MoM 
(r=-0.280, P<0.0001); and between log10 FT4 MoM and log10 FT3 MoM (r=0.633, 
P<0.0001) and log10 free -hCG MoM (r=0.199, P=0.005); and also between log10 FT3 
MoM and log10 free -hCG MoM (r=0.157, P=0.027). 
 
Antithyroid antibody positive twin pregnancies with normal outcome   
 
In the cases where both anti-TPO and anti-Tg were positive, compared to the 
antibody-negative group, the median TSH was higher but FT4, FT3 and free ß-hCG 
were not significantly different (Table 10.3). Serum TSH was above the 97.5th 
percentile in 2.0% of the antibody-negative group and this increased to 29.4% (5 of 17) 
in the group with both anti-TPO and anti-Tg positivity. There was no significant 
difference in the proportion of FT3 and FT4 below the 2.5th percentile between the 
antibody-negative and -positive groups (Table 10.3).  
 
 
Table 10.3. Comparison of the antibody-positive and antibody-negative groups for median 
thyroid stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3) and 
free -human chorionic gonadotropin (-hCG) and proportion of cases with TSH above the 
97.5th percentile and FT4 and FT3 below the 2.5th percentile of the respective reference 
range. 
 
Comparisons between each antibody-positive group with the antibody-negative group by chi-
square test with post hoc Bonferroni correction for categorical variables and by Kruskal-Wallis 












Thyroid stimulating hormone 
   Median MoM 1.00 2.00 0.64 2.73* 
   >97.5th percentile, n (%) 4 (2.0) 2 (16.7) 0 (0.0) 5 (29.4)* 
Free thyroxine 
   Median MoM   0.98 1.02 0.99 0.97 
   <2.5th percentile, n (%) 4 (2.0) 2 (16.7) 0 (0.0) 2 (11.8) 
Free triiodothyronine     
   Median MoM   0.99 0.94 0.91 0.88 
   <2.5th percentile, n (%) 4 (2.0) 2 (16.7) 1 (12.5) 2 (11.8) 
Free -hCG median MoM 1.00 1.39 1.19 1.13 





Pregnancies complicated by twin-to-twin transfusion syndrome 
 
In the TTTS group, 17 (89.5%) of the 19 pregnancies were antithyroid antibody 
negative and in this group,  compared to the antibody negative normal outcome twins, 
there was no significant difference in TSH MoM (1.38, IQR 0.52-2.05 vs 1.00, IQR 
0.26-1.36, P=0.424), FT3 MoM (0.97, IQR 0.86-1.09 vs 0.99, IQR 0.90-1.06, P=0.246),  
FT4 MoM (0.94, IQR 0.90-1.16 vs 0.98, IQR 0.91-1.08, P=0.773), or free ß-hCG MoM 





This study has demonstrated that in normal twin pregnancies at 11-13 weeks’ 
gestation, compared to singletons, maternal serum FT4 is not significantly different but 
TSH is about 40% lower. The most likely explanation for the low TSH is the high level 
of free ß-hCG, which is twice as high as in singletons. The levels of serum TSH, FT3 
and FT4 were similar in dichorionic and monochorionic twins, with or without TTTS, 
and there were no significant differences between the three groups in serum free ß-
hCG.  
 
In establishing reference ranges of thyroid function in twins we excluded pregnancies 
complicated by miscarriage or fetal death, fetal growth restriction, preeclampsia and 
preterm delivery because of the reported association between these pregnancy 
complications and clinical or subclinical hypothyroidism (Leung et al., 1993; Allan et al., 
2000; Casey et al., 2005). We also excluded pregnancies with known thyroid disease 
and those with anti-thyroid antibodies. In our population about 12% of pregnancies had 
detectable anti-TPO antibodies and 11% had anti-Tg antibodies, which are similar to 
the respective prevalence of 10% and 14% in our singleton pregnancies (Chapter 3). 
In the antibody-positive group when both antibodies were positive, compared to the 
antibody negative group, there were higher median TSH and percentage of cases with 
TSH values above the 97.5th percentile, whereas serum FT3, FT4 and β-hCG were 







positive women with subclinical hypothyroidism during pregnancy will develop clinical 
hypothyroidism within the subsequent 10 years (Haddow et al., 1999). Consequently, 
in establishing normal ranges of thyroid function it is necessary to exclude antibody 
positive patients.  
 
The measured serum TSH, FT3 and FT4 in twin pregnancies were converted to MoM 
of normal singleton pregnancy, corrected for gestational age in weeks, maternal age, 
BMI and racial origin as previously described (Chapter 3). In women of African racial 
origin the serum concentration of both TSH and FT4 is lower than in Caucasians, 
suggesting that the hypothalamo-pituitary-thyroid gland axis in the two racial groups is 
set at different thresholds. The minimum detectable concentration for TSH is 0.01 
mIU/l and in the Caucasian population the 2.5th centile raw values were all detectable. 
However, clinically most hospitals use the 5th or even the 10th centile as cut-offs. In the 
African population the 2.5th and the 5th centile can be undetectable depending on other 
maternal characteristics and gestation. This illustrates that more accurate assays will 
help in diagnosing hyperthyroidism in pregnancy in that group. None of the women in 
our cohort had undetectable serum TSH levels and this is probably due to the fact that 
we only examined 32 women of African origin. 
 
The most likely explanation for the finding that in antithyroid antibody negative twins, 
compared to singletons, maternal serum FT3 and FT4 were not significantly different 
but TSH was lower due to the increase in ß-hCG. Human chorionic gonadotrophin, 
which has an identical α-subunit and structurally similar ß-subunit to those of TSH, has 
thyrotropic properties and in early pregnancy there is an inverse association between 
maternal serum levels of TSH and hCG (Braunstein et al., 1976; Yoshikawa et al., 
1989; Glinoer et al., 1990; Ballabio et al., 1991; Yoshimura and Hershman, 1995; Grun 
et al., 1997). A study of 3,961 dichorionic and 759 monochorionic twins at 8-13 weeks’ 
gestation reported that the maternal serum free ß-hCG, expressed as MoMs for 
singleton pregnancies, increased from 1.5 MoM at 8-9 weeks to 2.0 MoM at 12-13 
weeks for dichorionic twins and from 1.0 MoM to 2.0 MoM for monochorionic twins 
(Madsen et al., 2011). Consequently, at the median gestational age of 13 weeks in our 





study the levels of free ß-hCG in twins, irrespective of chorionicity, were twice as high 
as in singletons. Similarly, the levels of free ß-hCG and TSH in monochorionic twins 





The study established reference ranges of maternal thyroid function in twin 
pregnancies at 11-13 weeks after appropriate correction for maternal characteristics 
which affect the measured serum concentrations of TSH, FT3 and FT4. These ranges 
can be used in clinical practice to help diagnose subclinical and overt hypo- and 
hyperthyroidism. Given the lower levels of TSH in twin pregnancies it is important to 
use the twin-specific normal range otherwise there is a risk of over-diagnosis of 
thyrotoxicosis in twin pregnancies. They can also form the basis for the study of early 
thyroid function in pathological pregnancies and the investigation of the consequences 
of overt and subclinical hypothyroidism on twin pregnancy outcome. 











The study in Chapter 3 established normal ranges for maternal thyroid function at 11-
13 weeks’ gestation after adjustment for maternal characteristics which affect the 
measured serum concentrations of thyroid stimulating hormone (TSH), free 
triiodothyronine (FT3) and free thryroxin (FT4). In antithyroid antibody negative women 
serum TSH increased whereas FT3 and FT4 decreased with gestation and all three were 
lower in Afro-Caribbean than in Caucasian women. Serum FT3 and FT4 decreased but 
TSH did not change significantly with maternal age, TSH and FT3 increased whereas 
FT4 decreased with body mass index, TSH decreased whereas FT3 and FT4 increased 
with serum free ß-hCG. In the antibody positive group, compared to the negative group, 
median TSH was higher and median FT3 and FT4 were lower. 
 
The study in Chapter 4 assessed thyroid function at 11-13 weeks’ gestation in women 
with known hypothyroidism diagnosed before pregnancy and receiving levothyroxine. 
On the basis of their individual results about 55% of the patients were biochemically 
euthyroid with normal serum TSH and normal or high FT4 and FT3. In the remaining 
45% at least one of the three biochemical tests was suggestive of persistent 
hypothyroidism. There was a small group with low FT4 and FT3 and high TSH. In a 
much larger group serum FT4 was normal or increased but either TSH was high and / 
or FT3 was low. These findings raise the question as to whether the objective in the 
treatment of hypothyroidism in pregnancy should be to normalize TSH or FT4 or FT3. 
 
The study in Chapter 5 demonstrated that in pregnancies resulting in miscarriage or 
fetal death during the second and third trimesters, compared to those with normal 
outcome, the median maternal serum concentration of TSH at 11-13 weeks’ gestation 
was increased and FT4 was decreased and the incidence of high TSH and low FT4 





was increased. Previously undiagnosed hypothyroidism diagnosed at 11-13 weeks’ 
gestation may be a contributing factor to about 5% of subsequent fetal losses. The 
study also showed that there were no significant differences between the fetal loss and 
normal groups in the incidence of antithyroid antibody positivity, contradicting a 
previous hypothesis that antithyroid antibodies exert a direct toxic effect on the 
pregnancy leading to fetal loss. 
 
The study in Chapter 6 demonstrated an association between impaired maternal 
thyroid function at 11-13 weeks’ gestation and subsequent development of late but not 
early preeclampsia (PE). High serum TSH was observed in 5 times as many 
pregnancies with late-PE compared with those who did not develop PE. This 
association of hypothyroidism and PE is independent of autoimmune mechanisms 
because the prevalence of antithyroid antibodies was not higher in the PE than in the 
non-PE group. The association between hypothyroidism and late-PE may be mediated 
by the role of thyroid hormones in glucose homeostasis and in the synthesis, 
metabolism and mobilization of lipids. Hypothyroidism may also play a direct role in 
causing pregnancy hypertension because thyroid hormones act directly on peripheral 
arterioles to cause dilation. The study also showed that measurement of maternal 
serum TSH can improve the prediction of late-PE provided by a combination of factors 
in the maternal history and the measurements of mean arterial pressure and uterine 
artery pulsatility index. 
 
The study in Chapter 7 demonstrated that in pregnancies delivering small for 
gestational age (SGA) neonates, maternal thyroid function at 11-13 weeks’ gestation 
was not significantly different from those delivering appropriately grown neonates and 
there was no evidence that in the SGA group the incidence of impaired thyroid function 
is increased. Consequently, the results of in vitro studies concerning the role of thyroid 
hormones on trophoblast proliferation and invasion (Barber et al., 2005; Oki et al., 
2004) may not be clinically relevant and thyroid function does not have a significant 
contribution to the prevalence of SGA neonates. 
 




The study in Chapter 8 demonstrated that there was no significant difference between 
pregnancies ending in spontaneous early preterm delivery and those delivering at term 
in the prevalence of anti-thyroid antibody positivity, subclinical hypothyroidism or 
isolated hypothyroxinaemia. It is therefore unlikely that maternal thyroid dysfunction at 
11-13 weeks’ gestation has an important contribution to the overall prevalence of 
spontaneous early preterm delivery.   
 
The study in Chapter 9 demonstrated that in euploid pregnancies there is a weak 
inverse association between free free ß-human chorionic gonadotropin (ß-hCG) and 
TSH. In trisomy 21 pregnancies free ß-hCG was increased and TSH was decreased 
and in trisomy 18 pregnancies free ß-hCG was decreased and TSH was increased. 
The data provide further support to the hypothesis that hCG rather than TSH may be 
the primary thyrotropic factor in early pregnancy. The study also showed that although 
serum TSH is altered in pregnancies with fetal trisomies 21 and 18 this measurement 
does not improve the performance of screening for these aneuploidies provided by 
fetal nuchal translucency, free ß-hCG and pregnancy associated plasma protein-A. 
 
The study in Chapter 10 established normal ranges of maternal thyroid function in twin 
pregnancies at 11-13 weeks’ gestation. The study demonstrated that in normal twin 
pregnancies at 11-13 weeks’ gestation, compared to singletons, maternal serum FT3 
and FT4 are not significantly different but TSH is about 40% lower. The most likely 
explanation for the low TSH is the high level of free ß-hCG, which is twice as high as in 
singletons. The levels of serum TSH, FT3 and FT4 were similar in dichorionic and 
monochorionic twins, with or without twin-to-twin transfusion syndrome and there were 
no significant differences between the three groups in serum free ß-hCG.  
 
 
11.2 SUGESTIONS FOR FUTURE STUDIES 
 
The reference ranges established in this thesis can form the basis for routine 
screening for subclinical maternal thyroid dysfunction at 11-13 weeks’ gestation. The 
controversy concerning the value of routine screening and treatment of subclinical 
hypothyroidism will ultimately be resolved through randomised studies demonstrating 





that such policy would improve outcome both in terms of reducing pregnancy 
complications and adverse long term neurodevelopment in children. When such 
studies are undertaken it is likely that the gestational age at screening will be at 11-13 
weeks because both in the UK and in many other countries women attend for such a 
visit as part of the well established routine screening for aneuploidies.  
 
In women with hypothyroidism treated by thyroxine we found that although the level of 
serum FT4 was invariably normal or increased in a high proportion of cases there was 
high TSH and low FT3, high TSH and normal FT3 or normal TSH and low FT3. 
Consequently, if the objective in the treatment of hypothyroidism in pregnancy is to 
normalize the levels of the biologically active FT3 it is not useful to monitor the levels of 
FT4 but it is essential to measure the levels of both TSH and FT3. Recommendations 
on whether the objective in the treatment of hypothyroidism in pregnancy is to 
normalize TSH and / or FT3 rather than FT4 should ultimately be based on the results 
of major prospective studies examining the differential incidence of adverse pregnancy 
outcomes in the groups with low FT3 and normal TSH and FT4 and in those with high 
TSH and normal FT4 and FT3 compared to those in which all three biochemical 
markers are normal. 
 
We found that previously undiagnosed hypothyroidism diagnosed at 11-13 weeks of 
gestation may be a contributing factor to about 5% of subsequent fetal losses. The 
extent to which the diagnosis of subclinical hypothyroidism and appropriate therapy 
can prevent fetal loss and the cost-effectiveness of such strategy require further 
investigation.  
 
Our finding that the performance of first trimester prediction of PE by biophysical and 
biochemical markers can be improved by the addition of serum TSH will require 
confirmation by prospective studies. Similarly, the extent to which the prevalence of PE 
can be reduced by early screening for thyroid dysfunction and its appropriate therapy 
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